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Abstract 
 
This thesis focuses on clinical manifestations and genetic risk factors in a cohort of 
individuals with Behçet’s Disease (BD) from the United Kingdom (UK).  
 
Chapter 1 outlines the history of BD and discusses the spectrum of clinical presentations. 
The history of human leukocyte antigen B*51 (HLA-B*51) associations in BD is covered 
and current knowledge of other genetic associations explored. The relevance of the killer 
immunoglobulin-like receptor 3DL1/S1 (KIR3DL1/S1) and its ligand, the Bw4 epitope, 
is discussed and current knowledge of KIR3DL1/S1 biology is reviewed. Chapter 2 
outlines the materials and methods used in the following chapters. Results are described 
in Chapters 3, 4 and 5. Chapter 3 explores established genetic associations in BD 
between HLA –A and –B, and the MHC Class I Polypeptide-Related Sequence A (MICA). 
Here, the concept of ancestry informative markers (AIMs) is introduced, with a view to 
reducing heterogeneity caused by population admixture. I confirm the importance of 
HLA-B*51 in the UK cohort and in a subgroup made up of individuals of European 
ancestry. The allele MICA*009, is also confirmed as a risk factor for BD, however, its 
association is likely to be caused by strong linkage disequilibrium to HLA-B. Chapter 4 
investigates alleles of KIR3DL1/S1 and their associations in BD. In this chapter, the 
construction of ‘functional genotypes’ to estimate KIR3DL1/S1 expression phenotype is 
discussed. The combination of a low-expressing KIR3DL1 allotype and KIR3DS1 was 
found to increase the risk of disease, whereas a high-expressing KIR3DL1 allotype in 
combination with a KIR3DL1-null allotype decreases the risk of disease. The phenotype 
of circulating Natural killer (NK) and CD8 T cells is then explored. Low percentages of 
NK cells were present in PBMC analysed from individuals with BD. Furthermore, 
KIR3DL1 and KIR3DS1 were expressed at much lower levels than expected. The creation 
of target cell lines to test the functional effects of the KIR3DL1/S1 ‘functional genotypes’ 
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is then discussed. I was unable to find any significant differences in degranulation 
provoked by HLA-B*51, B*52 or B*35+ target cells. Chapter 5 describes the results of 
a prospective survey of ophthalmic manifestations of BD in the UK. The incidence of 
ophthalmic BD is 0.04 per 100,000 in the UK. Patient demographics and geography are 
discussed in detail in this chapter. Chapter 6 draws together the findings from the Thesis 
and Chapter 7 discusses limitations and further work.  
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Context 
 
In 2008, I was a second-year ophthalmic trainee based in London and keen to travel the 
world. Prof. Miles Stanford was my clinical supervisor at the time and had mentioned that 
he had an interest in Behçet’s Disease. I wanted to spend some time in the Middle-East 
and I liked the idea of studying the immunology of Behçet’s Disease. Together, we came 
up with five potential cities in which I could work; Cairo, Damascus, Beirut, Istanbul and 
Jerusalem. For a variety of logistical, security and academic reasons, Istanbul was the best 
option. Professor Stanford reached out to Prof Ahmet Gul at the University of Istanbul 
Medical School in Çapa, who agreed to meet with us. The following year, I travelled to 
Istanbul to meet the team there. Our research plan was to base my PhD on work previously 
carried out by Dr. Seema Shafi, one of Prof. Stanford and Dr. Graham Wallace’s former 
PhD students. Seema had focused her attention on various isoforms of MHC class I 
polypeptide-related sequence A (MICA) in Behçet’s Disease, exploring the effects of 
transfecting various allotypes of MICA into Chinese Hamster Ovary (CHO) epithelial 
cells. She found that transfecting MICA and human leukocyte antigen (HLA) B*51 and 
B*52 into CHO cells resulted in provoking differing levels of degranulation from 
peripheral blood mononuclear cells (PBMC) during co-culture. One hypothesis was that 
this may have been in part due to differing levels of inhibition provided by KIR3DL1 
allotypes expressed on PBMC.  
 
My project would be to investigate allelic variation at the KIR3DL/S1 locus in Behçet’s 
Disease. As Behçet’s Disease is relatively rare in the United Kingdom and KIR3DL1 is 
known to be highly polymorphic, we needed to plan to sufficiently power the study in 
order to have confidence in our findings. Hence the reason for basing the project in 
Istanbul. Prof Gul has previously published work describing large numbers families with 
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Behçet’s Disease in Istanbul and family-based genetic association studies have 
significantly more power than case-control studies for rare diseases. 
 
Being an ophthalmologist, I had little laboratory training in medical school. So between 
2008 and 2014, I spent a lot of time in the clinical transplantation laboratory in Guy’s 
Hospital under the guidance of Dr. Robert Vaughan and Dr. Emma Lougee, who taught 
me the basics of molecular biology. I collaborated on a number of research projects, 
carrying out polymerase chain reactions (PCR), running agarose gels and working on a 
single-specific oligonucleotide probe (SSOP) Luminex platform. Through this training I 
was introduced to Dr Paul Norman, who was at the time based in Prof. Peter Parham’s 
laboratory in Stanford, CA, USA and was very helpful in planning my PhD project. 
 
Between 2009 and 2014, life, training, family and parental illness prevented me from 
starting my PhD abroad and so in February 2014, I registered for a PhD in Queen Mary 
University London under the supervision of Prof. Farida Fortune, who kindly offered to 
host my project in her laboratory. This PhD wouldn’t have been possible without her 
support and supervision as well as all the people mentioned above and in the 
acknowledgments section of this Thesis.  
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1 Introduction 
1.1 History of Behçet’s Disease 
 
Behçet’s Disease (BD) is a chronic, relapsing-remitting variable-vessel vasculitis, which 
can manifest with oral aphthous ulcers, genital ulcers, papulopustular and erythema 
nodosum-like skin lesions, uveitis, retinal vasculitis, thrombophlebitis, arterial 
aneurysms, neurological disease, gastrointestinal disease and arthritis. The disease is 
found primarily along the ancient Silk-Road from the Mediterranean Basin across Asia to 
Japan (Sakane et al., 1999; Verity et al., 1999). 
 
The constellation of symptoms that make up BD have been described by a number of 
historical figures from the years 400 before the common era (BCE) -1937 common era 
(CE) (Figure 1-1). Behçet’s disease was introduced to the modern mainstream literature 
in 1937 by Hulusi Behçet, a Turkish dermatologist and venereologist working in Istanbul 
Medical Faculty. He described three patients who presented with skin lesions, ocular 
inflammation and oral ulceration and published his findings in Dermatologische 
Wochenschrift – a German publication, which focused on dermatological disease and 
manifestations of syphilis. Behçet stated that these patients had no signs of tuberculosis, 
syphilis or septicaemia and concluded that they were suffering from a previously 
undescribed condition. He hypothesised that the disease was caused by a dental infection, 
possibly viral, triggering the observed symptoms. Behçet presented his theory at the 
Dermatology Association of Paris in the same year. Over the following years a number 
of cases were reported from Europe, Israel, America and Japan and in 1947, the year 
before Hulusi Behçet’s death, during an International Medical Congress in Geneva the 
disease was named Morbus Behçet and later Behçet’s Disease (Sungnack Lee, 2001). 
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Despite this, it is unlikely Behçet was the first physician to describe the clinical entity 
now known as BD.  
 
In the 4th century BCE, Hippocrates of Kos wrote: 
 
…but there were also other fevers, as will be described. Many had their mouths affected 
with aphthous ulcerations. There were also many defluxions about the genital parts, and 
ulcerations, boils (phymata) externally and internally, about the groins. Watery 
ophthalmies of a chronic character, with pains; fungous excretions of the eyelids, 
externally and internally, called fici, which destroyed the sight of many persons. There 
were fungous growths in many other instances, on ulcers, especially on those seated on 
the genital organs. There were many attacks of carbuncle through the summer, and other 
affections called ‘rot’; also large ecthymata, and large herpetic lesions in many 
instances."- The Third Book of the Epidemion (460-377 BCE), (Hirschberg, 1899). 
 
This constellation of symptoms bears striking similarity to the syndrome now known as 
BD. Six hundred years later, in 200 CE a Chinese physician Zhong-Jing Zhan described 
a patient with a less-complete clinical phenotype: 
 
The disease of fox puzzling resembles damage due to cold. [The patient is] silent, desires 
to sleep but is not able to close their eyes, lying down and standing up restlessly. Sores in 
the throat are called puzzling, while sores in the yin are called fox-like. There is no desire 
to eat or drink, and [the patient] is averse to the odor of food. The face and eyes may be 
red, black or white. If sores develop in the upper region of the body, there will be 
hoarseness. (Zhang et al., 2013) 
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While a number of authors in the 19th century described clinical phenotypes including 
peripheral arthritis and uveitis, the next clear description of orogenital ulceration in the 
presence of relapsing hypopyon iritis was described in 1908 by Blüthe, followed by 
Planner and Remenovsky in 1923 and Shigeta in 1924 (Monacelli et al., 1966). 
 
Seven years prior to Behçet’s publication in Dermatologische Wochenschrift, an 
ophthalmologist based in Athens described a patient with uveitis, orogenital ulceration 
and, the following year thrombophlebitis. Benedictos Adamantiates published his 
findings in Proceedings of the Medical Society of Athens and Annales d’Oculistique in 
1931 and also described how the condition may present as monosymptomatic or 
oligosymptomatic (Zouboulis, 2002).  
 
Behçet's Disease is a heterogeneous condition and can be challenging to diagnose. In 1990 
the international study group (ISG) created the diagnostic criteria for BD (ISG, 1990). To 
satisfy the ISG definition of BD, patients must present with oral ulceration and at least 
two other features of BD (Table 1-1). In 2014, the International Team for the Revision of 
the International Criteria for Behçet's Disease published updated criteria based on a 
scoring system (ICBD criteria) (Table 1-2). 
 
 
 
 
 
 
 
 24 
Figure 1-1. Physicians Credited With Describing The Clinical Entity Now Known As 
Behçet’s Disease 
From left to right, Hippocrates (400BCE), Zhang Zhongjing (200CE), Benediktos 
Adamantiades (1930), Hulusi Behçet (1937) 
 
                  
 
The criteria was tested across 27 countries and was found to be more sensitive 93.9% vs 
81.2% but less specific than the ISG criteria 92.1% vs 95.9% (although this increased to 
98.5% in countries which carried out the pathergy test in more than 90% of their patients 
(International Team for the Revision of the International Criteria for Behçet’s, 2014). The 
rationale for a new scoring system was based around the over-emphasis of oral ulceration 
in the 1990 ISG criteria. The 2014 ICBD criteria made it easier to offer a diagnosis of BD 
and to recruit to clinical trials, although the authors emphasised that gold-standard 
remained an assessment by a clinician experienced in seeing individuals with BD. 
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Table 1-1. International Study Group Criteria For Behçet’s Disease, 1990.  
Patients must have oral ulceration PLUS two or more of the minor criteria to fulfil the 
criteria for diagnosis. 
 
Recurrent Oral 
Ulceration: 
 
 
Minor aphthous, major aphthous, or herpetiform ulceration 
observed by physician or patient, which recurred at least 3 times in 
one 12-month period. 
Minor Criteria: 
Recurrent genital 
ulceration: 
Aphthous ulceration or scarring, observed by a physician or patient. 
Eye lesions: Anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp 
examination; or retinal vasculitis observed by an ophthalmologist. 
Skin lesions: Erythema nodosum observed by physician or patient, 
pseudofolliculitis, or papulopustular 
lesions; or acneiform nodules observed by a physician in post-
adolescent patients not on corticosteroids. 
Positive Pathergy 
test 
Read by a physician at 24 - 48 hours 
 
Table 1-2. The International Criteria For Behçet’s Disease, 2014.  
A score of four or more is required for a diagnosis of Behçet’s Disease. 
 
Sign/Symptom Score 
Ocular lesions 2 
Genital aphthosis 2 
Oral aphthosis 2 
Skin lesions 1 
Neurological manifestations 1 
Vascular manifestations 1 
Positive pathergy test 1 
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1.2 Behçet’s Disease: Clinical Manifestations 
 
As mentioned above, BD offers diagnostic challenges and is difficult to manage. There 
are no laboratory tests, biomarkers or imaging studies that offer a definitive diagnosis. 
There is significant geographic variability in the clinical phenotype of the disease and as 
such, generalisations regarding age, ethnicity and sex must be made with caution.  
 
Behçet's Disease is a variable-vessel vasculitis, which affects most organ systems. 
Patients classically have a history of oral aphthous ulceration (often from childhood) and 
develop associated symptoms between the ages of 20-30 years. Several times a year a 
patient may experience a ‘flare’ at which point their mucocutaneous manifestations may 
worsen and other systems may become involved.  
 
Typically, BD is a condition affecting younger patients and it is relatively unusual for 
patients over the age of 60 years to present with severe symptoms. It is currently unclear 
why some patients are only affected by mucocutaneous manifestations of the disease, 
whereas others develop neurological, ocular or gastrointestinal disease requiring long 
periods of immunosuppression. 
 
1.2.1 Orogenital Ulceration 
 
Orogenital aphthae are a hallmark feature of BD. Oral ulceration occurs in 97-100% of 
patients (Yurdakul et al., 2008) and can occur in three forms (Taylor et al., 2014):  
 
1. Minor aphthae – less than 10mm, can occur in isolation or in clusters. Healing 
takes between 7-10 days. Periods of ulceration are typically followed by ulcer-
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free periods of varying length. Minor aphthae can affect the labial and buccal 
mucosa as well as the tongue and oropharynx. 
2. Major aphthae are larger than 10mm in diameter and affect deeper tissues. Healing 
can take up to a month and often leaves significant scarring. 
3. Herpetiform ulcers are tiny clusters of ulcers less than 1mm in diameter and are 
often associated with severe pain. 
 
Pharyngeal ulceration may be mistaken as tonsillitis and patients can be misdiagnosed for 
some time before other features of BD clarify the diagnosis (Lehner, 1977). 
 
Differentiation between recurrent aphthae in BD from the ulceration seen in other 
associated diseases is often difficult for the following reasons: 
 
1. Aphthae may precede a definitive diagnosis of BD in up to 71% of patients (Dilsen 
et al., 1993). 
2. Aphthae may be absent at presentation of systemic disease (Shimizu et al., 1998). 
3. The systemic manifestations of BD are not idiosyncratic and occur in a number of 
other diseases involving recurrent oral ulceration.  
 
Genital ulceration occurs in 57–93% of patients (Zouboulis, 1999). The ulcers are similar 
in morphology to oral aphthae but occur less frequently and often scar. These ulcers cause 
significant morbidity due to pain in urinating and walking. The scrotum is the most 
commonly affected area in men, although ulceration can occur anywhere on the shaft or 
glans of the penis as well as in the perianal area. In women, ulceration most commonly 
affects the vulva and labia, but can be found in the vagina and cervix. There are a number 
of other causes of orogenital ulceration (Table 1-3) including drug reactions, viral 
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infections and neoplasm, so a detailed history must be taken before a diagnosis of BD can 
be made on the basis of orogenital ulceration. 
 
1.2.2 Dermatological Disease 
 
Patients with BD may present with pseudofolliculitis, pustulosis and erythema nodosum. 
These are non-specific signs and can occur in a number of other disease processes. In 
addition, adult-onset acneiform lesions can occur, typically on the upper back and are 
more common in men. 
 
A positive pathergy reaction is part of the ICBD 2014 diagnostic criteria (although only 
if performed in >90% of patients). The pathergy reaction is caused by a neutrophilic 
inflammatory response induced by a sterile needle prick and is read at 24-48hrs (Sobel et 
al., 1973). If a raised erythematous papule >2mm in diameter is present, then the test is 
positive. 
 
Historically, a positive pathergy reaction was considered pathognomonic of BD 
(Katzenellenbogen et al., 1965), however, there are a number of other conditions that can 
also cause positive results such as pyoderma gangrenosum, chronic myeloid leukaemia, 
rheumatoid arthritis and Crohn’s disease (Varol et al., 2010). 
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Table 1-3. Causes Of Orogenital Ulceration 
There are a variety of causes of orogenital ulceration. The following table is adapted from 
(Keogan, 2009). 
 
 
 
Causes of oral 
ulceration and 
orogenital ulceration. 
Recurrent oral ulcers – genital 
ulceration not reported or 
very rare 
Recurrent oral or orogenital 
ulceration 
Idiopathic Recurrent oral stomatitis 
Periodic Fever, Aphthous 
Stomatitis, Pharyngitis, 
Cervical Adenitis (PFAPA) 
Familial Hibernian fever 
Complex aphthosis 
Multi-system, 
immune-mediated 
disease 
Systemic Lupus 
Erythematosis (SLE) 
Behçet's syndrome 
Reiter's syndrome 
Mouth and genital ulcers 
with inflamed cartilage 
(MAGIC) 
Gastrointestinal Ulcerative colitis 
Coeliac disease 
Other malabsorption states 
Crohn's disease 
Nutritional Iron 
B12 and folate deficiency 
 
Dermatological 
 
Sweet's syndrome 
Erythema multiforme 
Bullous skin disease 
Erosive lichen planus 
Fixed drug reaction 
Infection Human Immunodeficiency 
Virus (HIV) 
Chickenpox 
Hand, foot and mouth disease 
Cytomegalovirus (CMV) (in 
immunocompromised 
patients) 
Herpes simplex virus 
(HSV1) 
Drug reaction Nicorandil (anal ulcers also 
reported) Bisphosphonates 
Non-steroidal anti-
inflammatory drugs 
(NSAIDs) 
Haematological 
 
Cyclical neutropenia 
Lymphoma 
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1.2.3 Rheumatological Manifestations 
 
Joint involvement in patients with BD has been reported to occur in 11-93% of patients 
(Caporn et al., 1983; Salvarani et al., 2007). The wide range in frequency is likely to be 
due to differing diagnostic criteria and natural patient variation across the world. In a 
recent study from Iran involving 2,312 patients, the authors reported rheumatological 
complications in 50% of individuals over 5 years (Fatemi et al., 2015). 
 
Typically, patients present with a non-erosive inflammatory monoarthritis. A number of 
joints may be involved; most commonly the knee (34%), ankle (26%) , elbow (11%) and 
wrist (10%) (Fatemi et al., 2015). Behçet's disease-related arthritis can be self-limiting 
and last from weeks to months.  
 
1.2.4 Neurological Disease 
 
Neuro-Behçet’s disease can either manifest as parenchymal or vascular disease (Table 
1-4). Parenchymal involvement can often be mistaken for other diseases (such as 
demyelination) and can occur anywhere from the basal ganglia to the pyramids and spinal 
cord. Patients with vascular disease may present with symptoms of raised intracranial 
pressure due to cerebral sinus thrombosis, or develop aneurysmal disease and arterial 
occlusion. Patients may also present with meningitis or meningoencephalitis.  
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Table 1-4. Neurological Manifestations Of Behçet’s Disease  
Neuro-BD is typically classified as either parenchymal or non-parenchymal. Amended 
from (Al-Araji and Kidd, 2009) 
 
Central nervous system 
Parenchymal 
• Brainstem 
• Diffuse (“brainstem plus”) 
• Spinal cord 
• Cerebral 
• Asymptomatic (“silent”) 
Non-parenchymal 
• Cerebral venous thrombosis: intracranial hypertension 
• Intracranial aneurysm 
• Extracranial aneurysm/dissection 
Peripheral nervous system (relation to Behçet’s disease uncertain) 
• Peripheral neuropathy and mononeuritis multiplex 
• Myopathy and myositis 
Other uncommon but recognised syndromes 
• Acute meningeal syndrome 
• Tumour-like neuro-Behçet’s Disease 
• Psychiatric symptoms 
• Optic neuropathy 
 
Central nervous system (CNS) involvement carries a poor prognosis, usually appears late 
in the disease and follows a relapsing and remitting course in up to 40% of cases. It is 
usually considered a rare manifestation of BD occurring in 1% of cases (Tursen et al., 
2003).  
 
1.2.5 Vascular Disease 
 
Both arterial and venous disease can occur in BD and vascular involvement is the leading 
cause of mortality in BD (Saadoun et al., 2010). Large vessel involvement has been 
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reported in 1.8-39.4% of patients (Bang et al., 2001; Duzgun et al., 2006). Vascular 
involvement of BD is characterised by aneurysm and pseudoaneurysm formation in 
arteries and thrombotic occlusion in arteries and veins (S. S. Yang et al., 2013). In a survey 
of 1,200 patients in Turkey, 14% of patients had venous involvement (mostly venous 
thrombosis) and 1.6% had arterial involvement, including aneurysms of the femoral, 
abdominal, popliteal and pulmonary arteries (Kuzu et al., 1994). A more recent study in 
China retrospectively analysed 796 patients with BD. They found 13% of patients had 
vascular involvement and in 28% it was their initial presenting feature. The authors also 
found that 20% of patients with vascular involvement had cardiac disease, compared to 
3% of BD patients with no documented vascular disease (Fei et al., 2013). 
 
1.2.6 Ocular Disease 
 
The frequency of ocular BD varies around the world. In some ethnic groups, inflammatory 
eye disease occurs in over 50% of patients (Yazici et al., 2007). Uveitis is the most 
common ocular manifestation and can be present in 90% of patients (P. Yang et al., 2008). 
Behçet’s uveitis can be challenging to treat and up to 90% of untreated patients will lose 
all vision in both eyes within 4 years (Benezra et al., 1986). One of the current 
epidemiological challenges in BD is to understand better the frequency of ophthalmic 
manifestations across the globe. There is currently no data describing the incidence and 
phenotypic range of ophthalmic disease within the United Kingdom.  
 
Behçet’s disease can affect the anterior structures of the eye and result in anterior uveitis 
with relapsing hypopyon and raised intraocular pressure. If there is no posterior segment 
involvement, these patients can be managed with topical treatment and close observation.  
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Posterior segment involvement can result in vitritis, retinal vasculitis, retinal infiltrates, 
optic disc swelling and retinal vascular occlusion. Posterior uveitis in BD can be sight 
threatening and should be managed urgently. Unless the inflammation is brought under 
control in a timely manner, anterior and posterior synechiae, cataract and rubeosis iridis 
with secondary glaucoma will occur. In patients with recurrent vascular occlusions 
secondary pipe-stem fibrosis occurs, leading to an ischaemic retina and a pale optic-disc. 
End-stage disease leaves patients with no perception of light in either eye. 
 
While there have been significant advances in the field of immunotherapeutics over the 
past 30 years, a significant number of patients continue to lose vision because of Behçet’s 
uveitis. In 2008, a study of 400 patients with BD in China reported that over 20% of eyes 
still became legally blind despite ‘aggressive treatment’ (P. Yang et al., 2008).  
 
 
1.3 Behçet’s Disease – Epidemiology 
 
Behçet’s Disease was labeled the ‘Silk-Road Disease’ by Shigeaki Ohno in 1982 (Ohno 
et al., 1982). This was based on the observed disease prevalence in the region between 
Japan and the Middle East between 30-45 degrees latitude (Figure 1-2). 
 
The prevalence of BD varies across the world (Figure 1-1) and is significantly lower in 
countries that lie outside the path of the ancient Silk-Road. In the UK, prevalence has 
been estimated to be 0.64 per 100,000 (Lehner et al., 1979), although recent data from our 
unit suggest that a more accurate estimate is nearer 2 per 100,000 (unpublished data). By 
comparison, a prospective study in 2003 estimated the prevalence of BD in Istanbul to be 
as high as 420 per 100,000 (Azizlerli et al., 2003).  
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Figure 1-2. Map Displaying Human Leukocyte Antigen (HLA)-B*51 Allele Frequency 
Across The World And The Location Of The Silk-Road 
Possession of HLA-B*51 is concentrated across the ancient Silk-Route. Migration routes 
across the Bering Straits led to the appearance of HLA-B*51 in North and eventually, 
South America. Despite similar levels of HLA-B*51 frequency in some areas of South 
America to those in Central Asia, the prevalence of Behçet’s Disease is significantly 
lower. Reproduced with permission (Verity et al., 1999)  
 
 
 
As can be seen in Table 1-5 and Figure 1-2, HLA-B*51 carries a strong geographic 
correlation with BD. Whether HLA-B*51 is directly involved in the pathogenesis of BD, 
or whether it is correlated with the disease due to strong LD with another causative allele 
remains to be determined (E. H. Hughes et al., 2005; T. Hughes et al., 2013; Kirino et al., 
2013; Ombrello, Kirino, et al., 2014; Remmers et al., 2010).  
 
Behçet’s disease is thought to occur due to an environmental trigger in genetically 
predisposed individuals. It is a complex condition and not fully explained by a single gene 
mutation. A small group of individuals have been identified with a Behçet’s-like disease 
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(Zhou et al., 2016), which behaves in a monogenic Mendelian-manner and arises from 
pathogenic variants of the tumour necrosis factor α induced protein 3 (TNFAIP3). When 
assessing individuals with BD-like symptoms it is important to consider other 
autoinflammatory diseases that may present with a BD-crossover clinical phenotype (e.g. 
Cryopyrin associated period syndrome (CAPS), or Familial Mediterranean Fever (FMF)). 
These individuals respond well to anti-interleukin 1 monoclonal antibody therapy and are 
managed quite differently to those with BD (Lopalco et al., 2015). 
 
Differences in disease prevalence among recent migrants compared with those residing 
in their home country help establish a role of the environment, while differences in disease 
prevalence among individuals of different ancestries residing in the same region reflect 
the role of genetics in disease pathogenesis (Takeuchi et al., 2015). For instance, the 
prevalence of BD is reduced among Turks who recently immigrated to Germany (15.1 
per 100,000) compared with those residing in Turkey (80-420 per 100,000), but is 
nevertheless high compared with individuals of German ancestry who live in Germany 
(0.30 per 100,000) (Papoutsis et al., 2006). 
 
1.4 The Genetic Basis For Behçet’s Disease  
 
There is some evidence of familial aggregation in BD, which supports the involvement of 
genetic factors in its pathogenesis (Gul et al., 2000). A study examining a Turkish 
population reported that 4.2% of siblings of individuals with BD fulfil the ISG criteria for 
BD themselves (Gul et al., 2000). Aggregation varies with ethnicity and is highest 
amongst Turks (18.2%) followed by Koreans (15.4%) and Jews (13.2%). Patients of 
Chinese and Japanese extraction have lower rates of familial aggregation (2.6 and 2.2% 
respectively) (Fietta, 2005; Zouboulis, 1999). Stronger familial aggregation was observed 
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among early onset BD patients compared with individuals with disease onset in adulthood 
(Kone-Paut et al., 1999). Whether this tendency toward familial aggregation in younger 
patients represents a spectrum between the dominantly inherited TNFAIP3-related 
disease (Zhou et al., 2016) and sporadic BD remains to be seen.  
 
Table 1-5. Prevalence Of Behçet’s Disease Across The World And The Allele Frequency 
Of HLA-B*51 In Patients And Controls. 
 
Behçet’s Disease typically presents between 30-45° latitude. This table shows populations 
at various latitudes and their HLA-B*51 allele frequencies. Adapted from (Piga et al., 
2011). BMTR – UK Bone Marrow Transplant Registry. AF – Data available on 
www.allelefrequencies.net 
 
Latitude 
(°N) 
Region 
(country) 
Prevalence 
per 
100,000 
Mean 
Freq. 
HLA-
B*51 in 
controls 
(%) 
References Freq. 
HLA-
B*51 
in BD 
(%) 
References 
56 Scotland 
(UK) 
0.27 3.9 (Bodmer, 
1996) 
13 (Jankowski et al., 
1992) 
53 Yorkshire 
(UK) 
0.63 7  
 
BMTR 18 (Chamberlain, 
1977) 
52 German 
(Berlin, 
Germany) 
0.55 12 (Kotter et 
al., 2001) 
36 (Zouboulis et al., 
1997) 
52 Turkish 
(Berlin, 
Germany) 
20.75 25 (Kotter et 
al., 2001) 
75 (Zouboulis et al., 
1997) 
44 Reggio 
Emilia 
(Italy) 
3.8 18 (Capittini 
et al., 
2009) 
57 (Ambresin et al., 
2002) 
42 Chinese 14.0 24 AF 56 (Mineshita et al., 
1992) 
41 Istanbul 
(Turkey) 
420.0 15 (Arnaiz-
Villena et 
al., 2001) 
NA (Azizlerli et al., 
2003) 
41 North-East 
Turkey 
370.0 34 AF 26 (Yurdakul et al., 
1988) 
41 North 
West 
Turkey 
20.0 28 AF 28 (Cakir et al., 
2004) 
40 Spain 7.5 10 AF 37 (Riera-Mestre et 
al., 2010) 
43 Hokkaido 
(Japan) 
30.5 24 AF 28 (Mizuki et al., 
1999) 
37 Japan 13.5 14 (Ikeda et 
al., 2015) 
59 (Kaburaki et al., 
2010) 
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37 Korea 7.3 9 (Yoon et 
al., 2010) 
53 (Park et al., 2002) 
33 Iraq 17.0 27 AF 62 (Al-Rawi et al., 
1986) 
32 Israel 15.2 8 AF 29 (I. Krause et al., 
2007) 
32 Druze 
(Israel) 
146.4 12 AF 100 (I. Krause et al., 
2007) 
32 Arab 
(Israel) 
26.2 43 (I. Krause 
et al., 
2007) 
81 (I. Krause et al., 
2007) 
32 Jewish 
(Israel) 
8.6 38 (I. Krause 
et al., 
2007) 
72 (I. Krause et al., 
2007) 
32 Alexandria 
(Egypt) 
7.6 7 (El 
Menyawi 
et al., 
2009) 
58 (El Menyawi et 
al., 2009) 
26 Al 
Quassim, 
Saudi 
Arabia 
20.0 26 AF 72 (al-Dalaan et al., 
1994) 
 
1.4.1 HLA Nomenclature 
 
HLA nomenclature changed significantly in 2010. Currently, each HLA allele name has 
a unique number corresponding to up to four sets of digits separated by colons (Figure 
1-3). The length of the allele designation is dependent on the sequence of the allele and 
that of its nearest relative. All alleles receive at least a four-digit name, which corresponds 
to the first two sets of digits. Longer names are only assigned when necessary. There are 
a number of suffixes which can also be added to an HLA type (Table 1-6), these suffixes 
indicate the expression of the particular HLA in question (Robinson et al., 2015; Robinson 
et al., 2001).  
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1.4.2 HLA Associations In Behçet’s Disease 
 
 
Over the past 30 years, HLA nomenclature has become more sophisticated to allow for 
the huge allelic variation present across HLA. When Ohno et al. first discovered the 
association between HLA and BD, his paper reported “an association with HL-A5” (Ohno 
et al., 1973). Over the following decades this association has become more specific. At 
present, the strongest HLA association in BD is HLA-B*51:01:01 although in many 
papers it is referred to in lower resolution as HLA-B*51. The HLA-B*51 association has 
become recognised as the most frequently observed genetic factor in BD and is present in 
between 13-80% of patients depending on ethnicity (Gul, 2011).  
 
Figure 1-3. Current HLA Nomenclature System 
The current nomenclature was modified in 2010 and is explained below. 
 
 
 
HLA-B*51:01:01:01 
 
 
 
 
 
 
 
 
Alleles that only differ by sequence 
polymorphisms in the introns or in the 5' 
or 3' untranslated regions that flank the 
exons and introns are distinguished by the 
use of a fourth set of digits. 
The digits before the first colon 
describe the type, which often 
corresponds to the serological 
antigen carried by an allotype 
The digits after the colon are used 
to list the subtypes, numbers 
being assigned in the order in 
which DNA sequences have been 
determined. Alleles whose 
numbers differ in the two sets of 
digits must differ in one or more 
nucleotide substitutions that 
change the amino acid sequence 
of the encoded protein. 
Alleles that differ only by synonymous 
nucleotide substitutions (also called silent 
or non-coding substitutions) within the 
coding sequence are distinguished by the 
use of the third set of digits 
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Table 1-6. Suffixes In HLA Nomenclature  
There are a variety of suffixes that can be used to describe the expression of HLA allotypes 
 
Suffix Meaning Explanation 
N Null No surface expression 
L Low Low surface expression compared to normal levels 
S Secreted Secreted, but not present on cell surface 
C Cytoplasm Present in the cytoplasm but not the cell surface 
A Aberrant There is some doubt as to whether the protein is expressed 
Q Questionable Questionable expression given that the mutation seen in the 
allele was previously thought to affect normal expression 
 
In a study examining geographical variation of HLA-B*51 in BD, HLA-B*51 was 
sequenced in 24 patients with BD and 13 healthy controls of Japanese, Turkish, Jordanian, 
and Iranian decent (Takemoto et al., 2008). The authors confirmed that all individuals 
carried HLA-B*51:01:01 with no variation in the exons, introns, or 5'-flanking region. 
This study confirmed that the allele associated with BD is likely to be HLA-B*51:01:01 
(as opposed to a different subset of HLA-B*51 alleles). The following year, a large meta-
analysis examining the role of HLA-B5 and HLA-B*51 in BD was carried out. Eighty 
papers met the inclusion criteria for analysis. The authors found that in a pool of 4800 BD 
patients and 16, 289 controls from across the world, the pooled odds ratio (OR) was 5.78 
(5.00-6.67 95% CI). Moreover, the effect was similar for patients from regions with a 
lower incidence of HLA-B*51 in the control population, such as Northern Europe (Table 
1-7) (de Menthon et al., 2009).  
 
Over the years there have been numerous studies analysing the effect size of HLA-B*51 
in BD, ranging from 1.18 (0.34-4.07 95% CI) (O'Duffy et al., 1976) to 34.63 (4.13 – 
290.22 95% CI) (Pittoni et al., 2003) (Table 1-7). Comparisons between these studies 
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should be drawn with care for a number of reasons; firstly, the sample populations and 
the control populations may overlap in different studies; secondly the techniques used for 
genotyping may vary and thirdly publication bias may skew the data (publication bias 
analysis in the de Menthon paper was equivocal and depended on the techniques used for 
analysis (de Menthon et al., 2009)). 
 
Whether the HLA-B*51 has a causative role in disease pathogenesis or is merely 
associated with the disease due to confounding factors has been a matter of speculation 
for decades. It is noteworthy that all 80 papers analysed by de Menthon et al. reported an 
odds ratio of > 1. Given the overall OR of 5.78, it is less likely that the association between 
HLA-B*51 and BD is entirely due to confounders such as LD (Campbell et al., 2002).  
 
In 2014, Ombrello et al. performed a large association study involving 1,190 BD cases 
and 1,257 matched controls from Turkey and an ethnically diverse European reference 
panel of 5,225 individuals. The study focused on single nucleotide polymorphisms (SNP) 
within the major histocompatibility complex (MHC) and used both direct typing and 
imputation based methods based on previous genome wide association (GWA) data 
(Ombrello, Kirino, et al., 2014). Using stepwise and multivariate logistic regression over 
HLA-B and adjusting for multiple SNPs revealed no additional genome-wide significant 
associations for markers in the HLA-B or the major histocompatibility complex class I 
chain related gene A (MICA) region. 
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Table 1-7. Pooled Odds Ratios For HLA-B*51/B5 And Their Association With Behçet’s 
Disease 
While HLA-B*51 has a robust effect on disease-risk, there is significant heterogeneity 
between study-populations across all ethnicities. Phet – P for heterogeneity statistic. n 
pop – number of populations studied. Adapted from (de Menthon et al., 2009) 
 
 
Pooled prevalence for HLA-B*51/B5 
Subgroups n 
Pop 
BD 
(95% CI) 
Control 
(95% CI) 
OR (95% 
CI) 
I2 
(%) 
Phet 
Overall 80 57.2 (53.4-
60.0) 
18.1 (16.1-
20.3) 
5.78 (5.00-
6.67) 
60.6 0.0001 
Eastern Asia 25 55.0 (49.8-
60.1) 
19.6 (16.0-
23.7) 
5.18 (4.15-
6.47) 
52.2 0.001 
Middle East/North 
Africa 
27 63.5 (58.8-
68.0) 
21.7 (18.2-
25.7) 
6.25 (4.87-
8.03) 
70.4 0.0001 
Southern 
Europe 
15 60.6 (51.9-
68.7) 
16.8 (13.3-
21.0) 
7.20 (4.89-
10.62) 
57.2 0.003 
Northern 
/Eastern Europe 
11 39.0 (28.2-
51.1) 
11.2 (8.1-
15.3) 
5.31 (3.35-
8.40) 
55.6 0.013 
North America 2 34.2 (6.0-
80.8) 
18.0 7.6-
37.1) 
2.35 (0.56-
9.82) 
57.0 0.13 
 
Two regions between HLA-B/MICA and HLA-A/HLA-F achieved genome-wide 
significance (P<1.7×10−8). Of note, HLA-B*51, B*15, B*27, B*57, and each contributed 
independently to BD risk (Figure 1-4). Protective effects were seen from HLA-A*03 and 
HLA-B*49. 
 
One year prior to the publication by Ombrello et al., Hughes et al. reported contrasting 
findings from a Turkish discovery (503 cases and 504 controls) and Italian validation (144 
cases and 1,270 controls) cohort (Figure 1-5). The authors used dense HLA typing and 
imputation to mine the region for associated SNPs. The results were subjected to a meta-
analysis using control haplotypes from the 1,000 Genomes Project and the data revealed 
that the strongest association signal was a SNP, rs116799036, located approximately 24 
kb upstream of HLA-B and 18 kb upstream of MICA with genome-wide significance.  
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Figure 1-4. Fine Mapping Of The HLA Locus In A Turkish Cohort 
The authors used a European reference panel and found two regions achieving genome 
wide significance (P<1.7×10−8): the region between HLA-B/MICA and HLA-A/HLA-F. 
Reproduced with permission from (Ombrello, Kirino, et al., 2014). 
 
 
Figure 1-5. Meta-Analysis Of 24,834 Markers In Turkish And Italian Cohorts 
The authors found that the effects of rs116799036 were significant despite controlling for 
HLA-B*51. When the effects of rs116799036 were controlled for, the association with 
HLA-B*51 were abrogated. Reproduced with permission from (E. H. Hughes et al., 2005) 
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To determine whether the effect of rs116799036 could be explained by LD to HLA-
B*51:01, and vice versa, Hughes et al. performed conditional analyses. Surprisingly, a 
genome-wide significant association of rs116799036 remained after conditioning on 
HLA-B*51:01. On the other hand, the genome-wide significant association of HLA-
B*51:01 completely disappeared after conditioning on rs116799036. These findings 
suggested HLA-B*51 may not have a primary association with BD, but be associated via 
epistasis. 
 
The association of rs116799036 identified by Hughes et al. was also identified by 
Ombrello et al. but the effect was seven orders of magnitude weaker than that of HLA-
B*51. Furthermore, the association of HLA-B*51 with BD remained significant even after 
conditioning for the effect of rs116799036.  
 
Various theories have been suggested to explain the role of HLA-B*51 in disease 
pathogenesis. HLA class I molecules play a central role in the immune system and, despite 
the lack of direct experimental evidence for this theory, it is hypothesised that HLA-B*51 
triggers BD by means of selective binding of pathogenic peptides (Verity et al., 1999). 
 
In favour of a causative hypothesis is the strong association between the disease and 
presence of HLA-B*51:01:01 in different populations (Takemoto et al., 2008). Dense 
genotyping arrays using large discovery and validation cohorts have found a similar 
association (Kappen et al., 2015; Ombrello, Kirino, et al., 2014). Furthermore, it seems 
logical that an error in antigen presentation may cause an inflammatory disease such as 
BD. However, this argument does not explain the pathogenesis in HLA-B*51- individuals, 
nor does it propose a pathogenic pathway that could be investigated further.  
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1.4.3 The Role of HLA-B*51 in Behçet’s Disease 
 
HLA-B*51’s role in the development of BD has yet to be clarified. Available data suggests 
that there is no single pathogenic mechanism associated with HLA-B*51, and its effects 
may be mediated by a combination of different HLA Class-I associated functions and 
structural properties. 
 
1.4.3.1 Presentation of HLA-B*51-Restricted Peptides to CD8 T Cells 
 
One possible role may be the presentation of HLA-B*51-restricted peptides to CD8+ T 
cells inducing a disease-specific adaptive immune response. A key characteristic of HLA-
B*51 is its ability to bind a large pool of peptides including those with low-affinity, thus 
allowing promiscuous behavior in the presentation of peptides to CD8+ T cells 
(Gebreselassie et al., 2006).  
 
It has also been reported that there are increased proportions of CD8+ T cells and γδ+ T 
cells in patients with active disease, especially those who possess HLA-B*51, compared 
toinactive patients and healthy controls (Yasuoka et al., 2008).  
 
However, to date, there have been no in vivo studies that have shown HLA-B*51 
restricted CD8+ T cell activation or disease-specific pathogenic cytotoxic immune 
responses.  
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1.4.3.2 Structural and Ligand-Binding Properties of HLA-B*51 
 
The structure of HLA-B*51 molecule may itself trigger an autoinflammatory response. 
The unique folding and ligand binding properties of HLA-B*51 molecule distinguish it 
as a slow-folding MHC molecule (Giza et al., 2018; Sakaguchi et al., 1997). Low affinity 
peptides can lead to slow assembly and misfolding of the HLA-B*51 molecule, which 
could lead to an autoinflammatory response and stress within the endoplasmic reticulum 
(ER). The ER stress and unfolded protein response have been proposed as possible 
pathogenic mechanisms associated with HLA-B*27 in ankylosing spondylitis, another 
MHC Class I-associated disease, based on data coming from HLA-B*27–transgenic 
animal models (Turner et al., 2007). But, there is as yet no evidence supporting the HLA-
B*51-associated ER stress in the pathogenesis of BD. 
 
1.4.3.3 Presentation of HLA-B*51 Derived Peptides by HLA Class II 
 
It is possible that peptides derived from the digestion of HLA-B proteins, including HLA-
B*51, can be presented by HLA Class-II molecules and induce an adaptive immune 
response.  
 
There have been previous reports that a polymorphic amino acid sequence derived from 
digestion of HLA-B*27 shared homology with retinal S-antigen, an antigen associated 
with uveitis (Wildner et al., 1994). While it is intriguing to hypothesise that 
autoinflammatory responses could be generated from breakdown of specific HLA Class 
I molecules, this observation cannot explain the specific association of HLA-B*51 allele 
with BD.  
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1.4.3.4 Increased Neutrophil Activation In HLA-B*51+ Transgenic Mice 
 
There is no established animal model for BD. Historically, there have been a number of 
attempts to create such an animal. The herpes simplex virus (HSV) mouse model has been 
suggested as a candidate, as some animals get recurrent mucosal ulceration and 
inflammatory bowel and joint disease. (Cho et al., 2013; Choi, Kim, et al., 2011). There 
is no established HLA-B*51 transgenic animal model for testing all possible pathogenic 
mechanisms related to HLA-B*51in BD pathogenesis. One group in Japan, developed an 
HLA-B*51+ transgenic mouse model, which developed no symptoms of BD, but did 
display increased neutrophil activation, compared to HLA-B*35 and wild-type mice 
(Takeno et al., 1995). This observation has not been repeated or fully explained by the 
inclusion of HLA-B*51 into the system, however similar enhanced neutrophil activity has 
been observed in reported in HLA-B*51+ healthy individuals as well as in BD (Sensi et 
al., 1991; Takeno et al., 1995).  
 
1.4.4 Genome Wide-Association Studies  
 
To date, eight genome wide association studies (GWAS) investigating BD have been 
carried out and a number of candidate genes have been implicated as well as non-coding 
regions located between the HLA-A - HLA-F loci (Meguro et al., 2010; Mizuki et al., 
2010). These GWAS studies have mainly been carried out in the regions of the world 
where BD is most prevalent (Turkey, Japan, China, Korea and Iran), although recently a 
mixed population of patients with BD from the Netherlands was reported (Fei et al., 2009; 
Hou et al., 2012; Kappen et al., 2015; Kirino et al., 2013; Y. J. Lee et al., 2013; Mizuki et 
al., 2010; Remmers et al., 2010; Xavier et al., 2015). All GWAS studies reported an 
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association within the MHC, but there has been considerable inter-study heterogeneity 
with regard to other reported associations. The key associations are reported in Table 1-8. 
 
Table 1-8. Other Single Nucleotide Polymorphisms Associated With Behçet’s Disease 
There have been eight genome wide association studies in BD. While some of the findings 
have been replicated across different populations, others have only been found in specific 
study populations. PBMCs – peripheral blood mononuclear cells, LPS – 
lipopolysaccharide, MDP – muramyl dipeptide. Gene acronyms can be found in the 
glossary. Adapted from Takeuchi et al, 2015. (Takeuchi et al., 2015). 
 
 
Variant Gene Location Risk Allele OR Population Function 
     Discovery Validation  
rs1495965 IL23R, 
IL12RB2 
Intergenic G 1.35 Japanese Turkish  
rs924080 IL23R, 
IL12RB2 
Intergenic A 1.28 Turkish 
and 
Japanese 
  
rs1518111 IL10 Intron A 1.45 Turkish Greek, 
UK, 
Iranian, 
Middle 
Eastern, 
Arab, 
Japanese, 
Han 
Chinese 
Reduces 
expression 
in 
monocytes 
rs1800871 IL10 Promoter T 1.45 Japanese Turkish, 
Korean, 
Han 
Chinese 
 
 
rs9494885 TNFAIP3 Intergenic C 1.81 Han 
Chinese 
 No 
difference 
in 
expression 
in PBMCs 
rs7574070 STAT4 Intron A 1.27 Turkish 
and 
Japanese 
 Increases 
expression 
rs897200 STAT4 Intergenic A 1.45 Han 
Chinese 
 Increases 
expression 
of STAT4 
and IL17 
rs7616215 CCR1 Intergenic T 1.39 Turkish Japanese Decreases 
expression 
in 
monocytes 
and reduces 
monocyte 
chemotaxis 
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rs13092160 CCR1, 
CCR3 
Intergenic T 3.13 Han 
Chinese 
 Decreases 
expression 
in PBMCs 
rs2617170 KLRC4 Missense C 1.28 Turkish 
and 
Japanese 
 Tag for 
haplotype 
associated 
with 
increased 
cytotoxicity 
of PBMCs 
M694V MEFV Missense V 2.65 Turkish  Increases 
response to 
LPS 
rs17482078 ERAP1 Missense TT 4.65 Turkish  Tag for 
haplotype 
with 
reduced 
peptide 
trimming 
activity 
rs681343 FUT2 Synonymous T 1.30 Iranian 
and 
Turkish 
 r2=1 with a 
nonsecretor 
allele 
(rs601338) 
 
rs1781046 IL12A Intergenic A/G 1.66 Turkish 
and mixed 
population 
  
R381Q, 
G149R 
IL23R Missense, 
missense 
 Protective Japanese 
and 
Turkish 
 Reduces 
IL-23 
dependent 
IL-17 
(R381Q) 
D299G, 
T399I 
TLR4 Missense, 
missense 
 Protective Japanese 
and 
Turkish 
 Reduces 
reponse to 
LPS 
R702W, 
G908R, 
L1007fs 
NOD2 Missense, 
missense, 
frameshift 
 Protective Japanese 
and 
Turkish 
 Reduces 
response to 
MDP 
 
1.4.5 The Major Histocompatibility Complex Class I Chain Related Gene A (MICA) - 
Nomenclature 
 
As previously mentioned, the international ImMunoGeneTics information system 
(IMGT) has created specific nomenclature for genes and proteins involved in the immune 
response. The nomenclature for MICA alleles follows the standardised rules of the IMGT 
(Lefranc et al., 2005). MICA sequences are defined for each allele the following IMGT 
criteria: 
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1. First sequence published 
2. Longest sequence 
3. Mapped sequence  
IMGT allele names are identified by the gene name followed by an asterisk and a 3-digit 
number, i.e. MICA*001. 
 
1.4.6 MICA Transmembrane Polymorphisms 
 
In 1997, Mizuki et al. found that a polymorphic microsatellite or Short Tandem Repeat 
(STR) was found in exon 5 (Mizuki, Inoko, et al., 1997). The STR consists of a variable 
number of trinucleotide GCTs encoding 4, 5, 6 or 9 Alanine (A) repeats and were 
accordingly named as A4, A5, A6, A9 and A10. There is also an A5.1 allele that contains 
five triplet repeats plus one additional nucleotide ‘G’. This insertion leads to a frameshift 
and results in a stop codon and premature termination. A substantial body of literature 
exists describing these STRs and their disease associations. A paper may only refer to the 
STR when describing the allele. This thesis will follow World Health Organisation 
(WHO) guidelines (Frigoul et al., 2005) and refer to an allele by its IMGT nomenclature 
followed by the STR in parenthesis, i.e. MICA*009 (A6).  
 
1.4.7 MICA Background 
 
The MIC locus is located approximately 46kb from HLA-B between HLA-B and TNFα 
(Bahram et al., 1994). The MICA transcript of 1482bp encodes a 383 amino acid 
polypeptide of 43kDa that is structurally very similar to classical MHC class I molecules. 
It is composed of 3 extracellular domains referred to as α1 (encoded by exon 2), α2 
 50 
(encoded by exon 3) and α3 (encoded by exon 4), a transmembrane region (encoded by 
exon 5) and a carboxy-terminal cytoplasmic tail (encoded by exon 6) (Bahram, 2000). 
However, it does not carry peptide cargo; is not complexed to b2-microgloubulin (B2M) 
and does not associate with transporter associated with antigen processing (Groh et al., 
2002). It is closely related to a sister protein, MICB, encoded from the same locus.  
 
Both MICA and MICB are stress inducible ligands for a C-type lectin receptor, natural 
killer group 2, member D (NKG2D), expressed primarily by subsets of cytolytic CD8+ T 
cells, gd T cells, and NK cells (Bauer et al., 1999). MICA proteins are expressed on 
primary tumours of epithelial origin (Dayanc et al., 2013; Ghadially et al., 2017) on 
leukaemias (N. Kato et al., 2007; Weiss-Steider et al., 2011); and on virus-infected cells 
(Goto et al., 2015; Tong et al., 2013). Recognition of MICA ligands by NKG2D 
homodimer receptors induce cytotoxic activity of NK cells and subsequent lysis of tumour 
or virally infected cells (Weiss-Steider et al., 2011). 
 
MICA is recognised as the most polymorphic, human, non-classical class I gene, with at 
least 87 alleles (http://hla.alleles.org/data/mica.html). Several studies have shown 
MICA*008 (A5.1) to be the most frequent allele in a variety of populations, with an allele 
frequency up to 74% in Caucasian populations (Fodil et al., 1999; Lucas et al., 2008; Luo 
et al., 2014; Norris et al., 2001; W. Tian et al., 2006). MICA*002 (A9) and MICA*004 
(A6) are more frequent in Sub-Saharan Africa (W. Tian et al., 2003) and MICA*020 and 
*027 are most frequent amongst South American Indians (Oliveira et al., 2008).  
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1.4.8 MICA In Behçet’s Disease 
 
Extensive work has been carried out over the past 2 decades to investigate the effect of 
MICA on BD pathogenesis and heritability (Frigoul et al., 2005). MICA*009 (A6) has 
been implicated in BD in Southern European, Middle Eastern, Central Asian and East 
Asian populations (Table 1-9). The majority of studies have found that the MICA*009 
(A6) effect is abrogated when controlling for HLA-B*51 as the two genes are in strong 
LD with each other. However, there is evidence to suggest that possession of HLA-B*51 
and A6 may have a cumulative effect increasing the risk of developing BD and, in Korean 
patients, it may carry the majority of the susceptibility (Park et al., 2002). It has also been 
suggested that the HLA-B*51/A6 effect may be largely mediated by a SNP at rs76546355 
(Carapito et al., 2015).  
 
A meta-analysis investigating the effects of MICA polymorphisms in BD was carried out 
in 2014 (Y. H. Lee et al., 2015). The authors found that MICA A6 and MICA*009 were 
both significantly associated with BD in all populations (OR 1.653, 95% CI 1.409-1.937, 
P<1.0x10-8), in Europeans (OR 1.436, 95% CI 1.111-1.857, P=0.006) and in Asians (OR 
1.999, 95% CI 1.551-2.575, P=8.0x10-8), but not in the Iranian, Arabic or Jewish 
populations. As expected, the association was significantly stronger for BD patients who 
also carried the HLA-B*51 gene. MICA*009 was also significantly associated with BD 
overall (OR 3.948, 95% CI 2.680–5.815, P<1.0x10−8); in Europeans (OR 3.392, 95% CI 
2.118-5.433, P=5.6x10-6) and in a Turkish population (OR 5.417, 95% CI 2.744-10.69, 
P=1.1x10-7). The authors found that MICA*009 was also strongly associated with HLA-
B*51+ individuals, but not HLA-B*51- individuals. 
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Table 1-9. MICA Allele And Microsatellite Repeat Associations In Behçet’s Disease 
 NS - No allele or microsatellite found to be significant. 
 
 
The association of MICA and MHC class I haplotypes with BD, suggests a major role in 
the disease for cells regulated by these molecules including NK cells and subsets of T 
cells (Mizuki, Ota, et al., 1997; Yabuki et al., 1999). While it is generally agreed that any 
association is likely to be due to linkage disequilibrium (LD) with HLA-B*51 (Cambra et 
al., 2009; Gao et al., 2006; W. Tian et al., 2001), MICA may have a functional role 
independent of HLA-B*51. Wallace et al. demonstrated that while MICA was in LD with 
HLA-B*51 and HLA-B*52, it only co-segregates with HLA-B*51 in the BD population 
(Wallace et al., 1999).  
 
MICA 
Allele 
MICA Exon 
5 TM 
microsatellite 
repeat Ethnicity 
Significant 
effect after 
Controlling 
for HLA-
B*51 Reference 
MICA*009 A6 East Asian Yes (Mizuki, Ota, et al., 1997; Park et al., 2002) 
NS A6 Southern European No (Picco et al., 2002) 
MICA*009 A6 Middle Eastern No (Carapito et al., 2015; Wallace et al., 1999) 
NS A5/A6 Central Asian No (Y. L. Chung et al., 2003) 
NS NS East Asian No (Mizuki et al., 1999; Mizuki et al., 2000) 
NS NS Southern European No 
(Gonzalez-Escribano et 
al., 1999; Mizuki et al., 
2000; Salvarani et al., 
2001; Yabuki et al., 1999) 
NS NS Middle Eastern No (Cohen et al., 2002; Mizuki et al., 2001) 
NS NS North African No (Ben Ahmed et al., 2003) 
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The affinity of MICA as a ligand for NKG2D is not uniform. Low affinity MICA have a 
valine at codon 129 and include MICA*019 and MICA*009, these receptors have a 10-
50 fold weaker affinity for NKG2D compared to those with methionine in position 129. 
Munoz-Saa et al. noted that none of their 42 BD patients expressed a high affinity 
phenotype for NKG2D compared to 14% of controls. Furthermore, autoimmune diseases 
such as anterior uveitis, ankylosing spondylitis and psoriatic arthritis are all associated 
with high affinity alleles. (Amroun et al., 2005; Gonzalez et al., 2001; Ricci-Vitiani et al., 
2000) 
 
Shafi et al. utilised a functional genomics system with a Chinese hamster ovary (CHO) 
cell line transfected with HLA-B*51/52 and MICA*008/*009/*027 to examine the role of 
MICA polymorphisms on NK and γδT cells. The investigators found that while certain 
alleles were more highly expressed, expression did not directly correlate with 
cytotoxicity. The group also identified that peripheral blood mononuclear cells (PBMC) 
from patients with BD produced a varied response to HLA-B*51/MICA*009 
combinations, but the response to HLA-B*52/MICA*009 was uniform. Moreover, 
peripheral blood mononuclear cells (PBMC) from healthy controls showed uniform 
responses for both combinations. This suggests that other molecules involved in the 
cytotoxic response may be responsible for the differences seen (Figure 1-6).  
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Figure 1-6. Percentage Inhibition Of Killing By Peripheral Blood Mononuclear Cells 
From Healthy Controls And Patients With Behçet’s Disease 
Healthy controls (left) showed a uniform response to target cell killing, whereas PBMC 
from HLA-B*51+ patients with BD (right) had a variable ability to kill. The reason for 
this difference in cytotoxicity levels was not fully explained by varying MICA/HLA alleles 
alone.  Personal communication (Shafi et al, unpublished data). 
 
 
 
1.5 Infectious Aetiologies  
 
When Hulusi Behçet first described the condition in 1937, he believed that BD was caused 
by a viral agent as he noted ‘inclusion-like’ bodies on smears from the anterior chamber 
of eyes with hypopyons and mucosal ulcers (Behçet, 1937). Since then, there have been 
a number of attempts to elucidate which, if any infectious agent may cause BD or 
contribute toward it.  
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1.5.1 Viruses  
 
In 1953, Sezer et al. inoculated fluid from the eyes and aphthae of patients with BD into 
the chorioallotoic membrane of fertile chick-eggs and found inclusion-bodies similar to 
those described by Behçet in 1937. These inclusion bodies were then transferred into the 
brains of wild-type mice, which subsequently developed BD-like symptoms and died. 
(Sezer, 1953a, 1953b). Later, Eglin et al. used in situ hybridisation to identify HSV-1 
from mucosal lesions of patients with BD (Eglin et al., 1982), which lead a number of 
groups to start measuring the presence of  HSV antibodies and DNA in blood (Bang et 
al., 2008; Choi, Lee, et al., 2011; Hamza et al., 1990; Hamza et al., 1991; Hamzaoui et 
al., 1992; Kim do et al., 2013), as well as saliva (Kim do et al., 2013; S. Lee et al., 1996). 
 
Other herpes viruses have also been investigated in BD. Tojo et al. measured the 
relationship between HSV-1 and 2 as well as the human herpes virus 6 (HHV-6) and 7 in 
tissue samples from patients with BD and other related inflammatory disorders. Four 
cases were positive for HSV-1; 1 of 11 BD cases, 2 of 3 neutrophilic dermatosis cases 
and 1 of 3 idiopathic erythema nodosum cases. The authors concluded that there might be 
some relationship between BD and the presence of HSV-1 and/or HSV-2 DNA and that 
HHV-6 and HHV-7 do not seem to be involved in disease pathogenesis (Tojo et al., 2003).  
 
More recently, proteomic analysis has been used to detect target HSV protein as well as 
serum IgA and IgG reactivities in BD patients and BD-like mice (Zheng et al., 2015). 
Compared with controls, patients with BD and BD-like mice exhibited higher titres of 
IgA reacting with recombinant HSV protein. Further proteomics analysis revealed that 
human heat shock protein 71 (HSP71) cross-reacted with target antigen against anti-HSV 
antibodies. The authors suggested that HSV infection and impaired human HSP71 activity 
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may be associated with the activation of autoreactive lymphocytes, rather than HSV 
directly being the cause of BD.  
 
Serum anti-HSV-1 antibodies are found in a higher proportion of patients with BD than 
in controls and circulating immune complexes including the HSV-1 antigen have been 
reported in BD patients (Lehner, 1997). When the data is compelling, many of these 
finding are replicated in HC and at present these findings have not been adopted into 
clinical practice and patients with BD are not routinely treated with antiviral agents to 
manage their disease. Similarly, several other viral agents, including hepatitis C virus, 
parvovirus B19, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus, have also 
been described as associated with BD, although their role in disease pathogenesis remains 
unclear (Akdeniz et al., 2003; Ilter et al., 2000; Kiraz et al., 2001; Seoudi et al., 2015; Sun 
et al., 1998; Sun et al., 1996). 
 
1.5.2 Bacteria and Bacterial Superantigens 
 
Oral aphthae are frequently the first manifestation of BD (Mumcu et al., 2009; Seoudi et 
al., 2015) oral microbial flora have long been implicated in the pathogenesis of disease. 
Clinical observations such as increased oral manifestations after dental treatment, 
hypersensitivity to streptococcal skin tests, overgrowth of atypical streptococci in patients 
with BD and recent reports of beneficial antibacterial treatment suggest a role for 
streptococci in BD (Japan, 1989; Lehner, 1997). 
 
In 1992, Hirohata et al. investigated KTH-1, an extract of Streptococcus sanguis SSH-83 
that causes increased IL-6 and IFN gamma secretion by CD8 T cells in patients with BD 
(Hirohata et al., 1992). KTH-1 also up regulates gamma delta T cells in short-term T cell 
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cultures, and KTH-1- specific gamma delta T cell lines secrete the proinflammatory 
mediators IL6, IL8, and TNFα (Mochizuki et al., 1994). In addition to streptococcal 
antigens, Hirohata et al. described the ability of Escherichia coli and Staphylococcus 
aureus to activate lymphocytes and release increased amounts of IFN α and IL-6 in BD. 
The same group found that CD8 T cells from BD patients require lower doses of the 
staphylococcal superantigens SEB and SEC1 to secrete IFN α, leading to the hypothesis 
that there is a degree of T cell hyperreactivity in BD (Hirohata et al., 1998). 
 
1.6 Heat Shock Proteins 
 
The 60 and 65 kilodalton (kDa) heat shock proteins (HSP) have also been thought to 
contribute toward the development of BD. HSPs are proteins expressed by cells 
undergoing stress. Initially, this was described after exposure to heat, but subsequently it 
has been demonstrated that HSPs are upregulated after a number of stress-inducing 
conditions in order to stabilise the surface expression of other cell-signalling receptors 
(Whitley et al., 1999). There is  substantial homology (>70%) between mammalian and 
microbial HSP, leading to the hypothesis that CD8 T cells responsive to bacterial HSP 
may provoke an autoinflammatory response in humans via immunological adjuvantcy  
(Kaufmann et al., 1991).  
 
HSP65 is expressed abundantly in epidermal regions of active skin lesions, such as 
erythema nodosum and mucocutaneous ulcers in BD (Ergun et al., 2001). In 1991, Lehner 
et al. suggested that HSP65 may function as a pathogenic antigen in BD by identifying 
anti-HSP65 antibodies that are cross-reactive with oral mucosal homogenates and oral 
streptococci (Lehner et al., 1991). Additional HSP derivatives were found to lead to 
increased activation in BD patients. T cell responses to mycobacterial HSP65-derived 
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peptides and to their 50–80% homologues on human HSP60 were shown to be 
significantly higher in patients with BD from UK, Japan, and Turkey than in controls 
(Direskeneli et al., 2000; S. Kaneko et al., 1997).   
 
Purified protein derivative and HSP65-specific long-term T cell lines are also highly 
reactive to human HSP60-derived peptides in both patients with BD and HC.  Most 
purified protein derivative-stimulated lines responded to a specific epitope 425–41 of 
HSP60 in patients with BD, whereas epitope 336–51 dominated in controls, suggesting 
that the patterns of response and the immunodominance of epitopes may differ in patients 
with BD from those of HCs (Direskeneli et al., 2000).  
 
Cross reactivity is also demonstrated for anti-HSP60 antibodies. Both antistreptococcal 
and antiretinal HSP60 antibodies are raised in the serum samples of patients with BD and 
uveitis, with significant cross-inhibition (Tanaka et al., 1999). Increased anti- HSP65 
antibody responses are also present in the cerebrospinal fluid (CSF) of patients with 
neuro-BD with parenchymal involvement (Tasci et al., 1998). 
 
1.7 Innate Immunity - A Role For Natural Killer Cells In Behçet’s Disease 
 
Natural killer (NK) cells are lymphocytes of the innate immune system. They are involved 
in the early stages of defence against foreign and self-cells undergoing stress. When 
stimulated, NK cells secrete an array of cytokines including interferon gamma (INFg), 
tumor necrosis factor a, (TNFa), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), and chemokines such as chemokine ligand 3 (CCL3), macrophage 
inflammatory protein 1 a (MIP1a) and CCL4 (MIP1b) (Dorner et al., 2002). NK cells 
are also cytotoxic, inducing apoptosis of target cells. NK cells identify their targets 
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through a set of activating or inhibitory receptors, which recognise non-self-targets as 
well as self-proteins that are upregulated as a result of stress. They can also kill cells that 
down-regulate expression of self-MHC molecules during times of infection or 
transformation (Raulet, 2004; Walzer et al., 2005). In both viral and bacterial animal 
models of infection, IFNγ production by NK cells has been identified as the key event for 
successful pathogen eradication (Byrne et al., 2004), which is driven by early IL-12 
production (Bancroft, 1993; Orange et al., 1996). 
 
Natural killer cells comprise 10-15% of circulating lymphocytes in humans, falling 
mostly into two distinct populations. Approximately 90% are CD56DimCD16+ cells, 
capable of killing and antibody dependent cytotoxicity. These cells produce relatively 
little IFNγ (Caligiuri, 2008; Inngjerdingen et al., 2011). The other 10% are 
CD56BrightCD16- and are weakly cytotoxic. These cells do not proliferate vigorously in 
response to IL-2, but produce substantial amounts of IFNγ (Cooper et al., 2001). It has 
been suggested that CD56BrightCD16- cells utilise their cytokine production to play a 
regulatory role in immune responses while CD56dimCD16+ cells are terminally 
differentiated cytotoxic effector cells (De Maria et al., 2011).  
 
Natural killer cells are decreased in patients with autoimmune diseases such as multiple 
sclerosis, systemic lupus erythematosus, Sjogren’s syndrome, rheumatoid arthritis (RA) 
and type I diabetes (French et al., 2004; Z. Tian et al., 2012) and have been found to be 
increased in ankylosing spondylitis, a condition associated with HLA-B*27, which also 
expressed the Bw4 epitope (Azuz-Lieberman et al., 2005). However, their role in 
autoinflammatory diseases such as BD is less clear, with conflicting evidence of NK cell 
involvement (Hamzaoui et al., 1988; F. Kaneko et al., 1985; Suzuki et al., 1992).  
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A complex balance of activating and inhibiting surface receptors control NK cells. 
Furthermore, depending on their location, NK cells can express variegated levels of 
activating and inhibiting receptors tailored to their environment.  
 
1.7.1 Natural Killer Cell Licensing 
 
Natural killer cells are ‘licensed’ to recognize and kill cells that do not express self-MHC. 
In 1986 Karre et al. described this phenomenon as the ‘missing self’ hypothesis (Karre et 
al., 1986). This states that NK cells are activated to detect and kill cells that are thought 
to be non-self, such as infected cells or those undergoing neoplastic changes. This theory 
was not able to explain the finding that NK cells from MHC-deficient mice and humans 
do not effectively kill target cells (Furukawa et al., 1999). Discovery of the killer 
immunoglobulin-like receptor (KIR) gene complex and the role the role of KIR as a ligand 
for HLA has added significantly to the understanding of NK cell biology and licencing. 
 
In any one individual, some NK cells do not have a corresponding inhibitory HLA ligand 
i.e. KIR3DL1+ cells in a Bw6 homozygote. It is unclear how such cells could be prevented 
from killing autologous cells. Yokoyama et al. proposed that KIR on NK cells must 
recognize their cognate HLA ligand in order to acquire functional competence through 
licensing (K. Kato et al., 2006). An alternate ‘disarming’ hypothesis proposes that NK 
cells that fail to recognise MHC class I via inhibitory KIR become anergic (Raulet, 2006). 
Hence, paradoxically, an inhibitory receptor interaction appears to be required for an NK 
cell to acquire function. In the context of infection, unlicensed NK cells may become 
activated in response to cytokines from infected cells. This may permit a broader 
repertoire of NK cells to contribute to the response to pathogens without the risk of 
autoimmunity (Kimura et al., 2005). Moreover, the licensing concept embraces gene 
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dosage, i.e. KIR3DL1+ cells in donors who are homozygous for Bw4 display increased 
responsiveness to tumour stimulation compared to heterozygotes and those who lack the 
ligand. By contrast NK cells lacking KIR3DL1 show no difference in activity (Boulet et 
al., 2008).  
 
1.7.2 The Killer Immunoglobulin-Like Receptor 3DL1/S1 (KIR3DL1/S1) 
 
HLA-B*51 presents antigen to CD8+ cytotoxic T cells, but is also known to interact with 
the killer immunoglobulin-like receptor 3DL1 (KIR3DL1). KIR are found on NK, T and 
γδT cells and interact with HLA-B*51 via its Bw4 epitope (Gumperz et al., 1995). 
Positions 7 and 8 of the KIR3DL1 peptide interact at positions 77, 80, 81, 82, and 83, 
which form the HLA-Bw4/Bw6 epitope (Peruzzi et al., 1996). Bw4 is present on a third 
of all HLA-B types and is defined by leucine at position 82 and arginine at position 83. It 
is associated with strong inhibition of NK cell activity via KIR3DL1 receptor interaction. 
The Bw6 epitope (Ser 77, Asn 80, Leu 81, Arg 82, and Gly 83) does not interact with 
KIR3DL1 (Parham et al., 2011). The Bw4 epitope can be found on numerous other HLA 
types (http://hla.alleles.org/antigens/HLA-Bw46.html) some of which are also associated 
with BD, such as HLA-B*27:02 (Gul et al., 2002).  
 
In humans, NK receptors belong to either the immunoglobulin-like superfamily (IgSF) or 
the C-type lectin-like receptor (CTLR) superfamily. KIR are part of the IgSF and have 
specific ligands in the HLA class I family (Lanier, 1998). Inhibitory KIR (i.e., KIR2DL 
and KIR3DL), contain immunoreceptor tyrosine-based inhibition motifs (ITIM) in their 
cytoplasmic domains. Activating KIR molecules (i.e., KIR2DS and KIR3DS) lack ITIM 
and have a charged residue in their transmembrane domains, which likely pair with the 
DAP12 signalling adapter. KIR2DL4 is unusual as it consists of a long intracellular region 
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but only one ITIM and a positively charged amino acid in the transmembrane region. 
Unlike other clonally distributed KIR, KIR2DL4 is transcribed by all NK cells and acts 
as an activating receptor on recognition of HLA-G (Faure et al., 2002; Rajagopalan et al., 
2012). Inhibitory KIR consistently binds with a higher affinity than their activating 
counterparts (Katz et al., 2001).  
 
1.7.2.1 KIR3DL/S1 Allelic Divergence 
 
Ancestral linages of KIR3DL/S1 alleles have been extensively investigated by Parham et 
al. over the past decade. Evidence has arisen to suggest that the polymorphic nature of the 
KIR gene cluster has, in part, developed as a result of changing cognate HLA-ligands 
(Parham et al., 2011). As part of this development, KIR genes have expanded from one 
common ancestral KIR – KIR3DX around 120 million years ago (Guethlein et al., 2015). 
At this time, placental mammals expanded their KIR3DL lineages to varying degrees. 
Figure 1-7 describes the evolution of KIR3DL/S1 in humans. As a result of this extensive 
allelic divergence, KIR3DL1 allotypes have variegated expression as can be seen in  
Figure 1-8. KIR3DL1*005 and *007 are low-expressing (KIR3DL1LOW) allotypes but 
evolved from different ancestral KIR3DL1 alleles (Figure 1-7). The reason for two alleles 
having similar function, but different ancestry is unclear, but suggests that both high and 
low-expressing KIR3DL1 allotypes are required for a robust, but controlled innate 
immune response.  
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Figure 1-7 Phylogenetic Relationships And Geographic Distribution Of KIR3DL1/S1 
Alleles 
Three divergent 3DL1/S1 allelic lineages are maintained in all human populations. The 
distance between two nodes corresponds to one nucleotide change in the coding region.. 
Nodes with coloured circles are the alleles present in the modern human population, the 
area representing the frequency worldwide and the different colours the distribution 
between major population groups. Allelic lineages are denoted by the background 
shading: *015, magenta; *005, cyan; and 3DS1, green. 3DL1*001, a recombinant of the 
*015 and *005 lineages, has a purple background. Dashed lines indicate four other 
recombination events: R1, acquisition of activating signalling function to form 3DS1 from 
3DL1 (the 22 unique substitutions in the 3DS1 signalling domain are not shown as nodes, 
because they were acquired en bloc); R2, causing 3DL1*007 and 3DL1*004-like alleles 
to have the same cytoplasmic tail; R3, forming a chimera of 3DL1 and 3DL2; and R4, 
representing two independent events when 3DL1 acquired the D0 domain of 3DS1 to give 
the 3DL1*009 and 3DL1*042 alleles – Reproduced with permission from (Parham et al., 
2011). 
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Figure 1-8. KIR3DL1 Allotypes Allow Predictable Binding Patterns To Be Observed In 
Healthy Controls.  
Viable CD3-CD56+ NK cells from healthy human donors were assessed by KIR3DL1 
PCR-SSP and stained for flow cytometry using DX9 (anti-KIR3DL1) and Z27 (anti-
KIR3DL1/S1) mAbs. (A) Phenotyping panel of healthy donor PBMC, gated on NK cells 
to represent all available major allele subtype combinations. Labels indicate the most 
common allele in each KIR3DL1 subtype. A representative donor from each subtype 
combination is displayed. (B) Z27 staining MFI from individuals expressing KIR3DL1LOW 
(l) or KIR3DL1HIGH (h) (C) Percentage of PBMC that are NK cells, segregated based on 
donor compound KIR3DL1 subtypes. (D) Percentage of peripheral blood NK cells that 
express KIR3DL1, organized based on donor KIR3DL1 subtypes. Bar graphs represent 
means 6 SEM and a minimum of two independent experiments with three to five donors 
per group. Means are compared by student t test (B) or one-way ANOVA (C and D). 
**P<0.01, ****P< 0.0001. – Reproduced with permission from (Boudreau et al., 2016). 
KIR – Killer Immunoglobulin-like Receptor, PBMC – Peripheral Blood Mononuclear 
Cells, ANOVA – Analysis of Variance 
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1.7.3 KIR3DL1 Expression In Behçet’s Disease 
 
Saruhan-Direskeneli et al. found no association of KIR3DL1 expression on NK or T cells 
in patients with BD, a finding not altered by the presence of Bw4 motif in patients 
(Saruhan-Direskeneli et al., 2004). Similar results were found by Middleton et al. after 
analysing 14 KIR genes in a cohort of Turkish patients and ethnically matched controls 
using a sequence-specific oligonucleotide probe (SSOP) method. They reported an 
increased frequency of KIR3DL1 and its ligand Bw4 (P=0.0003) and a corresponding 
decreased frequency of KIR3DL1 without Bw4 (P=0.00004) in patients compared to 
controls. However, this difference was abrogated when the presence of HLA-B*51 was 
controlled for (P=0.7075) (Middleton et al., 2007).  
 
The frequency of 16 KIR genes (2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3, 
2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1, 2DP1 and 3DP1) was assessed in Korean 
patients with either HLA-B*27-associated ankylosing spondylitis and uveitis or BD 
related uveitis. In the patients with ankylosing spondylitis, the frequency of KIR3DL1 
was significantly lower than healthy controls (P=0.043), while there was no difference in 
patients with BD (Moon et al., 2013). These studies support the evidence that KIR3DL1 
interacts with HLA-B*51 via Bw4; however, there is currently insufficient evidence to 
suggest that KIR3DL1 or its subtypes have a role in the pathogenesis of BD. The KIR 
cluster is highly polymorphic, second only to the HLA in complexity and is an unsuitable 
candidate for GWAS analysis as SNP probes targeting the region are unable to bind due 
to allelic and copy number variation within the gene. Other methods including targeted 
sequencing and functional analysis of different alleles must be explored further.  
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There is functional data to suggest HLA-B*51+MICA*009+ target cells inhibit cell 
mediated cytotoxicity from BD-derived PBMC in an unpredictable way (Figure 1-6), 
although the mechanism for this remains unclear. Of note, HLA-B52+MICA*009+ cells 
do not behave in a similar manner when exposed to the same PBMC. Work from Shafi et 
al. (Shafi et al., 2011) demonstrated that polymorphisms within MICA do not cause varied 
levels of killing, but polymorphisms within KIR3DL1 have yet to be closely examined in 
this context.  
 
1.7.4 Functional Activity Of Natural Killer Cells In Behçet's Disease 
 
In order to investigate the functional activity of NK cells in BD, Yamaguchi et al. assessed 
47 patients with BD, (10 with active disease). CD69+ NK cells were significantly 
increased in active BD, but their cytotoxic function was similar to inactive and control 
subjects the investigators also reported that IL-12Rβ2 mRNA levels were decreased in 
NK cells from patients with active BD, compared to inactive patients or healthy controls. 
 
Furthermore, NK cells from inactive patients suppressed IFNγ production by CD4+ T cells 
from patients with active disease (Yamaguchi et al., 2010). These findings suggest that 
while NK cells proliferate in active BD, they may be rendered hyporesponsive due to an 
abnormality in IL-12 signaling. 
 
Hamzaoui et al. also described hyporesponsive NK cells in bronchoalveolar lavage 
samples from patients with pulmonary BD. The authors did not examine the effects of IL-
12, but instead focused on IL-2/IL-15Rβ (CD122), which was found to have reduced 
surface expression. CD122 is shared by the IL-15 receptor and is partly responsible for 
maintenance and cytotoxicity of NK cells (Hamzaoui et al., 2013). 
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In 2017, Hasan et al. phenotyped the NK cell compartment in a cohort of 60 individuals 
with BD and 60 healthy controls. The investigators identified that circulating NK cells 
were significantly reduced in the BD group. In addition, active disease was correlated 
with reduced numbers of circulating NK cells. In a study examining the effects of Herpes 
Simplex Virus (HSV) in BD, Hamzaoui et al. noted that both NK cell activity and the 
number of NK cells was found to be reduced in BD, despite an elevation in IFNγ titres 
and the presence of activated T cells (Hamzaoui et al., 1990).  
 
Conversely, in a study evaluating the effect of IFNα-2a on lymphocytes populations in 
BD, Treusch et al. reported increased percentages of CD56+CD16+ NK cells in PBMC 
from active BD patients compared to healthy controls prior to treatment. Interferon-α-2a 
is often used as a second or third line therapeutic agent in BD, particularly in the presence 
of ocular disease. The investigators found a significant decrease in circulating NK cells 
in active BD patients after treatment compared to controls. This reduction may be a direct 
effect of IFNα-2a or secondary to induction of remission of BD. IFNα-2a has been 
postulated to work directly on NK cells by inducing apoptosis and indirectly by reducing 
IL-18, IL-12 and/or IL-21 (Treusch et al., 2004). 
 
Takeno et al. studied 40 Japanese patients with BD (60% had ocular disease) and noted 
that 10% had increased levels of circulating NK cells compared to normal controls. The 
authors characterised NK cells and found that the expression of KIR3DL1 in the BD 
group was highly variable (12.99±12.49%) compared to controls (16.5±6.4%). The 
authors also looked at KIR3DL1 and Bw4 expression, but found no differences between 
Bw4+ and Bw4- patients, which is in keeping with previous findings (Gardiner et al., 
2001; Gumperz et al., 1995). They hypothesised that defects in the NK cell repertoire may 
permit persistent viral infection leading to BD or that NK cells lacking appropriate 
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inhibitory KIR (such as KIR3DL1) may fail to recognise self-MHC and cause autologous 
tissue damage (Takeno et al., 2004). 
 
1.8 Chapter Summary 
 
Behçet’s Disease is a multisystem disease, which mainly affects young people of working 
age. It can manifest in a variety of clinical phenotypes and is associated with significant 
morbidity and mortality. There is no cure for BD and current management is chiefly based 
around long-term immunosuppression. 
 
The pathogenesis of BD remains unknown. Recent large-scale GWAS have identified a 
number of susceptibility loci, both in and out of the MHC. The candidate genes mentioned 
in Table 1-8 are likely to represent the ‘tip of the iceberg’ and more rare variants will be 
uncovered over the coming years each with a diminishing effect size (Ombrello, Sikora, 
et al., 2014). Despite being described more than 30 years ago, the majority of disease 
hereditability comes from HLA-B*51, the role of which remains unclear.  
 
KIRs regulate cells of the innate immune system and are either activating or inhibitory. 
The KIR3DL1/S1 gene is highly polymorphic and 110 alleles have been described 
(https://www.ebi.ac.uk/ipd/kir/stats.html) to date. Furthermore, KIR3DL1 is known to 
interact with the Bw4 epitope of HLA-B*51, however, no work has been done looking at 
KIR3DL1 variants and their inhibitory relationship to HLA-B*51. Previous work from 
our group suggests that polymorphisms within KIR3DL1 may contribute to an alteration 
in cell mediated cytotoxicity, most likely via the interaction with Bw4. This alteration 
may lead to a positive feedback loop causing prolonged inflammation and a chronic 
inflammatory state; this is the focus of my thesis (Figure 1-9).  
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While such interactions alone will not elucidate the pathogenesis of BD, it is hoped that 
they will clarify key aspects of human NK cell regulation that will be of benefit to 
understanding many aspects of human cell-mediated immune responses in health as well 
as in disease.  
 
1.9 Hypothesis 
 
The working hypothesis of this thesis is that specific KIR3DL1/S1 alleles are associated 
with BD. If this is the case, then I further hypothesise that certain KIR3DL1/S1 allotypes 
show varied levels of inhibition to cell-mediated killing when presented with their ligand, 
HLA-B*51.  
 
Experimental support for this hypothesis would add weight to the prospect that disease-
associated alleles of KIR3DL1/S1 may contribute to lymphocyte dysregulation in BD. 
Conversely, refuting the hypothesis may reduce support for this perspective. 
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Figure 1-9 Putative Role For KIR3DL1-HLA-B*51 Interaction Causing A Prolonged 
Chronic Inflammatory State In Behçet’s Disease 
 
Infection or inflammation at mucocutatneous surfaces may persist due to dysfunction of 
the innate immune response in predisposed individuals. ERAP1 may have a role in 
processing peptides that are presented by HLA-class-I molecules. KIR3DL1 inhibits cell-
mediated cytotoxicity via interaction with HLA-B*51. This effect is balanced by activating 
interactions via NKG2D and MICA. Production of cytokines including IL-10 and IL-15 
contribute to abnormal NK cell function leading to prolonged inflammation and further 
episodes. NK cell, Natural killer cell; ERAP, endoplasmic reticulum aminopeptidase 1; 
HLA, human leukocyte antigen; KIR, killer immunoglobulin-like receptor; MICA, MHC 
class-I polypeptide-related sequence A; NKG2D, Natural killer group 2; receptor D; IL, 
interleukin. Reproduced with permission from (Petrushkin et al., 2015) 
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1.10 Aims Of The Thesis 
 
1. To investigate whether established HLA and MICA associations are applicable to 
a large cohort of individuals with BD from the UK.  
 
2. To establish whether specific KIR3DL1/S1 alleles are associated with BD. 
 
3. To investigate the expression of KIR3DL1/S1 in a group of individuals with BD 
with known KIR3DL1/S1 alleles. 
 
4. To create a group of cell lines expressing relevant HLA-B ligands to determine 
the functional effects of KIR3DL1/S1 in vitro.  
 
5. To determine whether HLA-B*51-KIR3DL1/S1 interaction results in increased 
degranulation compared to HLA-B*52-KIR3DL1/S1 interactions.  
 
6. To investigate the incidence and phenotypic heterogeneity of ophthalmic BD in 
the UK.  
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2 Materials and Methods 
2.1 Ethics, Consent And Study Participants 
 
This project was carried with institutional ethics approval (Immunoregulation at the 
mucosal barrier, P/03/122) granted by the east London & the city research ethics 
committee. Individuals fulfilling the ISG criteria for BD (Disease, 1990) and unrelated, 
demographically matched controls, were approached in the London BD Centre of 
Excellence. Patients and controls were given information regarding the study and a 
consent form to read and take away with them. On their next visit, patients and healthy 
controls were consented and given a research number, which was used to identify that 
individual for the rest of the study. Original consent forms were held in a specified, locked 
cabinet in a locked room in a secure building (Blizard Institute, Queen Mary University 
of London (QMUL)). Patients with BD were recruited regardless of their age, whereas 
HCs were recruited over the age of 45 wherever possible to avoid the possibility of 
incorrectly labelling an individual as ‘healthy’ if they had an unmasked auto-
inflammatory disease (discussed further in Chapter 3.3). 
 
2.2 Power 
 
Calculating the power required in this project was challenging due to the rare nature of 
the disease in the UK as well as the polymorphic nature of HLA and KIR. In particular, 
KIR3DL1 alleles have not been explored in a BD population. 
 
I used the population prevalence of KIR3DL1*001 in the UK as a basis for the power 
calculation. KIR3DL1*001 is found in approximately 15% of the UK population (Norman 
et al., 2007b). I assumed a prevalence of 7.5% in the control group and planned a 
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recruitment ratio of 1:2 BD:HC. In order to achieve a power of 80% with an α of 0.05, 
234 individuals with BD and 468 HCs needed to be recruited. Power calculations were 
carried out using clincalc.com power calculation tool for two independent samples with a 
dichotomous endpoint (www.clincalc.com/stat). As KIR3DL1 is not a dichotomous allele, 
it is unlikely that this power calculation will be accurate, and it would be ideal to collect 
a larger number of cases and controls to allow for contingency.  
 
2.3 Venepuncture And Blood Product Handling 
 
Blood was taken from participants in a clean-room in the BD clinic using appropriate 
equipment and safety precautions. Consent was re-affirmed prior to venepuncture. For 
DNA extraction, 10 millilitres (ml) of blood was taken supplemented with the 
anticoagulant; ethylenediaminetetracetic acid (EDTA). For PBMC analysis, 40 ml of 
blood was taken. 
 
The blood bottles were labelled with the participants’ research number and taken to the 
Blizard Institute for DNA/PBMC extraction. DNA was extracted within 1 week of 
venepuncture. During that time, the blood bottles were stored at 4 degrees Celsius (°C). 
PBMC were extracted immediately.  
 
2.4 Molecular Techniques 
 
2.4.1 DNA Extraction  
 
DNA was extracted using a QIAamp DNA Blood Maxi-Kit (Cat No. 51192, Qiagen, 
Hilden, Germany). Manufacturer’s instructions were followed. 10 ml of anti-coagulated 
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blood was brought to room temperature and vortexed before being mixed with 500ul 
Qiagen protease in a 50 ml labelled, skirted conical tube. Twelve millilitres of Buffer AL 
(lysis buffer) was then added and shaken for 1 minute (min). The tube was then incubated 
at 70°C for 10 minutes (min) in a water bath. 10 ml of 100% ethanol was then added to 
the contents of the 50 ml conical tube and shaken vigorously for 1 min.  
 
A QIAgen maxi-column was then prepared and labelled. Half the contents of the 50ml 
conical flask was transferred to the membrane and centrifuged at 1,850 times gravity (g) 
for 3 mins. The eluent was then discarded and the remainder added to the membrane and 
centrifuged at 1,850g for a further 3 min.  
 
To wash the membrane, 5 ml of Buffer AW1 was applied to the column and left to 
incubate at room temperature for 5 mins prior to centrifuging at 4,500g for 1 min. This 
was followed by 5 ml of Buffer AW2 being applied to the membrane and immediately 
centrifuged at 4,500g for 15 mins, to ensure all ethanol was removed from the membrane.  
 
To elute the sample, a freshly labelled 50 ml conical tube was prepared and the maxi-
column inserted. 1 ml of Buffer AE was added to the membrane and incubated at room 
temperature for 5 mins. The sample was then centrifuged at 4,500g for 2 mins. An addition 
1ml of Buffer AE was then added to the membrane and incubated for 5 mins at room 
temperature before being centrifuged at 4,500g for 2 mins. The resulting 2 ml of eluent 
was then vortexed and measured for DNA concentration. A Nanodrop nanospectrometer 
(ThermoFisher, Waltham, MA, USA) was used to quantify DNA concentration. A 
260/280 ratio of 1.8 was considered the target for DNA purity. DNA was stored at 100 
nanograms per microliter (ng/ul) and either diluted with Buffer AE or concentrated using 
a heated centrifuge with a vacuum applied. DNA was labelled both with a permanent 
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marker and a label designed to withstand -80°C temperature. DNA was then stored at -
80°C.  
 
2.4.2 Library Preparation And Bioinformatics Pipeline 
 
 
Primers were designed for HLA-B, MICA, KIR3DL1 and a panel of 25 ancestry 
informative markers (AIMs) by Charles Mein at the Genome Centre in QMUL. The DNA 
samples were transported to the Genome Centre and the library preparation was carried 
out by Thedoros Xenakis on a Fludigm Platform (Fluidigm, South San Francisco, CA, 
USA). Sequencing was carried using a MiSeq platform (Illumina, San Diego, CA, USA) 
at the Genome Centre. HLA-B alleles were assigned using NGSengine software (GenDX, 
Utrecht, the Netherlands) and KIR3DL1/S1 alleles were assigned using the PING pipeline 
(Norman et al., 2016). 
 
2.4.3 mRNA Extraction  
 
 
mRNA was extracted using the Dynabeads mRNA DIRECT purification kit (Cat No. 
61012, ThermoFisher, Waltham, MA, USA) according to manufacturer’s instructions. 
1x106 cells (either from cell culture or PBMC) were pelleted at 400g for 8 mins. The pellet 
was washed with phosphate buffered saline (PBS) and centrifuged again at 400g for 8 
mins. 300ul of lysis/binding buffer was then added and gently pipetted until the pellet had 
dissolved on ice. The lysate was then forced through a 21-gauge needle 3 times using a 2 
ml syringe to shear DNA and reduce viscosity.  
 
Dynabeads were vortexed prior to use and 50ul of beads were placed in a sterile tube on 
a DynaMag-2 magnet (Cat No. 12321D, ThermoFisher, Waltham, MA, USA). The 
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supernatant was then removed and the beads washed with 100ul of Lysis/Binding Buffer. 
The beads were then put back on the magnet and the supernatant aspirated. 300ul of lysate 
was then added to the beads and the sample gently pipetted to mix the contents. The lysate 
and beads were then put on a tube roller and gently rotated for 10 mins at room 
temperature to allow hybridization of the beads.  
 
The tube containing the hybridized beads was then placed back on the magnet for 2 mins 
and the supernatant removed. The beads were then washed twice with 400ul Washing 
Buffer A at room temperature, using the magnet to separate the beads between each wash. 
The beads were then washed once with 400ul of Washing Buffer B at room temperature 
and the magnet used to separate the supernatant for aspiration.  
 
To remove mRNA from the beads, 13ul of Elution Buffer was added to the beads and 
incubated at 80°C for 2 mins. The beads were then placed back on the magnet and the 
supernatant removed to a fresh labelled PCR 0.2ml tube on ice. 
 
2.4.4 cDNA Preparation From mRNA 
 
The Roche Transcriptor First cDNA Synthesis Kit (Cat No. 04379012001, Roche, Basel, 
Switzerland) was used according to manufacturer’s instructions. A reverse transcription 
(RT) master mix of 4.0ul 5x RT Buffer, 2.0ul deoxyribose nucleoside triphosphates 
(dNTP) mix (10uM), 0.8ul Random OligoDT mix, 0.4ul RNAse inhibitor and 0.4ul 
Reverse Transcriptase was made during the lysis incubation period of mRNA extraction. 
7ul of RT master mix was added to 13ul of mRNA in a 0.2ml PCR tube. The following 
RT settings were used on a Veriti (ThermoFisher, Waltham, MA, USA) thermocycler 
(Table 2-1). 
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Table 2-1. Thermocycler Settings For cDNA Synthesis. 
Temp Time (mins) Repeat 
42°C 30.00  1x 
85°C 5.00  1x 
4°C  5.00 1x 
  
The cDNA was then diluted with 50ul nuclease free (NF) water and stored at -20°C for 
use in downstream applications.  
 
2.5 HLA Analysis 
 
HLA-B analysis was carried out using the NGS Engine Software package (GenDx, 
Utrecht, Netherlands). Samples were analysed in collaboration with the Parham 
Laboratory, Department of Structural Biology, Stanford University, CA, USA. HLA-A 
was analysed using sequence specific oligonucleotide probes (SSOP) (Immucor, 
Peachtree Corners, GA, USA). There were 28 HLA-B samples with ambiguous or 
unlikely reads which were also confirmed with SSOP.  
 
For the amplification, DNA was normalised to 50ng/ul and 2ul were added to a master 
mix comprised of: 13.5ul nuclease free (NF) water (Cat No. W4502-1L, Sigma Aldrich, 
St Louis, MI, USA), 6.6ul Loci specific master mix (HLA-A or B), 0.2ul Taq polymerase 
(Cat No. M7806, Promega, Madison, WI, USA). Thermocycler settings can be seen in 
(Table 2-2). After amplification, the 2ul of amplified DNA was added to 8ul of Loci-
Specific Probes and the sample was hybridised on a thermocycler with the following 
settings (Table 2-3). 
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Table 2-2. Thermocycler Settings For HLA-A And B Amplification: Sequence Specific 
Oligonucleotide Probe (SSOP) Protocol. 
 
 
Table 2-3. Thermocycler Settings For Hybridisation Of SSOP Probes To DNA 
 
Temp Time Cycles 
97.0°C 2:00 1x 
47.0°C 10:00 1x 
56.0°C 8.00 1x 
56.0°C ¥ 1x 
 
After 8 minutes at 56°C, but while the sample is still on the thermocycler, the adhesive 
lid was removed from the plate and 20ul of SAPE buffer was added. The plate was then 
moved to a Luminex Liquichip 200 (Luminex, Austin, TX, USA) for analysis. Data was 
then exported to MatchIT DNA (Immucor, Peachtree Corners, GA, USA) for typing.  
 
2.6 Agarose Gel Electrophoresis  
 
Visualisation of amplified DNA products from PCR reactions was performed by agarose 
gel electrophoresis in the presence of 0.001% SYBR-Safe (Cat No. S33102, 
ThermoFisher, Waltham, MA, USA). To make the gel, the appropriate amount of agarose 
Temp Time Cycles 
 
 
95.0°C 3:00 1x 
95.0°C 0:15 
12x 60.0°C 0:30 
72.0°C 0:30 
95.0°C 0:10 
28x 63.0°C 0:30 
72.0°C 0:30 
72.0°C 2.00 5x 
20.0°C ¥ 1x 
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was weighed and added into an appropriate volume of 1X Tris-Acetate EDTA (TAE) 
buffer (Cat No. B49, ThermoFisher, Waltham, MA, USA) to make a 1% TAE agarose 
gel and then microwaved for 2-3 minutes to fully dissolve the agarose in the 1X TAE 
buffer. This was followed by the addition of 0.001% SYBR-Safe before being poured in 
to a gel mould. The gel was then allowed to solidify before being placed in a gel tank 
containing sufficient TAE buffer to completely cover the gel. Samples were then 
combined with 6x Gel Loading Dye Blue (Cat No. B7021S, New England Biosystems 
(NEB), Ipswich, MA, USA), loaded into the gel and run through at approximately 90-
300V for 30-60 minutes, before visualization of DNA bands under ultraviolet 
light. Different size gels were used for different applications. Generally, a small 50ml gel 
was used for DNA analysis and cloning, whereas a large 1400ml gel was used for HLA-
typing. 
 
2.7  Polymerase Chain Reaction Single Specific Primer (PCR SSP) 
 
PCR SSP was used for HLA-typing if there was an ambiguous result from SSOP. Primers 
were based on those described by Bunce et al (Bunce et al., 1995). 
2.7.1 HLA-A Typing SSP 
 
22.5ul of DNA at 50ng/ul was added to the following master mix: 130ul of NF water (Cat 
No. W4502-1L, Sigma Aldrich, St Louis, MI, USA) 52.5ul Buffer (Cat No. M7806, 
Promega, Madison, WI, USA), 17.5ul 63/64 control DNA product (Eurogentec, Liege, 
Belgium): 
 
Forward Primer 5’-3’ (FP) - TGCCAAGTGGAGCACCCAA 
Reverse Primer 5’-3’ (RP) - GCATCTTGCTCTGTGCAGAT 
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26.25ul dNTPs (Cat No. R0182, ThermoFisher, Waltham, MA, USA), 12.25ul 
Magnesium Chloride (MgCl2) (Cat No. M7806, Promega, Madison, WI, USA), 2ul Taq 
polymerase (Cat No. M7806, Promega, Madison, WI, USA). The same was then vortexed 
and aliquoted into 25 wells with HLA-A primers pre-seeded and dried. The plate was then 
sealed and placed in a thermocycler (Table 2-4). 
 
Table 2-4. Thermocycler Settings For HLA-A And HLA-B PCR SSP Analysis.  
Temp Time (min) Cycles 
94.0°C 1:00 1x 
94.0°C 0:25 
5x 70.0°C 0:45 
72.0°C 0:30 
94.0°C 0:25 
20x 63.0°C 0:45 
72.0°C 0:30 
94.0°C 0:25 
5x 55.0°C 1:00 
72.0°C 2:00 
20.0°C ¥  
 
The samples were then loaded into a 1% agarose gel and run as detailed above. The DNA 
image was then captured under ultraviolet (UV) light and analysed.  
 
2.7.2 HLA-B Typing SSP 
 
47ul of DNA at 50ng/ul was added to the following master mix: 260ul of NF water, 109ul 
Buffer, 55ul dNTPs, 47ul 63/64 control DNA, 26ul MgCl2, 4.5ul Taq polymerase. The 
same was then vortexed and aliquoted into 50 wells with HLA-A primers pre-seeded and 
dried. Thermocycler settings were the same for HLA-A and B and can be found in (Table 
2-4). Primers for HLA-Typing can be found in Appendix 1. 
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2.8 Construction of Cell Lines 
 
Two cell lines were used in this project. The Chinese Hamster Ovary (CHO)-Flp-In cell 
line (Cat-No. R75807, ThermoFisher, Waltham, MA, USA), was obtained to use as a 
control cell line for cloning analysis and the 721.221 lymphoblastoid cell line, which is 
typically used in NK-cell cytotoxicity assays. The benefits and challenges of each cell 
line are listed in Table 2-5. 
 
Table 2-5. Benefits And Challenges Of Chinese Hamster Ovary (CHO) Epithelial Cell 
Line And 721.221 Lymphoblastoid Cell Line 
CHO – Chinese Hamster Ovary, HLA – Human Leukocyte Antigen, KIR – Killer 
Immunoglobulin-like Receptor, NK – Natural Killer, B2M – Beta 2 Microglobulin 
 
 Benefits Challenges 
CHO-cell line • Easy to transfect 
with the Flp-
recombinase system 
(see Chapter 2.10) 
• Easy to grow 
• No innate 
expression of 
ligands for HLA or 
KIR – so effects of 
HLA transfection 
can be studied in 
isolation 
• Cytotoxicity assays are 
challenging as the cell 
line is adherent 
• Not routinely used as a 
target cell line for NK 
cytotoxicity 
 
721.221 cell line • Easy to grow 
• Routinely used for 
NK cytotoxicity 
assays 
•  Expresses HLA 
constructs due to 
innate expression of 
B2M 
• Harder to transfect 
• Harder to sort cells using 
antibiotic resistance due 
to their non-adherent 
nature  
• Harder to obtain stable 
expression using 
transfection, rather than 
transduction techniques. 
 
The CHO-MICA*009 cell line was obtained from the Hayday Laboratory, 
Immunobiology, Guy’s Hospital, London, UK with thanks. The 721.221 (221) cell line 
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was obtained from the Moffat Laboratory, Centre for Trophoblast Research, Cambridge 
University, Cambridge, UK with thanks.  
 
Eight cell lines were constructed in this project, not all of which were used in the final 
analysis.  
 
1. pcDNA5- MICA*009/B2M/HLA-B*51- hygromycin resistant 
2. pcDNA5- MICA*009/B2M/HLA-B*52- hygromycin resistant 
3. pcDNA5- MICA*009/B2M/HLA-B*35- hygromycin resistant 
4. pcDNA5-MICA*009 – hygromycin resistant 
5. pcDNA3.1-HLA-B*51 – neomycin resistant 
6. pcDNA3.1-HLA-B*52 – neomycin resistant 
7. pcDNA3.1-HLA-B*35 – neomycin resistant 
8. pcDNA3.1-B2M – Zeocin resistant 
The construction of each cell line is detailed below. The challenges encountered whilst 
constructing the cell lines is detailed in Chapter 4.  
 
2.8.1 pcDNA5-FRT/MICA*009/B2M/HLA-B  CHO-Cell Line  
 
Throughout this chapter, the same primers and techniques were used for HLA-
B*51/*52/*35. Thus, I have referred generically to ‘HLA-B’ when referring to these 
amplicons.  
 
A pcDNA5-FRT vector (Cat-No. R75807, ThermoFisher, Waltham, MA, USA) encoding 
hygromycin resistance was used to transfect the triple construct into the CHO-Flp-In cell 
 83 
line. MICA*009 was amplified from a pre-existing CHO-MICA*009 cell line using 
primers designed to amplify the whole coding DNA sequence (CDS): 
 
MICA*009 FP – TTCCTGCTTCTGGCTGGCAT 
MICA*009 RP – TAGGCGCCCTCAGTGGAG 
 
The coding region of B2M was amplified from a healthy control individual with specific 
primers:  
 
B2M FP – TCTCGCTCCGTGGCCTTAGC 
B2M RP – AGCAATTCAGGAAATTTG 
 
The HLA-B*51:01:01 (henceforth HLA-B*51), B*52:01:01 (henceforth HLA-B*52) and 
B*35:01:01 (henceforth HLA-B*35) used in each construct were synthesised to ensure 
accuracy (Genscript, Nanjing, China). HLA-B was amplified using the following primers: 
 
HLA- B FP – ACAACCATGCGGGTCACG 
HLA- B RP – AGAGCCCTGGGCACTGTC 
 
2.8.1.1 Amplification Of Template MICA*009, B2M And HLA-B cDNA 
 
1ul of HLA-B, MICA*009, B2M  and pcDNA5-FRT vector CDNA were separately 
normalised to 50ng/ul was added to 1.25ul F primer, 1.25ul R primer, 12.5ul Q5 high 
fidelity polymerase (Cat No. M091S, NEB, Ipswich, MA, USA), 9ul NF water in a PCR 
tube (Table 2-6). 
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Table 2-6. Thermocycler Settings For Amplifying Fragments For The Triple Construct 
Melting and annealing temperatures were adjusted for different size products 
 
Temp Time Cycles 
98°C 0:30 1x 
98°C 0:05-0:10 
30x 64-69°C 0:20-0:25 
72°C 0:10 
72°C 5:00 1x 
 
2.8.1.2 Purification Of Amplified cDNA Fragments 
 
The amplified products were then run on a 1% agarose gel with a 2-log ladder (Cat No. 
N0550S, NEB, Ipswich, MA, USA) and visualised under UV light. The relevant bands 
were then cut out of the gel and weighed.  
 
After weighing, DNA was extracted using the QIAquick Gel Extraction Kit (Cat No. 
28704, Qiagen, Hilden, Germany). Three times volume of Buffer QG was added (100mg 
~ 100ul, i.e. 300ul Buffer QG) and the mixture incubated at 50°C for 10 mins until the 
agarose had completely dissolved. The sample was vortexed and 1 gel volume of 
isopropanol (Cat No. I9516, Sigma Aldrich, St Louis, MI, USA) was added followed by 
a further vortex. The sample was then applied to a mini spin column and spun at 400g for 
1 min. The eluent was then reapplied to the column two further times to ensure maximum 
binding of the DNA product to the silica membrane. To wash the membrane, 750ul of 
Buffer PE was added to the column and left to incubate at room temperature for 1 minute. 
The sample was then vortexed at 13,000g for 1 min. Finally, the spin-column was placed 
in a clean, labelled collection tube and 50ul of NF water was added and left to incubate 
for 1 minute at room temperature before centrifuging at 13,000g for 1 min. The DNA 
product was then measured using a spectrophotometer and kept at -20°C until use.  
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2.8.1.3 Gibson Assembly 
 
MICA*009, B2M and HLA-B (henceforth referred to as the triple construct), was 
assembled using Gibson assembly. Gibson primers were designed using the Gibson 
Assembly designer (NEB, Ipswich, MA, USA). The stop-codon on the B2M CDS was 
removed and replaced with an internal ribosomal entry site (IRES) sequence built onto 
the end of the B2M CDS. Both the B2M and HLA-B CDS were then driven from an 
upstream cytomegalovirus promoter (pCMV) sequence. An additional pCMV was added 
immediately after the HLA-B sequence and before the MICA*009 sequence to ensure 
adequate expression of MICA*009 (Figure 2-1). 
 
Figure 2-1. Gibson Assembly Protocol and Primer Design for CHO MICA*009/B2M/ 
HLA-B Cell Line 
http://nebuilder.neb.com allows users to upload fragment sequences and calculates the 
primers and annealing temperatures required to carry out Gibson Assembly. Below is a 
screen shot for the triple construct with HLA-B*51. Details of the construct can be seen 
in Figure 4-7. 
 
 
 
 
Gibson assembly was carried out according to the manufacturer’s instructions (Cat No. 
E5510, NEB, Ipswich, MA, USA). The four fragment (vector, B2M/IRES, HLA-B, 
pCMV/MICA*009) assembly was carried out at a ratio of 1:1:1:1. Each fragment was 
normalised to 0.2pmol and mixed in a 1.5ml Eppendorf before drying down in a vacuum 
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concentrator (DNA Speedvac, Cat No. DNA120-115, ThermoFisher, Waltham, MA, 
USA). The sample was then resuspended in 5ul NF water and 2ul Gibson Assembly Mix 
(Cat No. E26112, NEB, Ipswich, MA, USA). The sample was then incubated at 50C for 
1 hour. 
 
2.8.1.4 Transformation Into E. Coli 
 
pcDNA5-MICA*009/B2M/HLA-B was transformed into NEB 5 α competent E. Coli 
(Cat No. C2987I, NEB, Ipswich, MA, USA). 2ul of vector was added to 25ul of NEB 5 
α in an Eppendorf tube on wet ice and incubated for 30mins. A heat shock was carried 
out at 42C for 30 seconds followed by another 2-minute incubation on wet ice. 1ml of 
super optimal broth with catabolite repression (SOC) (Cat No. S1797, Sigma Aldrich, St 
Louis, MI, USA), media was then added to the E. Coli and the sample incubated for 1 
hour at 37°C.  
 
2.8.1.5 Plating And Selection Of Colonies  
 
The transformed, chemically competent E. Coli were then plated on to agar plates 
supplemented with 0.2% carbenicillin (Cat No. C1389- Sigma Aldrich, St Louis, MI, 
USA). The sample was gently pipetted to mix the bacteria and then 100ul was plated onto 
a 10cm labelled, agar plate and evenly spread using sterile glass beads (Cat No. Z143928, 
Sigma Aldrich, St Louis, MI, USA). The remainder of the sample was then centrifuged at 
13,000g for 1 minute, the supernatant removed and the pellet resuspended in 100ul of 
SOC. This was then added to a second labelled plate. The same procedure was carried out 
with the digested vector to serve as a control. The plates were incubated in the dark at 
37°C for 12-16 hours before colonies were picked.  
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The following day, four colonies were punched out of the agar using a 200ul pipette tip. 
The tip was then submerged in 10 ml of Luria-Bertani (LB) broth (Cat No. L3022, Sigma 
Aldrich, St Louis, MI, USA) supplemented with 0.2% carbenicillin. The sample was then 
incubated on a shaker at 37°C for 16hrs.  
 
2.8.1.6 Isolation Of Plasmid DNA (Miniprep) 
 
The bacterial suspension was removed from the shaker and centrifuged at 13,000g for 
10mins at room temperature. Plasmid DNA was isolated using the QIAprep miniprep kit 
(Qiagen, Hilden, Germany). The supernatant and 200ul tip were discarded and the pellet 
resuspended in 1ml of P1 Resuspension Buffer + 100ug/ml RNase A. The suspension was 
transferred to a 1.5ml Eppendorf and centrifuged at 6,800g for 3 mins. The supernatant 
was removed and the pellet resuspended in 250ul P1 Resuspension Buffer +100ug/ml 
RNase A. 250ul of P2 Lysis Buffer was then added to the suspension and the sample 
rolled gently until fully lysed. The sample was then neutralised with 350ul N3 
Neutralisation Buffer and rolled until two clear phases appeared in the tube. The sample 
was then centrifuged at 17,000g for 10 mins and the supernatant removed to a QIAprep 
spin column. The column was centrifuged at 17,000g for 1 minute and the eluent 
discarded. The membrane was washed with 500ul Buffer PB, centrifuged at 17,000g for 
1 minute and the eluent discarded. 750ul of Buffer PE was then added to the column and 
centrifuged at 17,000g for 1 minute. The spin column was then centrifuged ‘dry’ at 
17,000g for 1 minute to ensure all ethanol had been removed from the membrane. To 
elute the DNA, the spin column was transferred to a clean, labelled 1.5ml Eppendorf tube 
and 50ul of NF water was added and allowed to incubate at room temperature for 5 
minutes. The sample was then centrifuged at 17,000g for 1 minute and the eluent 
measured on a spectrophotometer to establish concentration of plasmid DNA.  
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2.8.1.7 Sanger Sequencing Confirmation Of Inserts 
 
Two companies were used to send sampled for confirmation (SourceBio, Nottingham, 
UK and GATC, Konstaz, Germany). All four samples were sent for sequencing. 500ng 
of plasmid DNA was diluted with 5ul water either a forward or a reverse primer to amplify 
the region of interest. Sequences were usually returned within 1-3 days and were analysed 
with SnapGene software (GSL Biotech, Chicago, IL, USA). Samples with any mutations 
were discarded.  
 
2.8.2 pcDNA5-MICA*009  
 
The triple construct did not express HLA-B (discussed further in Chapter 4), so I created 
separate vectors each encoding a different antibiotic resistance gene to allow drug 
selection for each construct. The pcDNA5-MICA*009 plasmid was already constructed 
and obtained from the Hayday laboratory and had a hygromycin resistance gene.  
 
2.8.3 pcDNA3.1(+)-HLA-B 
 
A pcDNA3.1(+) vector encoding neomycin resistance was used to clone HLA-
B*51/*51/*35 (Figure 2-2). HLA-B fragments were amplified using the quantities 
described in Chapter 2.8.1.1 with the following primers. Thermocycler settings for 
amplification are in Table 2-7. The products were digested with HindIII HF and Not1 HF 
prior to ligation into the vector. 
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HLA-B FP – GCACTGAAGCTTATAGCCACCATGCGGGTCACGGCG 
HLA-B RP – AGAGCCCTGGGCACTGTC 
 
Table 2-7. Thermocycler Settings For Amplification Of HLA-B Fragment Prior To 
Restriction Enzyme Digestion 
 
Temp Time Cycles 
98°C 0:30 1x 
98°C 0:05 
30x 69°C 0:20 
72°C 0:10 
72°C 5:00 1x 
 
2.8.3.1 Digestion Of HLA-B Amplicon  
 
10ul of 50ng/ul (500ng) amplified product and vector were digested for 1 hour with 0.5ul 
HindIII HF, 0.5ul Not1 HF restriction enzymes (Cat No. R3104S and R3189L 
respectively, NEB, Ipswich, MA, USA), 2ul Cutsmart Buffer (Cat No. B7204S, NEB, 
Ipswich, MA, USA) and 7ul of NF water at 37°C.  
 
 
In addition to the above, the digested vector was dephosphoralated using shrimp alkaline 
phosphatase (rSAP) (Cat No. M0371S, NEB, Ipswich, MA, USA) to prevent re-ligation 
of the cut ends. 1ul of rSAP was added to the digestion mix after 1 hour and left to incubate 
for a further 30 mins before being heat inactivated at 65°C for 5 mins.  
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Figure 2-2.  (a.) Method Used To Construct pcDNA(+) –HLA-B*51 With Neomycin 
Resistance Gene, (b.) pcDNA3.1(+) -HLA-B*51 In Detail 
(a.) Snapgene history to show amplification of synthesised HLA-B fragment with primers 
encoding HindIII and Not1 restriction sites. This was followed by insertion of the 
fragment by cutting and ligating the pcDN3.1(+) vector at the same restriction sites. (b.) 
Detail of the pcDNA3.1(+)-HLA-B*51 vector. Expression of gene of interest is driven by 
a CMV promoter immediately before the MCS. Expression of the neomycin resistance 
gene is driven by the SV40 promotor. HLA – Human Leukocyte Antigen, NeoR – neomycin 
resistance gene, AmpR – ampicillin resistance gene, PCR – polymerase chain reaction, 
CMV – cytomegalovirus, MCS – multiple cloning site. 
 
HindIII
NotI
pcDNA3.1(+)-HLA-B	NeoR
6466	bp
TRESNI
TNEMGARF Replace
HindIII (911) 		 NotI (979)
Insert
HindIII (1) 		 NotI (1107)
HindIII
NotI
pcDNA™3.1(+)
5428	bp
NotIHindIII
HindIII	B51	Not1
1113	bp
PCR
Amplify	1	..	1089	using:
HLA-B	HindIII
HLA-B	Not1
1 1089
HLA-B*51_01_01_01_01
1089	bp
a. 
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The digested vector and amplified HLA-B product was then run on an agarose gel, cut 
out and purified as described in Chapter 2.8.1.2. 
 
2.8.3.2 Ligation 
 
Ligation was carried out at a ratio of 3:1 (insert:vector). Ligations were carried out in 
combination with a control (vector only). 50ng/ul vector pcDNA3.1(+) in 4.2ul was added 
to 30ng insert HLA-B cDNA in 1.9ul, 2ul of T4 Ligase Buffer (Cat No. B0202S, NEB, 
SgrDI(6464)		
SspI(6347)		
ScaI(6023)		
PvuI(5913)		
AhdI(5543)		
PciI(4653)		
BstZ17I(4274)		
BsmI(4222)		
BstBI(3984)		
RsrII(3818)		
PflFI	-	Tth111I(3420)		
MscI(3384)		
MfeI		(161)
NruI		(208)
MluI		(228)
SpeI		(249)
CMV	enhancer
NdeI		(484)
NheI		(895)
BmtI		(899)
AflII		(908)
HindIII		(911)
BmgBI		(1300)
EcoNI		(1373)
PpuMI		(1378)
PmlI		(1558)
Bsu36I		(1595)
BsrGI		(1774)
XcmI		(1843)
NotI		(2017)
PaeR7I	-	PspXI	-	XhoI		(2023)
XbaI		(2029)
BbsI		(2255)
DraIII		(2569)
SexAI*		(2859)
StuI		(3091)
AvrII		(3092)
BsaBI*		(3161)
pcDNA3.1(+)-HLA-B	NeoR
6466	bp
b. 
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Ipswich, MA, USA), 1ul T4 Ligase (Cat No. B0202S, NEB, Ipswich, MA, USA) and 
10.9ul NF water at room temperature for 30mins.  
 
The sample was then transformed into E. Coli, plated out, colonies picked and plasmid 
DNA extracted as described in Chapters 2.8.1.4-2.8.1.7. 
 
2.8.4 pcDNA3.1(+) - B2M 
 
The zeocin resistance gene in the CHO-FRT cells was isolated by extracting mRNA from 
the CHO-FRT cells and synthesising cDNA as above. The Zeocin resistance gene was 
incorporated into the pcDNA3.1(+) vector using Gibson Assembly. B2M was then 
amplified and ligated into the pcDNA3.1(+) (Zeo) vector using restriction enzymes.  
Figure 2-3 outlines the methods used for creation of this plasmid. 
 
2.8.4.1 Amplification Of Zeocin Resistance Gene From CHO-FRT cDNA And 
pcDNA3.1(+) Prior To Gibson Assembly 
 
Specific primers to amplify zeocin were made and the fragment amplified using the 
settings in Table 2-8 and the quantities in Chapter 2.8.1.1 
 
Zeocin FP – CAGGATGAGGATCGTTTCGCATGGCCAAGTTGACCAGTGC 
Zeocin RP – TTCGAACCCCAGAGTCCCGCTCAGTCCTGCTCCTCGGC 
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Figure 2-3. (a.) Methods Used To Construct pcDNA3.1(+)–B2M with Zeocin Resistance 
Gene. (b.) Detail Of The pcDNA3.1(+)-B2M Vector 
(a.) Snapgene history to show amplification of the Zeocin resistance gene and 
pcDNA3.1(+) vector with Gibson Assembly primers, followed by Gibson ligation of the 
two-fragments. The B2M gene was amplified with primers encoding the HindIII and 
EcoRV restriction sites and ligated into the plasmid. (b.) Detail of the pcDNA3.1(+)-B2M 
vector. Expression of gene of interest is driven by a CMV promoter immediately upstream 
of the MCS. Expression of the Zeocin resistance gene is driven by the SV40 promotor. 
HLA – Human Leukocyte Antigen, ZeoR/BleoR – Zeocin resistance gene, AmpR – 
ampicillin resistance gene, PCR – polymerase chain reaction, CMV – cytomegalovirus, 
MCS – multiple cloning site, B2M – Beta 2 microglobulin.  
 
 
HindIII
EcoRV
pcDNA3.1	Zeo	B2M
5335	bp
TRESNI
TNEMGARF Replace
HindIII (911) 		 EcoRV (964)
Insert
HindIII (8) 		 EcoRV (388)
HindIII
EcoRV
pcDNA3.1(+)	Zeo
5008	bp
NOSBIG
YLBMESSA Insert	between	DNA	ends
1 .. 4673
Overlap	and	insert
1 .. 415
1 4673
NeoR/KanR
SV40	poly(A)	signal
ori AmpR
CMV	enhancer f1	ori SV40	promoter
NeoR/KanR
Linearized	Vector
4673	bp
PCR
Amplify	2927	..	2138	using:
Primer	40	Vect.FOR	ZeoR_pcDNA3.1(+)
Primer	41	Vect.REV	ZeoR_pcDNA3.1(+)
pcDNA™3.1(+)
5428	bp
1 415
BleoR
Fragment
415	bp
PCR
Amplify	1	..	372	using:
Primer	38	Frag.FOR	ZeoR_pcDNA3.1(+)
Primer	39	Frag.REV	ZeoR_pcDNA3.1(+)
1 372
BleoR
Zeocin-Accurate
372	bp
EcoRVHindIII
B2M	HindIII	EcoRV	PCR	Product
396	bp
PCR
Amplify	2	..	396	using:
B2M	HindIII	Kozak
B2m	EcoRV
2 396
B2M	HindIII	EcoRV	PCR	product
396	bp
PCR
Amplify	58	..	417	using:
B2M	HindIII	Kozak
B2m	EcoRV
58 417
B2M
B2M
974	bp
a. 
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Table 2-8. Thermocycler Settings For Amplification Of Zeocin Resistance Fragment 
Temp Time Cycles 
98°C 0:30 1x 
98°C 0:05 
30x 70°C 0:20 
72°C 0:15 
72°C 5:00 1x 
 
Specific primers to amplify the pcDNA3.1(+) vector were also designed and amplified 
using the settings in Table 2-9 and the quantities in Chapter 2.8.1.1. 
 
pcDNA3.1(+) FP - TGGCCGAGGAGCAGGACTGAGCGGGACTCTGGG 
pcDNA3.1(+) RP – GCACTGGTCAACTTGGCCATGCGAAACGATCCTCATCCT 
 
 
SgrDI(5333)		
SspI(5216)		
ScaI(4892)		
PvuI(4782)		
FspI(4634)		
AhdI(4412)		
BspQI	-	SapI(3406)		
BstZ17I(3143)		
BfuAI	-	BspMI(2889)		
BstBI(2853)		
FseI(2739)		
BglII		(12)
MfeI		(161)
NruI		(208)
MluI		(228)
SpeI		(249)
NdeI		(484)
SnaBI		(590)
Eco53kI		(816)
SacI		(818)
NheI		(895)
BmtI		(899)
AflII		(908)
HindIII		(911)
EcoRI		(1190)
PflFI	-	Tth111I		(1243)
EcoRV		(1291)
BstXI		(1301)
NotI		(1306)
PaeR7I	-	PspXI	-	XhoI		(1312)
XbaI		(1318)
EcoO109I	-	PspOMI		(1324)
ApaI		(1328)
BbsI		(1544)
StuI		(2380)
AvrII		(2381)
BsaBI*		(2450)
MscI		(2466)
BssHII	-	MauBI		(2499)
SgrAI		(2577)
pcDNA3.1	Zeo	B2M
5335	bp
b. 
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Table 2-9. Thermocycler Settings For Amplification of pcDNA3.1(+) Prior to Gibson 
Assembly 
Temp Time Cycles 
98°C 0:30 1x 
98°C 0:05 
30x 69°C 0:20 
72°C 0:25 
72°C 5:00 1x 
 
 
The Zeocin amplicon was then run on an agarose gel and purified over a silica membrane 
as detailed in Chapter 2.8.1.2. The pcDNA3.1(+) vector was also purified and then a 2 
fragment Gibson assembly was carried out at a 3:1 (insert:vector) ratio. 50fmol vector 
mixed with 150fmol of insert and dried in a vacuum concentrator. The DNA was 
resuspended in 5ul of NF water, 5ul Gibson Assembly Mix and incubated at 50°C for 15 
minutes. The sample was then transformed into E. Coli, plated out, colonies picked and 
plasmid DNA extracted as detailed in Chapter 2.8.1.4-2.8.1.7. The vector was sent for 
Sanger sequencing to check for mutations within the Zeocin resistance gene.  
 
2.8.4.2 Amplification, Digestion And Ligation Of B2M Into The pcDNA3.1(+) Zeocin 
Resistant Vector 
 
B2M was then amplified with primers encoding EcoRV and HindIII restriction sites using 
quantities described in Chapter 2.8.1.1 and thermocycler settings in Table 2-10. 
 
B2M FP - GGGAAAAAGCTTATAGCCACCATGTCTCGCTCCGTG 
B2M RP – ATATAGAATTCATATTACATGTCTCGATCCCAC 
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Table 2-10. Thermocycler Settings For Amplification Of B2M Prior To Ligation Into 
pcDNA3.1(+) 
Temp Time Cycles 
98°C 0:30 1x 
98°C 0:05 
30x 64°C 0:15 
72°C 0:05 
72°C 5:00 1x 
 
 
The amplified product and vector were then digested with EcoRV HF (Cat No. R3195S, 
NEB, Ipswich, MA, USA) and HindIII HF and re-run on an agarose gel to remove cut 
fragments as described in Chapter 2.8.3.1 – 2.8.3.2. After digestion, the pcDNA3.1(+) 
vector was also dephosphorylated and ligated at a 3:1 (insert:vector) ratio. The sample 
was then transformed into E. Coli, plated out, colonies picked and plasmid DNA extracted 
as described in Chapter 2.8.1.4 – 2.8.1.7. The vector was sent for sequencing to check for 
mutations within the B2M gene. 
 
2.9 Cell Culture 
 
2.9.1 Transfection Of CHO-FRT Cells With pcDNA5/B2M/HLA-B/MICA*009 Vector 
(Hygromycin Resistant) 
 
 
CHO-FRT cells (Cat No. R75807, ThermoFisher, Waltham, MA, USA) were maintained 
in Ham’s F-12 media (Cat No. B12-615F, Lonza, Basel, Switzerland) with 10% FCS (Cat 
No. 02-00-850, First-Link Ltd, Wolverhampton, UK), 1% penicillin/streptomycin (Cat 
No. P4333, Sigma Aldrich, St Louis, MI, USA) in 6-well plates and grown to 80% 
confluence. Prior to transfection, cells were washed with pre-warmed phosphate buffered 
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sale (PBS) and the media was substituted with 2 ml opti-mem low-serum media (Cat No. 
31985062, ThermoFisher, Waltham, MA, USA).  
 
Lipofectamine 2000 (Cat No. 11668019, ThermoFisher, Waltham, MA, USA) was used 
to transfect both pcDNA5/B2M/HLA-B/MICA*009 and pOG44 (Cat No. V600520, 
ThermoFisher, Waltham, MA, USA) into the CHO-FRT cells. This system utilises Flp-
recombinase encoded in the pOG44 vector to ensure stable transfection of the GOI into 
the FRT site of the CHO-FRT cells, disrupting zeocin resistance and conferring 
hygromycin resistance. The pOG44 and pcDNA5/FRT vectors are designed to be 
transfected at a ratio of 9:1 respectively (Table 2-11).  
 
After the DNA was added to the cells, the plates were incubated at 37°C, 5% CO2 
overnight. The following day, the cells were washed with pre-warmed PBS and the media 
replaced with Ham’s F-12 with 10% FCS, 1% penicillin/streptomycin. Forty-eight hours 
after transfection 200ug/ml hygromycin (Cat No. H3274, Sigma-Aldrich, St Louis, MI, 
USA) selection was added to the media.  
 
Table 2-11. Optimised Transfection Protocol For Lipofectamine 2000 
Mock Test 
15ul Lipofectamine 
2000  
+  
150ul Opti-mem 
9ug pOG44 plasmid 
DNA 
+  
150ul Opti-mem 
15ul 
Lipofectamine 
2000 
+  
150ul Opti-mem 
9ug pOG44 plasmid 
DNA 
 +  
1ug 
pcDNA5/B2M/HLA-
B/MICA*009 plasmid 
DNA 
+ 
150ul Opti-mem 
Incubate for 5 minutes at room temperature Incubate for 5 minutes at room temperature 
Mix and incubate at room temperature for 20 
minutes 
Mix and incubate at room temperature for 20 
minutes 
Add dropwise to labelled 6-well plate Add dropwise to labelled 6-well plate 
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2.9.2 Electroporation Of pcDNA3.1(+)-B2M And pcDNA3.1(+)-HLA-B Vectors Into 
CHO-MICA*009 Cells 
 
The CHO-cells transfected with the triple construct pcDNA5/B2M/HLA-B/MICA*009 
did not adequately express HLA-B (Discussed in Chapter 4). So, an alternative method 
was adopted. Rather than mounting three genes of interest into one large 8Kb vector, I 
used multiple vectors with different antibiotic resistance genes to introduce each gene to 
the CHO-cells. CHO-MICA*009 cells were already available from the Hayday 
laboratory, leaving B2M and the HLA-B constructs to be transfected. To do this I created 
4 vectors, each expressing one GOI, as discussed in Chapters 2.8.3 & 2.8.4: 
 
1. pcDNA3.1-B2M – Zeocin resistant 
2. pcDNA3.1-HLA-B*51 – neomycin resistant 
3. pcDNA3.1-HLA-B*52 – neomycin resistant 
4. pcDNA3.1-HLA-B*35 – neomycin resistant 
 
The pcDNA3.1-B2M vectors was electroporated into the CHO-MICA*009 cells to ensure 
that all CHO-cells were able to express B2M and therefore HLA-B, as without B2M, 
HLA-B would not be expressed on the surface of CHO-cells. Once a stable population of 
CHO-MICA*009/B2M cells were created, three separate populations were created by 
transfecting each HLA-B construct. The CHO-MICA*009/B2M/HLA-B cells were then 
flow sorted and maintained in media with antibiotic selection.  
 
CHO-MICA*009 cells were maintained in Ham’s F-12 media with 10% FCS, 1% 
penicillin/streptomycin and 200ug/ml hygromycin in T175 flasks.  
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Prior to electroporation, media was removed and the cells were washed with pre-warmed 
PBS. Three millilitres of accutase (Cat No. A1110501, ThermoFisher, Waltham, MA, 
USA) was added and the flask was incubated at 37°C, 5% CO2 for 5 minutes.  
 
The cells were then collected and pelleted at 300g for 5 minutes. Three million cells were 
collected and washed with ice cold serum-free Ham’s F-12 media. The cells were then 
resuspended in 250ul serum-free Ham’s F-12 media and transferred to an ice cold 0.4cm 
electroporation cuvette (Cat No. 1652081, Bio-Rad, Hercules, CA, USA). Ten 
micrograms in 2ul of highly purified pcDNA3.1(+)/B2M (containing a Zeocin resistance 
gene) was transferred to the cuvette and immediately transferred to a Bio-Rad MicroPulse 
Electroporator (Cat No. 1652100, Bio-Rad, Hercules, CA, USA) and pulsed at 0.25kV, 
950uF (high capacity and high range). The time correction was 50-60 seconds.  
 
Following electroporation, cells were added to 4 ml of pre-warmed Ham’s F-12 media 
with 10% FCS (no antibiotics) in a 6-well plate and allowed to recover for 24 hours before 
FACS sorting for a MICA+B2M+ population.  
 
The MICA+B2M+ population was allowed to recover in antibiotic-free medium for 24 
hours after FACS sorting before 100ug/ml zeocin and 200ug/ml hygromycin were added 
to the media. After 1 week of growth, pcDNA3.1(+)/HLA-B plasmids encoding 
neomycin-resistance were electroporated into the cell line using the same protocol. After 
resting, cells were FACS sorted for a MICA+B2M+HLA-B+ population.  
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2.9.3 Electroporation Of HLA-B Constructs Into 722.221 HLA-Null Cells. 
 
Despite good expression of the three constructs in the CHO-cells, they did not prove to 
be a good model for carrying out cytotoxicity assays (Discussed in Chapter 4). Thus, 
722.221 (221) cells were used to transfect the three HLA-B constructs instead. 221-cells 
were maintained in Roswell Park Memorial Institute (RPMI) (+ L-glutamine) media (Cat 
No. BE12-702F, Lonza, Basel, Switzerland) with 10% FCS and 1% 
penicillin/streptomycin. Prior to electroporation, cells were agitated with a 5ml pipette to 
break up clumps and 3x106 cells counted. 221-cells were washed three times in ice-cold 
PBS and centrifuged at 300g for 5 minutes per wash. The cells were then resuspended in 
400ul ice-cold PBS and transferred into Bio-Rad electroporation cuvettes, which had been 
pre-chilled to 4°C. Ten micrograms in 2ul of pcDNA3.1(+)/HLA-B vector encoding 
zeocin resistance was added to the centre of the cuvette and kept at 4°C until 
electroporation. 
 
Cuvettes were loaded into a Bio-Rad MicroPulser Electroporator and pulsed at 0.20kV, 
975uF (Saunders et al., 2015). The time correction was 30-40 seconds. Electroporated 
cells were transferred to 6-well plates with RPMI and10% FCS (no antibiotics) for 24 
hours and then flow sorted for HLA-B+ cells. The same procedure was carried out for 
HLA-B*51, B*52 and B*35 constructs.  
 
2.10 Fluorescence Activated Cell Sorting (FACS)  
 
Flow cytometry was used to confirm expression of the transfected constructs on the 
surface of the target cell lines. Several panels were used throughout the project. FACS 
experiments were carried out on a FACS Canto II (BD Biosciences, San Jose, CA, USA) 
 101 
and analysed with Flow-Jo software 8 &10 (TreeStar, Ashland, OR, USA) and a 
Novocyte 3000 (Acea Biosciences, San Diego, CA, USA) with Novoexpress software 
1.2.5 (Acea Biosciences, San Diego, CA, USA). 
 
2.10.1 Antibody And Fluorochrome Panels 
 
2.10.1.1 Target Cells (CHO And 721.221-Cells) 
 
A small, three-colour panel was used to identify MICA*009, B2M and HLA-B on the 
surface of CHO-cells. Only HLA was transfected into 221-cells, thus only one colour was 
used to ensure adequate expression (Table 2-12, Figure 2-4 ).  
 
2.10.1.2 Peripheral Blood Mononuclear Cell Phenotyping And CD107a Expression 
 
A larger eight colour panel was used to phenotype PBMC and carry out CD107a assays 
(Table 2-13, Figure 2-5). 
 
Table 2-12. Antibodies Used For Extracellular Staining Of Target Cells.  
Where more than one antibody is listed, the antibody listed first was used for functional 
assays. If poor staining was noted, then I tried a variety of antibodies to optimise the 
panel 
 
 
Antibody Marker Fluorochrome Manufacturer Clone Cat no. 
Mouse Anti-
human 
MICA/B 
MICA R-Phycoerythrin 
(PE) 
BD Bioscience 6D4 558352 
Mouse Anti-
human B2M 
B2M Fluorescein 
Isothiocynate 
(FITC) 
Biolegend 2M2 316304 
Mouse Anti-
human HLA-
Class I 
HLA-Class I Allophycocyanin 
(APC) 
 
Allophycocyanin 
and cyanine dye 
(APC-Cy7) 
Biolegend 
 
 
Biolegend 
W6/32 
 
 
W6/32 
311409 
 
 
311429 
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Figure 2-4. Emission Spectra For Target Cell Fluorochrome Panel 
 
 
 
Table 2-13. Antibodies Used For Extracellular Staining Of PBMC 
 
Where more than one antibody is listed, the antibody listed first was used for functional 
assays. If poor staining was noted, a variety of antibodies were used to optimise the assay. 
 
Antibody Marker Fluorochrome Manufacturer Clone Cat no. 
Mouse Anti-
human CD3 
CD3 Pacific Blue (P. 
Blue) 
Biolegend HIT3a 344824 
Mouse Anti-
human CD8 
CD8 FITC Biolegend SK1 300906 
Human Anti-
human CD56 
CD56 PE 
 
APC 
Miltenyi Biotec 
 
Biolegend 
AF12-
7H3 
HCD56 
130-100-622 
 
318309 
Mouse Anti-
human 
CD158e 
DX9 Viogreen 
 
APC 
Miltenyi Biotec 
 
Biolegend 
DX9 
 
DX9 
130-108-374 
 
312715 
Mouse Anti-
human TCR 
g/d 
g/d T PE Cy7 Biolegend 
 
B1 
 
331222 
 
 
Human Anti-
human 
CD158e1/e2 
CD158e1/e2 APC Vio 770 Miltenyi Biotec REA 
618 
130-104-884 
7-
Aminoactino
mycin D 
(7AAD) 
7AAD NA Biolegend NA 420403 
Human Anti-
human 
CD107a 
 
 
Mouse Anti-
human 
CD107a 
CD107a APC 
 
PE Vio 615 
 
 
PE 
Miltenyi Biotec 
 
Miltenyi Biotec 
 
 
BD Pharmingen 
REA 
792 
REA 
792 
 
H4A3 
130-112-000 
 
130-111-630 
 
 
555801 
 
 
 
 103 
Figure 2-5. Emission Spectra From Peripheral Blood Mononuclear Cell Phenotyping 
Panel And CD107a Assay 
Viogreen emits on the Amcyan channel and PE Vio615 emits on the PE Texas Red channel 
 
2.10.2 Preparation Of Samples For Flow Cytometry 
 
CHO-cells were first detached from the flask using an appropriate amount of accutase (1-
5 ml) and incubated at 37°C for 5-10 minutes until floating freely. After this stage, all cell 
types were treated according to the same protocol. Cells were washed in FACS Buffer 
(PBS, 1mM EDTA, 2% FBS, 0.1% Sodium Azide (Cat No. S2002, Sigma Aldrich, St 
Louis, MI, USA)) and centrifuged at 800g for 5 minutes. The supernatant was then 
removed and the cells resuspended in 10 ml of FACS Buffer for counting. Approximately 
1x105 target cells (CHO or 221-cells) were stained to monitor extracellular expression of 
transfected constructs. The number of PBMC collected varied considerably between 
donors. Where possible, 1x107 PBMC were used to examine the NK and CD8 T cell 
compartments. 
 
Counted cells were then aliquoted into a 5ml polystyrene FACS tube. The tube was then 
centrifuged at 1,200g for 5 mins to pellet the cells. The supernatant was then removed and 
the tube placed on wet-ice.  
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An antibody cocktail was prepared using the manufacturers recommended doses of each 
antibody in 100ul FACS Buffer. Where relevant, fluorescence minus-one (FMO) 
antibody cocktails were prepared. The cells were resuspended in 100ul of antibody 
cocktail and vortexed to ensure even staining. The mix was then left to stain on wet-ice 
in the dark for 30 minutes. After 30 minutes, the cells were washed once with 1ml of 
FACS Buffer to remove any unbound antibody and resuspended in 300ul of FACS Buffer 
for analysis on a flow cytometer.  
 
2.10.3 FACS Methodology 
 
To ensure reproducible results, the staining protocol above was carried out on all samples. 
In order to allow experimental repeats to be carried out, PBMC were frozen in aliquots. 
Once thawed and stimulated (where relevant), PBMC were used in functional assays on 
the same day to avoid deterioration of the samples. Manual compensation for each 
fluorophore was carried out at the start of each experiment. If a fluorophore was 
substituted for a different colour, then compensation was redone.  
 
2.10.4 CD107a Degranulation Assay 
 
2.10.4.1 Stimulating Peripheral Blood Mononuclear Cells 
 
Where possible, PBMC were stored in aliquots of 5x106 to be used in degranulation assays 
with three experimental repeats. Prior to carrying out the assay, PBMC were thawed at 
37°C and immediately washed with 10 ml PBS and re-pelleted at 800g for 5 mins. The 
cells were then stimulated with 1000U human IL-2 (Cat No. 130-097-742, Miltenyi 
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Biotech, Bergisch Gladbach, Germany) for 15-18hrs in RPMI + 10% FCS + 1% 
penicillin/streptomycin.  
 
2.10.4.2 Counting Natural Killer Cells 
 
After stimulation, PBMC were washed in PBS, counted using a haemocytometer and 
resuspended in culture media. A small aliquot of cells was then removed and the %NK 
cells determined using a flow cytometer (CD3-CD56+). An FMO for the flurophores 
attached to the anti-CD107a antibody was also run at this stage. The proportion of NK 
cells varied considerably. A target of 1x104 NK cells per experiment was set, however 
this was not possible for many samples due to low numbers of circulating NK cells.  
 
2.10.4.3 Preparing Target Cells 
 
The target cell lines were counted at a 1:1 ratio of NK to target cells. Prior to plating, the 
target cell line was stained for surface expression of relevant markers and sorted using 
FACS Aria III (BD Biosystems, San Jose, CA, USA) if less 80%.  
 
For the adherent CHO-cell line, 5x104 cells were plated out 3 days prior to the assay and 
allowed to grow to near-confluence. To increase the number of events, each cell line was 
plated in triplicate. To ensure antibiotic selection did not interfere with the assay, 
antibiotics were removed from the culture media 1 day prior to the assay. On the day of 
the assay, the target cells were assessed to ensure near-confluence and washed with PBS. 
100ul of antibiotic-free culture medium was then added and the cells incubated at 37°C, 
5% CO2.  
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The non-adherent 221-cells were removed to an antibiotic-free media the day before the 
assay and incubated at 37°C, 5% CO2. On the day of the assay, 221-cells were counted 
and aliquoted into 5ml polystyrene FACS tubes in 100ul culture media.  
 
2.10.4.4 Positive And Negative Controls 
 
A positive control was set up consisting of PBMC in 200ul cell culture medium enriched 
with Phorbol 12-myristate 13-acetate (PMA) (Cat No. P8139, Sigma Aldrich, St Louis, 
MI, USA) to a final concentration of 2.5ug/ml and ionomycin (Cat No. IO634, Sigma 
Aldrich, St Louis, MI, USA) to a final concentration of 0.5ug/ml. A negative control was 
set up with PBMC and no target cells in 200ul cell culture media.  
 
2.10.4.5 Setting Up The CD107a Assay 
 
The PBMC were then aliquoted into either a 96 well plate (CHO-cells) or a FACS tube 
(221-cells) in 100ul culture media and 5ul of anti-CD107a. The samples were then 
incubated at 37°C in the dark. After 1 hour, 2ul of monensin (Golgistop, Cat No. 554724, 
BD Bioscience, San Jose, CA, USA) was added and the samples returned to the incubators 
for 4 more hours.  
 
2.10.4.6 Preparing Samples For Staining 
 
The cell culture media containing PBMC was gently removed from each well of the 96 
well plate. PBMC from each sample run in triplicate were combined in a single FACS 
tube. The remaining adherent CHO-cells were then detached from the 96 well plate using 
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accutase and washed in PBS before being added to the PBMC. This step was taken to 
ensure any NK cells adherent to target cells were collected. The sample was then washed 
in FACS buffer and stained as above. 221-cells and PBMC were washed once in FACS 
buffer and stained. 
 
2.11 Prospective Surveillance of Ophthalmic Manifesations of Behçet’s Disease in 
the United Kingdom 
 
2.11.1 Application To The British Ophthalmic Surveillance Unit 
 
 
In order to carry out prospective surveillance of a rare ophthalmic manifestation in the 
UK, researchers can apply to use the infrastructure set up by the British Ophthalmic 
Surveillance Unit (BOSU), part of the Royal College of Ophthalmology (RCOphth).  
 
This application process is formal and researchers submit Part 1 of the application form 
to BOSU detailing the population to be studied, the denominator, inclusion and exclusion 
criteria and projected numbers of patients.  
2.11.2 Research Questions 
 
• What is the incidence of BD related eye disease in the UK 
• What is the clinical presentation and demographics 
• What was the initial management 
• What is the visual acuity at 3 months 
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2.11.3 Case Definition For Reporting Ophthalmologists 
 
Patients must adhere to the International Study Group 1990 definition of BD and have at 
least one of the following: uveitis, retinal vein occlusions, retinal infiltrates, or hypopyon.  
 
Clinicians should also report probable ‘ocular-BD’. Whilst, this is not a common entity, it is 
known to ophthalmologists in the field and is defined by the presence of the ocular features 
of BD but without the systemic features to fulfil the International criteria mentioned above.  
 
2.11.4 Expected Numbers And Rationale 
 
Behçet’s Disease is known to be most common across the ancient Silk Route and most of 
the epidemiological data has come from countries that are most affected. In 2001 Bang et al. 
reported a prevalence of 3.2/100,000, of these 50% (n=320) had eye disease(Bang et al., 
2001). Data from Germany suggested that the prevalence of BD in 1997 was 1.68/100,000 
with between 48%-66% (n=150-210) having BD related eye disease depending on the ethnic 
origins of the patient (Zouboulis et al., 1997). A smaller survey reported the incidence in 
northwest Spain at 0.66/100,000 with 30% having eye disease (n=34 over 5 
years)(González-Gay et al., 2000).  
 
To date, there has been no published data regarding the incidence of BD related eye disease 
in the UK.  
 
I estimated the UK prevalence of BD to be 3/100,000. Over 30 years (based on 2,000 
cases in UK as a whole) the incidence would be 1/1,000,000. I assumed that 20-50% have 
eye disease and would expect to survey 12-30 new cases of eye disease per year based on 
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the UK population of 64,000,000.  
 
There will additionally be patients who present with eye disease confirming the diagnosis 
of BD, which I think will be an additional 13 cases, (25-43 cases/year in total).  
 
There may also be cases reported where the patient presents with ‘ocular BD’ (eye 
involvement but not fulfilling the international criteria mentioned above). I anticipate this 
to be around 5 cases/year. Therefore, the total expected cases of BD related eye disease 
is 30-48 per year. 
 
2.11.5 Funding And Sponsorship 
 
The BOSU costs of this project were funded by Prof. Miles Stanford. Moorfields Eye 
Hospital were the sponsors of the project.  
 
2.11.6 Ethics And Health Research Authority Approval 
 
This project was granted ethical approval from North London Research Ethics Committee 
(IRAS 199980) in December 2015. A minor amendment was added in April 2016, which 
changed the data collection field ‘Month/Year of Birth’ to ‘Age’. This was done on 
request of the Health Research Authority and Sponsor to reduce the chances of patients 
being identified.  
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2.11.7 Consent And The Data Collection Tool 
 
All information collected in BOSU studies is non-identifiable, thus patients are not 
routinely consented to take part in surveillance studies. The data collection tool is peer 
reviewed by the BOSU committee and changes are made in conjunction with the 
researchers. The final data collection tool is submitted to the Health Research Authority 
and the Research Ethics Committee to obtain approval. 
 
2.11.8 Methodology 
 
 
Each month, all consultant and associate specialist ophthalmologists in the UK receive a 
Yellow Card with up to five ophthalmic conditions to report along with a self addressed 
envelope to the RCOphth. ‘New Ophthalmic Involvement in Behçet’s Disease’ was 
included on the Yellow Card one from November 2016-November 2017. When a new 
case is reported to BOSU, I received an email to notify me who had reported the case and 
where they worked.  
 
I then posted a letter describing the study and a data collection tool (Appendix 5 - 
Questionnaire for Reporting Clinicians – Prospective Surveillance of Ophthalmic 
Manifestations of Behçet’s Disease.), along with a self-addressed envelope. If there was 
no reply after two weeks a reminder was posted. After one month, if there was no 
response, I would telephone the individual and remind them verbally. Monthly telephone 
reminders would continue until either a response was received, or I was informed that the 
case was reported in error (Figure 2-6). 
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2.11.9 Data Collection 
 
Data was transcribed from the retuned paper questionnaires into a Microsoft Excel 2016 
spreadsheet (Microsoft Corporation, Redmond, WA, USA). While patient identifiable 
information was not collected, details about patient demographics were collected. This 
included age at presentation, ethnicity, gender and the first half of the patients’ postcode. 
Details of laterality was collected along with the specific dates the patient developed 
systemic signs of BD.  
 
Figure 2-6 . Timeline For Sending Out Questionnaires To Reporting Clinicians For 
Prospective Surveillance Study.  
 
In order to reduce the number of missed or incomplete cases, it is important to send a 
number of reminders to reporting clinicians. In this project, I sent biweekly reminders by 
mail and then followed up with telephone calls. BOSU – British Ophthalmic Surveillance 
Unit 
 
 
I collected information regarding systemic involvement and pre-existing therapy for BD. 
Visual acuity can be measured in a number of ways and was collected in either Logarithm 
of the Minimal Angle of Resolution (LogMAR), or Snellen format and converted to 
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LogMAR-equivalents for analysis. Any pre-existing reason for poor vision was also 
documented. Reporting clinicians were asked to identify the nature of ophthalmic 
involvement and the first line treatment given. 
 
Finally, I collected information regarding the referring unit and where the patient had 
been referred to or from. This was to allow identification of duplicate reporting from 
different centres.  
 
2.11.10 Analysis 
 
The purpose of this study was to establish the incidence of ophthalmic manifestations in 
BD.  Incidence was calculated by dividing the number of correctly identified cases by the 
population of the United Kingdom in 2017. Census data was obtained from the Office of 
National Statistics (ONS). 95% CI of the incidence was calculated using the Wilson 
Method and was calculated using Ausvet statistical package: Sergeant, ESG, 2019. 
Epitools epidemiological calculators. Ausvet. www.epitools.ausvet.com.au. Differences 
in visual acuity between groups was assessed using a two tailed Analysis of Variance 
(ANOVA) with P<0.05 being considered significant.  
 
2.12 Statistical Analysis 
 
Statistical analyses were carried out my myself. Immunogenetic data was imported into 
Microsoft Excel and manipulated within the spreadsheet. Fisher’s Exact Test was used to 
calculate P values for immunogenetic data. A Microsoft Excel plugin was used to carry 
out Fisher’s Exact Test within Microsoft Excel 
(http://www.obertfamily.com/software/fisherexact.html). Odds Ratios (OR) were 
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calculated in Microsoft Excel by dividing the odds of possessing an allele in the disease 
group by the odds in the control group. Standard errors were calculated using a standard 
formula and 95% confidence intervals were constructed for each OR. When n=0, the 
Haldane correction was used to approximate an OR(Haldane, 1945), this is a method of 
adding 0.5 to. 0 field and subtracting 0.5 from the total in order to avoid an error in the 
calculation.  
 
P values were corrected for multiple testing using the Bonferroni-Dunn Correction to 
reduce the risk of Type 1 error, this was carried out using GraphPad Prism Version 7 for 
Macintosh (GraphPad Software, La Jolla, CA, USA). Analysis of variance (ANOVA) was 
used to compare three or more group means and was used to determine whether specific 
ophthalmic manifestations of BD could have caused patients to lose more vision. Graphs 
were constructed in GraphPad Prism and Microsoft Excel. R2 correlations were carried 
out in the functional analyses to determine whether two variables were correlated or not. 
Correlation was carried out in GraphPad Prism. c2 was used to determine whether there 
was a difference in the expected and observed frequencies of alleles and was also carried 
out in GraphPad Prism. 
 
Post-hoc power was calculated in https://clincalc.com/stats/Power.aspx to allow an 
approximation of the risk of Type II errors to inform the discussion. In all cases an α of 
0.05 was assumed for post-hoc calculations. Post-hoc power was only calculated for 
significant results.  
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3 Confirming Known Genetic Risk Factors In A UK Cohort 
Of Individuals With Behçet’s Disease 
 
3.1 The UK Behçet’s Disease Cohort 
 
In 2013, the BD Centres of Excellence were commissioned by the National Health Service 
(NHS) England. These centres were created to give patients with a 
possible/probable/definite diagnosis of BD access to a multidisciplinary team of doctors, 
nurses, psychologists and support workers with a specialist interest in the condition.  
In addition to providing up-to-date and thorough clinical care, the centres have access to 
newer biologic therapies and are funded directly from NHS England. They also offer a 
unique platform for conducting research as patients are well-characterised and highly 
motivated to participate.  
 
There are now over 2000 patients registered across three sites in the UK. In order to 
investigate whether previously reported genetic risk factors are applicable to a UK cohort, 
I collected DNA from 267 BD patients and 445 HCs and analysed a number of 
immunogenetic loci.  
 
3.2 Behçet’s Disease And Healthy Control Demographics 
 
Patients for this project were recruited sequentially from the London clinic between 
01/2006-2/2015, irrespective of ethnicity or disease severity. Demographically matched 
HC were recruited from unrelated friends, partners and spouses of patients.  
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Inclusion criteria: 
• Confirmed BD as per ISG 1990 criteria (ISG, 1990) 
• Over the age of 16 years 
 
3.3 Age 
 
All individuals over the age of 16, fulfilling the inclusion criteria were eligible to be 
included in the study. Healthy controls were deliberately selected to be older than the 
cases to avoid recruiting individuals with unmasked inflammatory disease. Behçet’s 
Disease usually presents before the age of fifty, so wherever possible HCs were selected 
to be older than 40 years. As expected, the two populations were significantly different 
with respect to age (P=0.0001). The median age of the BD group was 41 years 
(interquartile (IQ) range 36-43 years). The median age of the HC group was 54 years (IQ 
range 52-58 years). Neither group was normally distributed (P<0.0001). Figure 3-1 is a 
histogram, illustrating the range of ages in both groups. 
 
Figure 3-1. Histogram Illustrating The Ages Of The Behçet’s Disease And Healthy 
Control Groups At The Time Of DNA Extraction.  
The median age of the HC group was 13 years older than the BD group.  HC – Healthy 
Control, BD – Behçet’s Disease. 
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3.4 Ethnicity 
 
 
A full family history was taken at the time of consenting to accurately capture an 
individual’s ethnicity. These were then condensed into United Nations ethno-geographic 
regions (https://unstats.un.org/unsd/methodology/m49/overview/), or identified as 
‘mixed ethnicity’ where this was not possible.  
 
Figure 3-2 shows the ethnicity of patients and healthy controls recruited in the study. As 
can be seen, 76% of individuals were European. These were patients who claimed that all 
their antecedents for 3 generations were from Europe. Twelve per cent of participants 
claimed to be of Middle-Eastern ancestry and 6% from South Asia. Table 3-1 shows the 
breakdown of ethno-geographic regions by country of birth for each participant. 
 
Figure 3-2. Self-Reported Ancestry Of Participants By UN Ethno-Geographic Regions 
The majority of participants were of European ancestry. Percentages are shown at the 
end of each bar.  
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3.5 Clinical Manifestations Of Behçet’s Disease 
 
Behçet’s Disease is a clinical diagnosis. There are two widely used diagnostic criteria. 
The ISG 1990 criteria (ISG, 1990), was designed principally as a research tool, whereas 
the ICBD criteria (International Team for the Revision of the International Criteria for 
Behçet’s, 2014) was designed to aid clinical diagnosis. All individuals recruited for this 
study fulfilled the ISG 1990 criteria. Table 3-2 shows a breakdown of clinical 
manifestations documented for each patient over their disease-course.  
 
In 2008, Mahr et al. published an epidemiological analysis BD in a Parisian county 
(Seine-Saint-Denis) (Mahr et al., 2008). The investigators collected data using health-
registry databases and questionnaires given to care-providers. Patients with BD were then 
subdivided by ethnicity based on the country of origin of their grandparents, resulting in 
five groups (European, Asian (including Turkish), Sub-Saharan African, North African, 
Non-continental French and Other). I used the data gathered from the 79 individuals in 
this study to compare the manifestations of BD in the UK cohort and found no difference 
between the percentage of individuals with different disease manifestations (P=0.5582). 
 
Table 3-1. Participant Ethno-Geographic Regions By Country Of Birth 
Europe 
Belgium 
France 
Germany 
Holland 
Ireland 
Sweden 
United Kingdom 
Greece 
Italy 
Spain 
Middle East 
Egypt 
Israel 
Jordan 
Palestine 
Syria 
Turkey 
South Asia Afghanistan Bangladesh 
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India 
Pakistan 
Sub-Saharan Africa Nigeria Uganda 
East Asia 
China 
Japan 
Korea 
Vietnam 
North Africa Morocco 
 
Table 3-2. Clinical Manifestations Of Behçet’s Disease In The UK Cohort Compared To 
Another European And Non-European Cohort.  
Column in bold represents the UK cohort described in this project.  
 United Kingdom % 
European % (Mahr et 
al., 2008) 
Non-European % (Mahr 
et al., 2008) 
Recurrent oral 
ulceration 100 100 100 
Cutaneous 
manifestations 81 95 88 
Genital ulceration 78 79 80 
Arthropathy/Arthritis 60 58 60 
Ocular manifestations 30 58 48 
Vascular 
manifestations 16 37 28 
Neurological 
involvement 15 5 12 
Gastrointestinal 5 Not Reported Not Reported 
 
Of note, the frequency of eye disease in both the European and non-European cohorts 
were higher than in the UK. There are a number of possibilities that could explain this 
finding: 
 
1. Ophthalmic disease in the UK cohort was reported by a uveitis specialist who saw 
all the patients and only documented BD-related eye disease. Mahr et al. extracted 
data from registries which are likely to have less granular detail and may include 
ophthalmic problems that are not BD-related. 
2. Individuals from the Middle-East and Southern Europe have been noted to have a 
higher incidence of ophthalmic involvement in BD. There is little reliable data to 
compare the incidence of BD-related eye disease in Northern Europe. 
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3.6 European Ancestry Informative Markers 
 
 
Study of HLA and its associated genes is complicated by huge variation within the region. 
In addition, there is substantial geographic variation. In order to conduct robust studies of 
specific HLA associations, it is useful to ensure the study population is defined and that 
the control group is matched. To try and reduce the noise caused by population admixture, 
In collaboration with the Genome Centre at QMUL, we applied a set of ancestry 
informative markers (AIMs) specific for European populations to the sequencing panel. 
Imperfect matching between cases and controls can lead to spurious associations, or 
failure to detect true associations (Marchini et al., 2004). In 1978, Menozzi et al. described 
the use of principle component analysis (PCA) in human genetics (Menozzi et al., 1978). 
Highly dimensional data can be summarised by PCA to capture the variables that best 
describe the data set, allowing visualisation of allele frequency differences amongst 
populations. It is possible to correlate principle components of data with meaningful 
geographic axes. Shriver et al. proposed that certain markers with distinct frequency 
differences across populations may be highly informative for assigning ancestry (Shriver 
et al., 2003). These markers are referred to as AIMs. A small number of AIMs may be 
used to perform population clustering. We used a panel of 25 AIMs designed to identify 
individuals from Europe in order to exclude individuals in the data set who may have had 
ancestry elsewhere in the world. Amplicons for each AIM were designed, amplified and 
sequenced in simultaneous runs to other immunogenetic loci. The sequences were then 
aligned and SNPs called. Principle component analysis was used to delineate the spread 
of AIMs. Only those individuals with SNPs equating to Europe were used in the European 
subgroup (Figure 3-3). This work was carried out by Ian Donaldson at the QMUL 
Genome Centre. 
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After quality control, there were 197 individuals (73% of the total BD cohort) with BD 
and 335 HCs (75% of the total HC cohort) in the European subgroup, enabling us to match 
BD and HC individuals at an ancestral level.  
 
Figure 3-3. Principle Component Analysis Of European Ancestry Informative Markers  
Using PCA, the AIMs were clustered and individuals not of European ancestry were 
excluded from the subgroup analysis 
 
3.7 Associations Between HLA-A & B And Behçet’s Disease In The United 
Kingdom Cohort  
 
3.7.1 HLA-A & B Allele Frequencies 
 
A total of 712 individuals were recruited, made up of 267 patients with BD and 445 
demographically matched healthy controls (HC). HLA-A was typed at medium-high 
resolution on a Luminex platform. HLA-B and MICA alleles were determined using 
sequence-based typing at high-resolution (Appendices 2 and 3) and ambiguous calls were 
confirmed on a Luminex platform or via SSP (Appendix 1). After quality control, HLA-
A alleles were obtained from 260 (97.38%) cases and 426 (95.73%) controls (Figure 3-4), 
HLA-B alleles were obtained from 266 (99.63%) cases and 443 (99.55%) controls (Figure 
3-5). 
 
Relevant HLA associations are shown in Table 3-3. Within the UK cohort, HLA-B*51 was 
associated with BD (P=1.52x10-8 Pc=4.42x10-7, Odds Ratio (OR)=2.86, 95% Confidence 
Behcet’s Disease
Health Controls
Behcet’s Disease
Health Controls
Individuals of European Ancestry 
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Interval (CI) 1.98-4.13). Smaller risk effects were also identified for HLA-B*18, but lost 
significance after correcting for multiple testing (P=0.0054, Pc=0.1236, OR=2.25, 95% 
CI 1.29-3.72), HLA-A*25 (P=0.0121, Pc=0.2427, OR=2.51, 95% CI 1.17 - 5.41) and 
HLA-A*26 (P=0.0291, Pc=0.4634, OR=1.76, 95% CI 1.00 - 3.10). Protective effects were 
found from HLA-B*58 (P=0.0017, Pc=0.0489, OR=0.09, 95% CI 0.01-0.64), HLA-B*15 
(P=0.0065, Pc=0.1558, OR 0.48, 95% CI 0.29-0.82), HLA-B*44 (P=0.0485, Pc=0.4586, 
OR=0.71, 95% CI 0.51-0.99) and HLA-A*33 (P=0.0131, Pc=0.2645, OR=0.45, 95% CI 
0.22 - 0.92), however the latter three alleles did not survive correction for multiple testing.  
 
Figure 3-4. HLA-A Allele Frequencies >1% Within The United Kingdom Cohort 
There were no HLA-A alleles that were associated with BD, after correcting for multiple 
testing 
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Figure 3-5. HLA-B Allele Frequencies > 1% Within The United Kingdom Cohort 
HLA-B*51 was associated with BD (*** indicate P<0.0001) after correcting for 
multiple testing. 
 
 
                 
 
 
 
 
Table 3-3. HLA-A And -B Associations In The United Kingdom Cohort.  
P was considered significant if <0.05. Pc – Bonferroni-Dunn correction for multiple 
testing, P and Pc in Bold are significant after correction for multiple testing. HLA – 
Human Leukocyte Antigen, UK – United Kingdom, HC – Healthy Control, BD – 
Behçet’s Disease, OR – Odds Ratio, 95% CI – 95% Confidence Interval 
 
HLA Type UK Cohort (HC n=445, BD n=267) 
 HC (n) 
HC 
(%) 
BD 
(n) 
BD 
(%) P Pc OR 95% CI 
Increased Risk         
HLA-B*51 52 6.06 80 15.56 4.34x10-5 0.0009 2.13 1.49-3.06 
HLA-B*18 23 2.68 30 5.84 0.0054 0.1236 2.25 1.29-3.92 
HLA-A*25 11 1.2 17 3.1 0.0121 0.2427 2.51 1.17-5.41 
HLA-A*26 24 3.2 26 5.1 0.0291 0.4634 1.76 1.00-3.10 
Reduced Risk         
HLA-B*58 19 2.21 1 0.19 0.0017 0.0489 0.09 0.01-0.64 
HLA-B*15 63 7.34 19 3.70 0.0065 0.1558 0.48 0.29-0.82 
HLA-B*44 126 14.69 56 10.89 0.0485 0.4586 0.71 0.51-0.99 
HLA-A*33 36 4.3 10 2.3 0.0131 0.2645 0.45 0.22-0.92 
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3.7.2 HLA-B Associations In The HLA-B*51- Individuals In The United Kingdom 
Cohort 
 
HLA-B*51- individuals were then analysed to see whether other HLA-B associations 
became relevant. In this analysis, the HLA-B*18 association strengthened and became 
significant after correcting for multiple testing (P=0.0018, Pc=0.0458, OR=2.47, 95% CI 
1.42-4.32).  
 
3.7.3 Presence/Absence And Gene-Dosage Of Bw4 Bearing Alleles In The United 
Kingdom Cohort  
 
Alleles were identified as coding for Bw4 or Bw6 based on current databases published 
by the European Bioinformatics Institute. Presence or absence of Bw4 was analysed for  
each individual and gene-dosage of Bw4-bearing alleles was calculated (i.e. an individual 
may have a maximum of four Bw4 bearing-alleles if both alleles of HLA-A & B encode 
an HLA allotype with the Bw4 epitope such as HLA-A*23/A*24 and HLA-B*51/B*44). I 
found no disease association between presence/absence or gene dosage of Bw4-bearing 
alleles in the UK cohort (Figure 3-6). 
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Figure 3-6. Gene Dosage Of Bw4 In The United Kingdom Cohort.  
There was no difference in the presence/absence or dosage of Bw4 between BD and HC. 
 
 
 
Table 3-4. HLA-A And -B Associations In The European Subgroup. 
 
Those in bold signify significant (P<0.05) results. Bonferroni was not applied the 
subgroup testing due to its punitive effects on power.  HLA – Human Leukocyte Antigen, 
UK – United Kingdom, HC – Healthy Control, BD – Behçet’s Disease, OR – Odds Ratio, 
95% CI – 95% Confidence Interval 
 
 
 
 
3.8 Associations Between HLA-A & -B And Behçet’s Disease In The European 
Subgroup  
 
I applied the AIMs to the UK cohort to create a European subgroup of BD and HCs. The 
European subgroup comprised 532 individuals of whom 198 had BD (37.2%) and 334 
were HC (62.8%). HLA-A alleles were available for 192 BD (97.5%) and 321 HC 
(95.9%). HLA-B alleles were available for 197 BD (100%) and 333 HC (99.4%).  
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 HC (n) HC (%) BD (n) BD (%) P OR 95% CI 
Increased Risk        
HLA-B*51 47 7.01 46 11.62 0.0131 1.74 1.14-2.67 
Reduced Risk        
HLA-B*58 15 2.24 2 0.51 0.0398 0.22 0.05-0.97 
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3.8.1 HLA-A & -B Allele Frequencies In The European Subgroup 
 
In the European subgroup, HLA-B*51 maintained an association with BD (P=0.0131, 
Pc=Not Applied (NA), OR 1.74, 95% CI 1.14-2.67) and HLA-B*58 conferred protection 
(P=0.0398, Pc=NA, OR=0.22, 95% CI 0.05-0.97) (Table 3-4). No other associations were 
identified. 
 
3.8.2 HLA-B Associations In HLA-B*51- Individuals In The European Subgroup  
 
I then conditioned on the HLA-B*51- individuals in the European subgroup. HLA-B*58 
retained its protective effects in this group (P=0.0011, Pc=NA, OR=0.06, 95% CI 0.01-
0.94), but no risk-alleles were identified.  
 
3.8.3 Presence/Absence And Gene-Dosage Of Bw4 Bearing Alleles In The European 
Subgroup 
 
I repeated the Bw4 presence/absence and gene dosage analysis in the European subgroup, 
but there were no associations between Bw4 and BD identified. 
 
3.9 HLA-A & -B Associations In Patients With Ophthalmic Manifestations Of 
Behçet’s Disease 
 
There is evidence to suggest that HLA-B*51 is associated with ophthalmic manifestations 
of BD (Gul et al., 2001). To investigate this in our cohort, I stratified the disease group 
into those with mucocutaneous disease (MC) and those with ophthalmic involvement. I 
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identified 80 individuals in the cohort with ophthalmic manifestations of BD. HLA-B*51 
was strongly associated with ocular involvement in our cohort (P=3.71x10-8, Pc=NA, 
OR=4.17, 95% CI 2.58-6.74), with an odds ratio 1.6x higher than in MC disease alone 
(P=1.78x10-5, Pc=NA, OR 2.57, 95% CI 1.70-3.91). Figure 3-7 shows the breakdown of 
ocular manifestations in BD found in the UK cohort. As can be seen, retinal vasculitis and 
panuveitis were the most common manifestations, occurring in 40% of individuals. 
Retinal infiltrates were identified in 30% and anterior uveitis and retinal vein occlusions 
were reported in 20%. Scleritis is unusual in BD and not typically thought to be an 
associated pathological finding, but was present in 5% of individuals.  
 
Figure 3-7. Ocular Manifestations of Behçet’s Disease in the United Kingdom Cohort 
(n=80) 
 
3.10 MICA Allele Frequencies In United Kingdom Cohort 
 
MICA allele level sequencing is discussed in materials and methods. Allele frequencies 
were calculated for the UK cohort and the European subgroup. After quality control, 
MICA alleles were available for 431 HC (96.9%) and 262 BD (98.1%). Figure 3-8 shows 
the breakdown of allele frequencies in the UK cohort.  
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There was a suggestion that MICA*009 (A6) contributed to the risk of developing BD 
(P=0.0002, Pc=0.0045, OR=1.80, 95% CI 1.31-2.47). There was also a small effect from 
MICA*019 (A5) (P=0.0383 Pc=0.4434, OR 1.72, 95% CI 1.05-2.81). Allele frequencies 
can be seen in Table 3-5. 
 
Five different TM repeats were found in the HC and BD population (A4, A5, A5.1, A6, 
A9). However, no specific TM repeat was associated with BD. Analysis of the frequency 
of TM repeats can be found in  
 
Table 3-6. The MICA TM repeat frequencies were compared against reported frequencies 
in European cohorts (http://www.allelefrequencies.net/mic6001a.asp) to test HWE and 
were not found to deviate substantially (c2 = 3.468, df 4, P=0.4812). 
 
 
Figure 3-8. MICA Allele Frequencies In The UK Cohort. 
MICA*009 (A6) is associated with BD (** = P<0.001) after correction for multiple 
testing. 
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Table 3-5. MICA Allele Frequencies In The UK Cohort (Ordered By Effect Size) 
There is an association between MICA*009 (A6) and BD. HC – Healthy Control, BD – 
Behçet’s Disease, OR – Odds Ratio, 95% CI – 95% Confidence intervals 
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MICA TM  
Repeat 
UK Cohort (HC n = 431, BD n = 262) 
  HC (n) 
HC 
(%) 
BD 
(n) 
BD 
(%) P Pc OR 95% CI 
Increased  
Risk          
MICA*009 A6 89 10.35 91 17.20 0.0003 0.0045 1.80 1.31-2.47 
MICA*019 A5 33 3.84 34 6.43 0.0383 0.4434 1.72 1.05-2.81 
MICA*012 A4 18 2.09 13 2.46 0.7096 0.9997 1.18 0.57-2.43 
MICA*017 A9 27 3.14 19 3.59 0.6462 0.9997 1.15 0.63-2.09 
MICA*001 A4 10 1.16 7 1.32 0.8053 0.9997 1.14 0.43-3.01 
MICA*008 A5.1 272 31.63 153 28.92 0.3082 0.9880 0.88 0.69-1.11 
MICA*007 A4 43 5.00 27 5.10 1.0000 1.0000 1.02 0.62-1.67 
Reduced  
Risk          
MICA*011 A6 18 2.09 11 2.08 1.0000 1.0000 0.99 0.47-2.12 
MICA*006 A6 14 1.63 8 1.51 1.0000 1.0000 0.93 0.39-2.23 
MICA*010 A5 52 6.05 28 5.29 0.6356 0.9997 0.87 0.54-1.39 
MICA*002 A9 106 12.33 56 10.59 0.3447 0.9904 0.84 0.6-1.19 
MICA*018 A4 29 3.37 15 2.84 0.6384 0.9997 0.84 0.44-1.57 
MICA*027 A5 14 1.63 6 1.13 0.4978 0.9990 0.69 0.26-1.82 
MICA*004 A6 104 12.09 52 9.83 0.2206 0.9608 0.79 0.56-1.13 
MICA*016 A5 15 1.74 6 1.13 0.4981 0.9990 0.65 0.25-1.68 
MICA*023 A5.1 16 1.86 3 0.57 0.0554 0.5499 0.30 0.09-1.04 
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Table 3-6. Frequency Of MICA Transmembrane Repeats In The UK Cohort. 
There is no association between TM repeats and BD. TM – Transmembrane, HC – 
Healthy Control, BD – Behçet’s Disease 
 
 
TM Repeat 
UK Cohort (HC n = 431, BD n = 262) 
HC (n) HC% BD (n) BD% P 
A4 100 11.63 62 11.72 1.0000 
A5 114 13.26 74 13.99 0.7503 
A5.1 288 33.49 156 29.49 0.1212 
A6 225 26.16 162 30.62 0.0706 
A9 133 15.47 75 14.18 0.5412 
 
 
 
Table 3-7. HLA-B Allele Frequencies In The MICA*009+, HLA-B*51- Population. 
Due to the strong LD that exists between MICA*009 and HLA-B*51, I investigated 
associations in the MICA*009+, HLA-B*51- population. There was a protective effect 
found between HLA-B*52 and MICA*009 in the HC group. HC – Healthy Control, BD – 
Behçet’s Disease, LD – Linkage Disequilibrium, Other – HLA-B Alleles with a frequency 
of less than 5%.  
 
 
HLA-B 
allele 
MICA*009+, HLA-B*51- individuals in the UK Cohort 
 (HC n = 82, BD n = 98)   
HC HC BD BD P Pc OR 95% CI 
(n) (%) (n) (%) 
B*52 20 24 5 5 0.0003 0.0028 0.21 0.07-0.59 
B*07 15 18 25 26 0.2827 0.7353 1.39 0.68-2.87 
B*35 12 15 6 6 0.0799 0.3934 0.42 0.15-1.17 
B*08 7 9 16 16 0.1778 0.6242 1.91 0.75-4.9 
B*44 7 9 12 12 0.4731 0.8401 1.43 0.54-3.83 
B*27 2 2 5 5 0.4572 0.8401 2.09 0.4-11.08 
B*40 2 2 10 10 0.0679 0.3886 4.18 0.89-19.67 
Other 17 21 19 19 0.8532 0.8532 0.94 0.45-1.94 
 
3.11 MICA Allele Frequencies In European Subgroup 
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The European AIMs were then applied to the MICA data to create a European subgroup. 
After quality control, MICA sequences were available for 181 BD (91.7%) and 318 HC 
(95.4%). A planned-comparison test confirmed that the associations found in the UK 
cohort were maintained within the European subgroup, but with a smaller effect size. 
MICA*009 (A6) (P=0.0013, Pc=NA, OR=1.85, 95% CI 1.28-2.68) contributed to the risk 
of developing BD. There was no association between any TM repeat in the European 
subgroup.  
 
 
3.12 MICA Allele Frequencies In HLA-B*51- Individuals 
 
Linkage disequilibrium (LD) between HLA-B*51 and MICA*009 (A6) was calculated in 
the UK cohort and European subgroup (D’=0.88 and 0.82 respectively). Given the strong 
LD between these regions, I was curious to analyse the MICA allele frequency in the HLA-
B*51- population. I found that MICA*009 (A6) maintained its disease association 
(P=0.0001, Pc=NA, OR=2.32, 95% CI 1.50-3.58). To ascertain whether this MICA 
association is independent of HLA or in LD with another HLA-B locus, the HLA alleles 
carried by individuals in this group were explored (Table 3-7). Protective effects from 
carriage of HLA-B*52 and MICA*009 (P=0.0003, Pc=0.0028, OR=0.21, 95% CI 0.07-
0.59) were found. This finding is not surprising as HLA-B*51 and B*52 are closely related 
and there are previous reports of LD between HLA-B*52 and MICA*009 despite its 
protective effects in BD (Eyerci et al., 2018). MICA transmembrane polymorphisms were 
then analysed for the HLA-B*51- population, but no specific TM repeat was associated 
with BD. 
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3.13 MICA Allele Frequencies In Ophthalmic Behçet’s Disease 
 
The group of BD cases with ophthalmic involvement was then analysed to ascertain 
whether there were any MICA associations specific to that group. I found a MICA*009 
(A6) association (P=0.0029, Pc=NA, OR=2.03, 95% CI 1.29-3.20) in keeping with the 
trend from the larger cohort, but no other significant results. There was no specific TM 
repeat associated with ophthalmic disease. 
 
 
3.14 Discussion Of Findings 
 
 
This study aimed to identify whether previously reported genetic susceptibility loci were 
applicable to a UK cohort of individuals with BD, a group which is not well described in 
the literature. 76% of individuals with BD in the UK claim to be of European ancestry. 
Using a panel of AIMs, 73% of individuals had AIMs that were consistent with a 
European lineage; a finding that closely correlated with the self-reported ethnicity from 
participants.  
 
HLA-B*51 was associated with BD with an OR of 2.13. The data was well powered to 
calculate this association with a post-hoc power of 98%. When the data was filtered to 
only examine those of European ancestry, HLA-B*51 remained significant, but the OR 
reduced to 1.74 (Table 3-3 and Table 3-4) and the post-hoc power reduced to 48%, 
suggesting that there was significant risk of type II errors. These effect sizes are lower 
than those previously reported in other cohorts as illustrated in Table 3-8, which 
summarises the effect sizes from 4,800 cases and 16,289 controls published in 2009 (de 
Menthon et al., 2009). In this paper, the authors found that the pooled OR for HLA-B*51 
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was 5.90 (95% CI 4.87-7.16). One of the limitations cited by the authors in this meta-
analysis was the considerable heterogeneity found in the literature. The effect of including 
25% non-Europeans in our cohort had a small but significant effect on the OR. Many 
cohorts do not fully investigate the ethnicities of participants; thus, any attributable 
heterogeneity may remain unaccounted for.  
 
Recent data from Ombrello et al. in 2014 found the OR for HLA-B*51 to be 3.0 (95% CI 
2.6-3.4) in a large Turkish cohort of 1190 BD cases and 1257 controls (Ombrello, Kirino, 
et al., 2014). In 2017, the same group used the Immunochip to identify immunogenetic 
loci implicated in BD in 1900 BD cases and 1779 controls and found the OR to be 3.26 
(95% CI 2.89-3.68) (Takeuchi et al., 2017).  
 
A number of other disease-susceptibility loci have been reported within and around the 
short arm of chromosome 6. A possible association between HLA-B*18, A*25 and A*26 
and BD was found, all of which were abrogated when controlling for multiple testing. In 
2002, Gul et al. found a weak protective effect from HLA-B*18 in a Turkish cohort (Gul 
et al., 2002). This was replicated in 2013, in a Spanish population (Montes-Cano et al., 
2013). Both of these effects were eliminated when correcting for multiple testing. There 
are no studies which support the finding that HLA-B*18 is associated with BD. An 
explanation for this finding could be the relative paucity of studies that have reported 
HLA allele frequencies in Eastern Europe, where HLA-B*18 is most commonly found 
(Figure 3-9). 
 
HLA-A associations are also recognised in BD. There are no previous reports of an HLA-
A*25 association, but there are several A*26 associations throughout the literature. Most 
recently, Al-Okaily et al. reported an association with an OR of 3.25 in a Saudi population 
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(Al-Okaily et al., 2016). Similar associations have been reported in Taiwanese, Japanese 
and Greek populations (Y. M. Chung et al., 1990; Kaburaki et al., 2010; Mizuki, Ohno, 
et al., 1997). Meguro et al. conducted a GWAS in 300 Japanese cases and controls, 
looking to identify risk loci within and around the MHC (Meguro et al., 2010). The 
authors reported an OR of 2.07 in the whole cohort and 2.96 in those who were HLA-
B*51-. The majority of the effect was contributed by HLA-A*26:01. There was also a 
significant effect from HLA-F*01:01:01 and HLA-G*01:01:02. There is substantial LD 
between the implicated HLA-F and –G loci with HLA-A*26, thus HLA-A*26 was thought 
to independently increase the risk of BD in this group.  
Table 3-8. Forest Plot Of Results Of Published Studies On The Association 
Between HLA–B*51/B5 And Behçet’s Disease 
Odds ratios for the risk of HLA–B*51/B5 allele carriers to develop BD compared with 
noncarriers. The dashed vertical line indicates the pooled value for the entire population 
considered. 95% CI = 95% confidence interval; E = Eastern; Serol. = serologic; JBDRC 
= Japanese Behçet’s Disease Research Committee; N = North; M = Middle; NR = not 
reported; S = Southern; ISG = International Study Group; Molec. = molecular. 
Reproduced with permission from (de Menthon et al., 2009). 
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HLA-B*58 was present in 2.2% of controls and 0.19% of cases in our cohort and was 
found significant in its protective effects. The data has post-hoc power of 60% and is 
therefore at risk of a type II error. The protective effects of HLA-B*58 have previously 
been reported in a Spanish cohort with a similar allele frequency. Less robust effects have 
been reported in Moroccan, Turkish and Italian Cohorts (Choukri et al., 2001; Gul et al., 
2002; Kera et al., 1999). It is not appropriate to draw direct comparisons between the 
effect of HLA-B*51 and B*58 in BD for several reasons. Firstly, the risk-effect of HLA-
B*51 in BD is established and has been widely and consistently reported across the 
literature, whereas there are only a handful of reports of the protective effects of HLA-
B*58. Secondly, HLA-B*51 is more frequently found across most populations than B*58 
(Figure 3-9). However, it is notable that both alleles encode the Bw4 epitope that interacts 
with KIR3DL1. 
 
It has been suggested that polymorphisms outside the Bw4 encoding region may have an 
effect on Bw4-KIR3DL1 affinity (Sanjanwala et al., 2008). Despite B*51 and B*58 both 
encoding the NIALR Bw4 motif, they differ at positions 67 of the α1 domain 
(Phenylalanine –Methionine); 94,95 and 97 of the α2 domain (threonine, tryptophan, 
threonine – isoleucine, isoleucine, arginine); 114 and 116 of the α2 domain (asparagine, 
tyrosine – aspartic acid, serine) and 171 of the α2 domain (histidine – tyrosine). 
Sanjanwala et al. conducted mutagenesis experiments on HLA-B*51:01 and B*15:13 and 
found that in addition to the substitutions above, B*15:13 also differed at positions 45, 46 
of the α1 domain, 113 of the α2 domain and 194 of the α3 domain. Of these positions, 
they found that the largest effects of mutagenesis on Bw4 binding were seen when 
changes were made to positions 67, 116 and 194, with smaller contributions from residues 
94, 95, 97, 113, and 171.  
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Associations between MICA alleles and TM repeats in BD were investigated. I found a 
modest association between MICA*009 (A6) and BD, with an OR of 1.80. MICA*019 
(A5) was more commonly found in the BD group, but the association did not survive 
correction for multiple testing. These findings are in keeping with MICA data from other 
populations. Despite the small sample size, a post-hoc power of 75.6% based on an α of 
0.05 was calculated, suggesting that the data is slightly underpowered and that there is a 
chance of type II error. 
 
Despite the MICA*009 (A6) association, there was no overall A6-effect seen in the cohort 
(Table 3-6). MICA*009 is in strong linkage disequilibrium (LD) with HLA-B*51 
(D’=0.88 in the UK cohort) and the association found is likely to be due to this LD. The 
same MICA alleles were associated with BD in the European subgroup, but no specific 
association with a TM repeat.  
 
In the HLA-B*51- individuals, there was a MICA*009 (A6) effect, independent of other 
HLA-B loci. Park et al. found that the TM repeat MICA A6 maintained an effect in the 
HLA-B*51- individuals in a Korean cohort, but did not analyse the alleles that the TM 
repeats were coded within (Park et al., 2002). However, I was unable to replicate these 
findings. In none of the analyses run did I find an A6 association.  
 
In this study, MICA*004 was the most commonly found MICA A6 allele followed by 
MICA*009, MICA*011 and MICA*006. This finding is in accordance with global MICA 
frequencies, where MICA*004 occurs in up to 27% of Brazilians, 50% of Yoruba 
Nigerians and 17% of English individuals (Marin et al., 2004; Norris et al., 2001; W. Tian 
et al., 2003). MICA*009 is more commonly found across the South and Central Asia (with 
high frequencies in Brazil and lower frequencies in Europe), MICA*011 and *006 have 
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been reported at low levels across the Asia, Europe and South America. All MICA allele 
frequencies were within HWE of those expected.  
 
Finally, I examined whether any specific MICA associations were found within the 
ophthalmic group. In the literature, MICA A4 has been associated with ankylosing 
spondylitis-related uveitis, but not with ankylosing spondylitis (Goto et al., 1997). I was 
able to identify MICA*009 (A6) as a risk factor for developing BD related uveitis, but 
did not find any TM repeats associated with eye disease. 
 
3.15 Chapter Summary 
 
In this study, HLA-B*51 was confirmed as the major risk factor for developing BD in a 
UK cohort. Furthermore, I identified that the effect of HLA-B*51 remains a risk factor in 
a European subgroup, albeit to a lesser degree. HLA-B*58 was found to be protective in 
a small number of individuals and HLA-B*18 a risk allele in HLA-B*51- individuals. HLA-
B*51 contributed more risk in those who developed ocular disease compared to MC 
disease alone. Finally, the association between MICA*009 (A6) and BD was confirmed 
in the UK cohort and in those of European ancestry. These findings are important for 
future work in this patient group. The role of HLA-B*51 in disease pathogenesis remains 
elusive. It is possible that the slow assembly of HLA-B*51 relative to other HLA-B 
allotypes, coupled with its ability to bind peptides promiscuously may result in suboptimal 
recognition from CD8 T cells. Equally, recent evidence to suggest that ERAP1 variants 
contribute towards development of BD are intriguing (Guasp et al., 2017). 
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Figure 3-9. Global Allele Frequencies of HLA-B*51, B*18 and B*58.  
 
Blue dots indicate an allele frequency of 0-10%, green 10-25% and orange >25% 
(www.allelefrequencies.net).  
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These variants may contribute toward altered peptide trimming leading to altered CD8 T 
cell recognition, alternatively, the pathogenic role of ERAP1 in BD might be related to 
its modulation of NK recognition of HLA-B*51. There are previous studies 
demonstrating that downregulation of ERAP1 expression in human tumour cell lines 
result NK cell-mediated killing, particularly if target cells express HLA allotypes that 
bind specific peptides. It might be that however, that the effect of HLA-B*51 in BD is 
partly explained by its interaction with KIR3DL1 via Bw4. This interaction remains 
largely unexplored in BD and will be discussed further in the next chapter.  
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4 KIR3DL1/S1 Associations And Function In Behçet’s Disease 
 
In Chapter 3, I confirmed the genetic associations previously reported in the UK Cohort 
and demonstrated that conditioning on a European subgroup made little difference to the 
overall associations. In this chapter, I discuss the impact of KIR3DL1/S1 allelic variation 
in the development of BD on a genetic level. I also attempt to construct a functional 
system to test the effects of KIR3DL1/S1 allotypes by transfecting various HLA-B 
constructs into two cell lines from different species.  
 
4.1 KIR3DL1/S1 Presence/Absence In Behçet’s Disease 
 
To investigate allelic variation within KIR3DL1/S1, I included amplicons to allow 
sequence level amplification and analysis of the KIR3DL1/S1 locus in the NGS panel 
discussed in Chapter 3 (Appendix 4 – KIR3DL1 Sequencing Primers ). After quality 
control, 256 (95.9%) KIR3DL1/S1 allotypes were obtained from cases and 433 (92.7%) 
from controls. I then applied European AIMs to the dataset to derive a European 
Subgroup. The European subgroup comprised 335 (77% of total) HCs and 198 (76% of 
total) individuals with BD 
 
There was no difference between the BD and HC population with regard to KIR3DL1/S1 
presence/absence at the gene-level in the UK cohort or the European subgroup (Table 
4-1). There was no deviation from Hardy-Weinberg equilibrium in either group 
(P=0.4533).  
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Table 4-1. Presence/Absence KIR3DL1/S1 in Behçet’s Disease and demographically 
matched controls.  
There was no association between KIR3DL1/S1 presence/absence in the data from the 
UK cohort (a.) and the European Subgroup (b.). HC – Healthy Control, BD – Behçet’s 
Disease, OR – Odds Ratio, 95% CI – 95% Confidence intervals. 
 
a. 
KIR3DL1/S1 UK Cohort 
  HC (n) HC (%) BD (n) BD (%) P OR 95% CI 
3DL1/3DL1 282 65% 150 59% 0.0878 0.9 0.65-1.24 
3DL1/3DS1 137 32% 97 38% 0.0967 1.2 0.87-1.66 
3DS1/3DS1 14 3% 9 4% 0.8296 1.09 0.46-2.55 
 
b.        
KIR3DL1/S1 European subgroup  
  HC (n) HC (%) BD (n) BD (%) P OR 95% CI 
3DL1/3DL1 205 61% 108 55% 0.2005 0.52 0.24-1.13 
3DL1/3DS1 120 36% 81 42% 0.1952 1.44 0.78-2.65 
3DS1/3DS1 10 3% 6 3% 1.0000 1.68 0.59-4.75 
 
4.1.1 KIR3DL1/S1 Presence/Absence In Patients With Ophthalmic Manifestations Of 
Behçet’s Disease  
 
In 2016, Erer et al. reported that patients with ocular manifestations of BD had an 
increased prevalence of KIR3DS1 compared to other patients, irrespective of HLA-B*51 
status (Erer et al., 2016). I analysed the ophthalmic subset to ascertain whether I could 
replicate this finding in the UK cohort. There was no increase in the prevalence of 
KIR3DS1 in those with ophthalmic disease. This finding was unrelated to HLA-B*51 
status. There was also no significant difference in the proportion of KIR3DL1/S1 
heterozygotes/homozygotes in the ophthalmic group (P=0.0845).  
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4.2 KIR3DL1/S1 Allelic Frequencies 
 
KIR3DL1/S1 alleles were categorised based on their known functional effects (Gardiner 
et al., 2001; Martin et al., 2007; Sanjanwala et al., 2008; Saunders et al., 2016; Tao et al., 
2014) to allow easy visualisation with regard to their functional roles. For those allotypes 
where functional data was not available, I assigned a presumptive inhibitory-potential 
based on the nearest KIR3DL1/S1 allotype for which data existed (Table 4-3). 
KIR3DL1/S1 allelic frequencies were then calculated in the UK group and the European 
subgroup. KIR3DL1*005 was more frequently found in the BD than the HC group, 
however, the effect was not significant after controlling for multiple tests. No specific 
KIR3DL1/S1 allele increased the risk of BD (Table 4-2). 
 
Table 4-2. KIR3DL1/S1 Allele Frequencies >5% In The UK Cohort And European 
Subgroup  
There are no associations that withstood correction for multiple testing.  Alleles with a 
frequency less than 5% were grouped in the ‘Alleles <5%’ category. Results in bold 
signify significant (P<0.05) results. Pc – Bonferroni-Dunn correction for multiple testing, 
UK – United Kingdom, HC – Healthy Control, BD – Behçet’s Disease, OR – Odds Ratio, 
95% CI – 95% Confidence intervals. Colour key –Table 4-3 
 
 
 
Allele HC (n)
HC 
(%)
BD 
(n)
BD 
(%) P Pc OR 95% CI
HC 
(n)
HC 
(%)
BD 
(n)
BD 
(%) P OR 95% CI
3DS1*0130101 187 22 102 20 0.4937 0.8119 1.08 0.83-1.42 160 24 92 23 0.8234 1.03 0.77-1.38
3DL1*0010101 134 15 76 15 0.8161 0.8929 1.04 0.77-1.41 125 19 68 17 0.5653 1.09 0.78-1.5
3DL1*00401 119 14 66 13 0.6832 0.8566 1.07 0.77-1.47 120 18 54 14 0.0720 1.31 0.93-1.86
3DL1*0050101 109 13 87 17 0.0255 0.3348 0.74 0.55-1.01 108 16 82 21 0.0683 0.78 0.57-1.07
3DL1*002 106 12 69 13 0.5042 0.8119 0.91 0.66-1.26 87 13 52 13 1.0000 0.99 0.68-1.43
3DL1*0150201 59 7 28 5 0.3600 0.8119 1.25 0.78-1.98
3DL1*008 50 6 24 5 0.4584 0.8119 1.23 0.75-2.03
Alleles < 5% 102 12 60 12 70 10 48 12
UK Cohort (HC n=433, BD n=256) European Subgroup (HC n=335, BD n=198)
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Table 4-3. The Functional Effects Of KIR3DL1/S1 Alleles Coloured By Their Inhibitory 
Potential 
Where no functional data existed, a presumed effect was assigned based on the nearest 
KIR3DL1 for which functional data was available. 
 
 
KIR3DL1/S1 alleles were then grouped by their inhibitory potential to test whether an 
association existed between high-expressing KIR3DL1 (KIR3DL1HIGH), low-expressing 
KIR3DL1 (KIR3DL1LOW), KIR3DL1 retained intracellularly (KIR3DL1NULL) or the 
activating allele KIR3DS1. No disease association between KIR3DL1/S1 inhibitory-
potential and BD was found. 
 
 
 
 Functional Effect Presumed Effect    Strong Inhibition (KIR3DL1HIGH) 
3DL1*0010101   
   
3DL1*002   
 
  Weak Inhibition (KIR3DL1LOW) 
3DL1*00401   
   
3DL1*00402   
 
  Null (KIR3DL1NULL) 
3DL1*0050101   
   
3DL1*0070101   
 
  Activating (KIR3DS1) 
3DL1*008   
   
3DL1*009   
   
3DL1*01501   
   
3DL1*0150201   
   
3DL1*01701   
   
3DL1*01702   
   
3DL1*019   
   
3DL1*020   
   
3DL1*022   
   
3DL1*025   
   
3DL1*03101   
   
3DL1*033   
   
3DL1*035   
   
3DL1*040   
   
3DL1*052   
   
3DL1*053   
  
 
 3DL1*062   
  
 
 
 
 
 
 
 
3DL1*063   
   
3DL1*069   
   
3DL1*072   
   
3DS1*0130101   
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KIR3DL1/S1 allotypes were analysed by calculating a ‘functional-genotype’ consisting 
of the cumulative functional effects of the allotypes present in each group. The 
combination of a low expressing allele (KIR3DL1LOW) and the activating allele KIR3DS1 
was associated with BD (P=0.0004, Pc=0.0040, OR=2.47, 95% CI 1.43-4.25), whereas a 
high expressing (KIR3DL1HIGH) and null allele (KIR3DL1NULL) was associated with 
protection from disease (P=0.0035, Pc=0.0350, OR=0.53, 95% CI 0.33-0.87) (Table 4-4). 
 
Table 4-4. Functional Effects Of KIR3DL1/S1 Genotype Combinations.  
 
A risk effect was identified in the BD group for individuals possessing the 
KIR3DL1LOW/KIR3DS1 genotype. A protective effect was found in the HC group for 
individuals possessing the KIR3DL1HIGH/KIR3DL1NULL genotype. Results in bold signify 
significant (P<0.05) results. Pc – Bonferroni-Dunn correction for multiple testing, UK – 
United Kingdom, HC – Healthy Control, BD – Behçet’s Disease, OR – Odds Ratio, 95% 
CI – 95% Confidence intervals. Colour key –Table 4-3 
 
 
When the European subgroup was analysed, a similar pattern emerged. The protection 
conferred from the KIR3DL1HIGH/KIR3DL1NULL genotype was more robust than the UK 
cohort as a whole, (P=0.0011, OR=0.36, 95% CI 0.19-0.68). Whereas, the risk-effect 
from the KIR3DL1LOW/KIR3DS1genotype was lower (P=0.0109, OR=2.35, 95% CI 1.23-
4.47). 
Allele 1 Allele 2 HC (n)
HC 
(%)
BD 
(n)
BD 
(%) P Pc OR 95% CI
HC 
(n)
HC 
(%)
BD 
(n)
BD 
(%) P OR 95% CI
KIR3DL1 HIGH KIR3DL1 HIGH 85 17 60 21 0.2467 0.8159 1.20 0.81-1.77 64 18 42 21 0.5755 1.22 0.77-1.94
KIR3DL1 HIGH KIR3DL1 LOW 71 15 36 14 0.4473 0.9199 0.97 0.62-1.5 47 11 30 15 0.7989 1.17 0.71-1.9
KIR3DL1 HIGH KIR3DL1 NULL 76 17 24 9 0.0035 0.0315 0.54 0.33-0.88 61 18 21 9 0.0186 0.37 0.2-0.71
KIR3DL1 HIGH KIR3DS1 83 19 39 14 0.2155 0.5705 0.77 0.51-1.18 62 16 24 12 0.0671 0.81 0.5-1.31
KIR3DL1 LOW KIR3DL1 LOW 17 4 7 3 0.5208 0.9077 0.74 0.3-1.82 18 6 5 1 0.1290 1.02 0.37-2.87
KIR3DL1 LOW KIR3DL1 NULL 23 5 16 6 0.6122 0.9077 1.23 0.63-2.39 18 5 8 4 0.5398 1.47 0.65-3.35
KIR3DL1 LOW KIR3DS1 24 6 35 14 0.0004 0.0053 2.47 1.43-4.25 32 6 33 18 0.0195 2.21 1.17-4.19
KIR3DL1 NULL KIR3DL1 NULL 10 2 7 3 0.8010 0.9077 1.18 0.45-3.15 10 3 9 2 0.3456 0.63 0.17-2.42
KIR3DL1 NULL KIR3DS1 30 7 23 9 0.3750 0.8206 1.30 0.74-2.29 21 6 21 11 0.0951 1.53 0.80-2.9
KIR3DS1 KIR3DS1 14 3 9 4 0.8296 0.9077 1.09 0.46-2.55 2 3 5 2 0.1078 1.02 0.37-2.87
Functional Genotype UK Cohort (HC n=433, BD n=256) European Subgroup (HC n=335, BD n=198)
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To ensure that the presumptive allotypes assigned did not skew the outcome, the analysis 
was re-run without these allotypes. This did not affect the overall results and the 
KIR3DL1HIGH/KIR3DL1NULL and KIR3DL1LOW/KIR3DS1genotype remained significant 
(Table 4-5). 
 
Table 4-5. KIR3DL1/S1 ‘Functional Genotypes’ Without Presumed Functional Effects In 
The Whole UK Cohort And In Those Of European Ancestry 
Despite removing the effects from presumptive allotype, a risk effect was identified in the 
BD group for individuals possessing the KIR3DL1LOW/KIR3DS1 genotype. A protective 
effect was found in the HC group for individuals possessing the 
KIR3DL1HIGH/KIR3DL1NULL genotype. Alleles in bold signify significant (P<0.05) 
results. Pc – Bonferroni-Dunn correction for multiple testing, UK – United Kingdom, HC 
– Healthy Control, BD – Behçet’s Disease, OR – Odds Ratio, 95% CI – 95% Confidence 
intervals. Where n=0, OR was calculated using the Haldane correction. Colour key – 
Table 4-3 
 
 
I then analysed the allelic composition of the implicated ‘functional genotypes’. In the 
UK cohort, there were two genotypes associated with BD: 
KIR3DL1*0050101LOW/KIR3DS1*0130101 (P=0.0210, OR 1.91 95% CI 1.07-3.43) and 
KIR3DL1*0070101LOW/KIR3DS1*0130101 (P=0.0008, OR 15.22, 95% CI 1.92-120.87). 
Conversely, KIR3DL1*0010101HIGH/KIR3DL1*00401NULL (P=0.0172, OR 0.36, 95% CI 
Allele 1 Allele 2 HC (n)
HC 
(%)
BD 
(n)
BD 
(%) P Pc OR 95% CI
HC 
(n)
HC 
(%)
BD 
(n)
BD 
(%) P OR 95% CI
KIR3DL1 HIGH KIR3DL1 HIGH 75 17 53 21 0.3107 0.8159 1.20 0.81-1.77 60 18 42 21 0.3634 1.22 0.77-1.94
KIR3DL1 HIGH KIR3DL1 LOW 63 15 36 14 0.9108 0.9199 0.97 0.62-1.5 40 12 29 15 0.4232 1.17 0.71-1.9
KIR3DL1 HIGH KIR3DL1 NULL 75 17 24 9 0.0048 0.0315 0.54 0.33-0.88 59 18 21 11 0.0326 0.37 0.2-0.71
KIR3DL1 HIGH KIR3DS1 81 19 37 14 0.1738 0.5705 0.77 0.51-1.18 54 16 21 11 0.0934 0.81 0.5-1.31
KIR3DL1 LOW KIR3DL1 LOW 16 4 7 3 0.6615 0.9077 0.74 0.3-1.82 18 5 5 3 0.1290 1.02 0.37-2.87
KIR3DL1 LOW KIR3DL1 NULL 22 5 16 6 0.6048 0.9077 1.23 0.63-2.39 14 4 6 3 0.6391 1.47 0.65-3.35
KIR3DL1 LOW KIR3DS1 24 6 35 14 0.0004 0.0053 2.47 1.43-4.25 26 8 33 17 0.0024 2.21 1.17-4.19
KIR3DL1 NULL KIR3DL1 NULL 10 2 7 3 0.8010 0.9077 1.18 0.45-3.15 9 3 8 4 0.4472 0.63 0.17-2.42
KIR3DL1 NULL KIR3DS1 30 7 23 9 0.3750 0.8206 1.30 0.74-2.29 19 6 18 9 0.1583 1.53 0.80-2.9
KIR3DS1 KIR3DS1 14 3 9 4 0.8296 0.9077 1.09 0.46-2.55 11 3 4 2 0.5889 1.02 0.37-2.87
KIR3DL1 HIGH Unknown 13 3 6 2 0.8104 0.9077 0.78 0.29-2.08 16 5 6 3 0.3757 0.70 0.24-2.03
KIR3DL1 LOW Unknown 5 1 0 0 0.1634 0.5705 0.31 0.04-2.60 5 1 1 1 0.4197 0.38 0.04-3.3
KIR3DL1 NULL Unknown 1 0 0 0 1.0000 0.9379 1.13 0.09-14.20 2 1 2 1 0.6302 1.14 0.09-14.37
KIR3DS1 Unknown 4 1 3 1 0.7148 0.9077 0.85 0.08-9.37 2 1 2 1 0.6302 0.85 0.08-9.46
Functional Genotype UK Cohort (HC n=433, BD n=256) European Subgroup (HC n=335, BD n=198)
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0.15-0.89) was found to be protective (Table 4-6). When the European subgroup was 
analysed, only KIR3DL1*0050101LOW/KIR3DS1*0130101 (P=0.0012, OR 3.26 95% CI 
1.46-7.27) retained significance in the risk genotype and there were no specific alleles 
implicated in the protective genotype. 
 
In order to examine whether the KIR3DL1/S1 ‘functional-genotypes’ conferring risk and 
protection are associated with BD, or merely the presence of Bw4/HLA-B*51 the above 
analysis was repeated, controlling for these variables. 
 
Table 4-6. KIR3DL1/S1 Genotypes Leading To Increased/Decreased Risk Of Developing 
Behçet’s Disease 
The risk genotype was made up of two KIR3DL1LOW allotypes – KIR3DL1*005 and 
KIR3DL1*007. There was only one allotype from the KIR3DL1HIGH group – 
KIR3DL1*001. Those in bold signify significant (P<0.05) results. UK – United Kingdom, 
HC – Healthy Control, BD – Behçet’s Disease, OR – Odds Ratio, 95% CI – 95 % 
Confidence interval, Colour key – Table 4-3 
 
 
 
In the UK cohort, the effect of possessing a KIR3DL1LOW/KIR3DS1 ‘risk’ genotype was 
significant in all groups except the HLA-B*51+ individuals. The protective effect of the 
KIR3DL1HIGH/KIR3DL1NULL ‘protective’ genotype was only significant in individuals 
possessing Bw4 (Figure 4-1). When the data was conditioned on the European subgroup, 
the effect of possessing Bw4 was abrogated in the KIR3DL1LOW/KIR3DS1 ‘risk’ 
genotype, whereas it was maintained in the KIR3DL1HIGH/KIR3DL1NULL genotype. 
HC (n) HC (%) BD (n) BD (%) P OR 95% CI HC (n) HC (%) BD (n) BD (%) P OR 95% CI
3DL1*007
3DS1*013
3DS1*013
0.08-1.60
KIR3DL1/S1 allele
Increased Risk
Decreased Risk
3DL1*001 3DL1*004
3DL1*005
12 5.74 2 2.02 0.059 0.46 2.34 28 6.47 0.0172 0.36 0.15-0.89
0.063 2.1 0.13-34.1115.2 1.92-120.87 1 0.48 1 1.01
17 17.17 0.001 3.3 1.46-7.27
1 0.23 9 3.64 0.0008
23 5.31 26 10.16 0.0210 1.91 1.07-3.43 11 5.26
UK Cohort (HC n=433, BD n=256) European Subgroup (HC n=335, BD n=198)
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Figure 4-1. The Effect Of Associated KIR3DL1/S1 ‘Functional Genotypes’ By Subgroup 
In the UK cohort and European subgroup, significant risk effects were found in the Bw4 
and HLA-B*51- groups. Significant protective effects in the UK cohort, were found in the 
Bw4 group only, whereas the protective effects were found in both the Bw4 and HLA-
B*51- groups in the European subgroup. Odds Ratios & 95% CIs for the 
KIR3DL1LOW/KIR3DS1 ‘risk’ (a.) and KIR3DL1HIGH/KIR3DL1NULL ‘protective’ 
genotypes (b.) for the UK cohort and the European subgroup. The size of the marker is 
proportional to the size of the group. All – All individuals possessing genotype; Bw4 – 
individuals possessing at least one allele encoding the Bw4 epitope; Bw6 – individuals 
who lack an allele encoding Bw4; HLA-B*51+ – individuals who possess at least allele 
encoding HLA-B*51; HLA-B*51- – individuals who lack an allele encoding HLA-B*51.  
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As discussed in Chapter 3, the BD population was then split into two subgroups; those 
with purely mucocutaneous (MC) disease (n=166) and those with mucocutaneous disease 
and ophthalmic involvement (n=80). No significant differences were found between the 
two groups with regard to KIR3DL1/S1 presence/absence and were unable to replicate the 
association between an increase in KIR3DS1 alleles and ophthalmic involvement as has 
been previously reported (Erer et al., 2016).  
 
The cumulative ‘functional-genotypes’ did not show any association between 
KIR3DL1LOW/KIR3DS1 and MC disease, However, examining the allele frequencies in 
the MC group revealed an increase in KIR3DL1*00701LOW/KIR3DS1*013 compared to 
HCs (P=0.0071, OR 13.04, 95% CI 1.51-112.49). Conversely, the 
KIR3DL1HIGH/KIR3DL1NULL genotype did reduce the risk of developing MC disease 
(P=0.0048, OR 0.45, 95% CI 0.25-0.81), but no specific allelic combination was 
significant.  
 
The ophthalmic group had significant risk conferred from the KIR3DL1LOW/KIR3DS1 
genotype (P=5.76x10-5, OR 3.92, 95% CI 2.06-7.47), (Figure 4-2). Both 
KIR3DL1*00501LOW/KIR3DS1*013 (P=0.0003, OR 3.27, 95% CI 1.65-6.48) and 
KIR3DL1*00701LOW/KIR3DS1*013 (P=0.0039, OR 18.83, 95% CI 2.08-170.47) were 
significant in making up the ‘functional genotype’. There were no protective effects 
observed in this group. 
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Figure 4-2. KIR3DL1/S1 ‘Functional Genotypes’ In Mucocutaneous And Ophthalmic 
Disease 
In the UK cohort and European subgroup, significant risk effects were found in the 
ophthalmic groups only, whereas significant protective effects were only found in the MC 
groups. KIR3DL1LOW/KIR3DS1 ‘risk’ (a.) and KIR3DL1HIGH/KIR3DL1NULL ‘protective’ 
genotypes (b.) for the UK cohort and the European subgroups. The size of the marker is 
proportional to the size of the group. MC – Mucocutaneous disease only; Ophthalmic – 
Behçet’s Disease with ocular manifestations.  
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4.3 Functional Assays To Examine The Expression Of KIR3DL1/S1 On 
Circulating Lymphocytes In Behçet’s Disease 
 
The aim of the functional work in this Chapter was to examine the phenotype of NK cells 
and KIR3DL/S1 expression in patients with BD. I then hoped to carry out cytotoxicity 
assays using the cell lines expressing HLA-B*51 (the primary HLA allele implicated in 
BD). HLA-B*52 (an allele very similar to HLA-B*51, but not implicated in BD) and 
finally HLA-B*35 (an allele that expresses Bw6, rather than Bw4 and therefore is not a 
ligand for KIR3DL1, nor is it associated with BD). I created a number of cell lines to test 
patient’s PBMCs against. First, I created adherent CHO-cell lines that do not express any 
human ligands for HLA or KIR. Second, I created non-adherent 221 cell lines, which 
express activating receptors and B2M, but not HLA Class-I.  
 
At the start of the project, I planned to recall patients after KIR3DL/S1 genotyping had 
completed, thus giving me the opportunity to test specific combinations of PBMC 
grouping individuals with comparable KIR3DL1/S1 genotypes to increase the power of 
the study. Unfortunately, it was not possible to recall the majority of these patients 
(discussed below) and I extracted PBMC from only 22 BD patients with known 
KIR3DL1/S1 allotypes. Therefore the power of the functional work is low and I have kept  
the results descriptive. 
 
 
In order to establish the effects of KIR3DL1/S1 allotypes in vivo I set out to characterise 
the NK and CD8 T cell subsets in patients with established KIR3DL1/S1 genotypes. 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood and frozen 
in aliquots to allow experimental repeats to be carried out.  
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4.4 Medication 
 
 
Medication is discussed here as the immunosuppressive drugs used to treat BD can have 
profound effects on lymphocyte populations. Behçet’s Disease can be managed in a 
number of ways and treatment is usually tailored to the needs of each individual. Broadly 
speaking, mild disease can be managed with oral colchicine and topical steroids during a 
flare (in the form of mouthwash for oral/pharyngeal ulceration or ointment for genital 
ulceration). Moderate disease is managed in the same way as mild disease, but with the 
addition of a disease-modifying drug such as azathioprine or mycophenolate mofetil. 
Severe disease is associated with significant morbidity and mortality. It is treated with 
high-dose systemic corticosteroids or a biologic agent such as an anti-TNFa monoclonal 
antibody plus one or more disease modifying drugs. I have not focused on the effects of 
medication in BD in this thesis, however it is important to be aware of the impact 
immunosuppressive medication may have on the lymphocyte compartment for functional 
analyses. There is substantial evidence that antiproliferative DMARDs such as 
azathioprine reduce circulating NK cells and gdT cells (Cseuz et al., 1990; Czeuz et al., 
1990; McCarthy et al., 2015; Orandi et al., 2017; Pedersen et al., 1986; Vacher-Coponat 
et al., 2006). Figure 4-4b shows the breakdown of patients taking biologic agents and 
disease-modifying drugs. Seven (31.9%) of the 22 donors were taking an anti-
proliferative agent at the time of venepuncture.  
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4.5 Natural Killer Cell Phenotypes In Behçet’s Disease Patients With Known 
KIR3DL1/S1 Allotypes. 
 
 
4.5.1 Circulating Natural Killer Cells Are Present In Low Numbers In Behçet’s Disease 
 
 
NK cells were identified as CD3-CD56+. Results are expressed as a percentage of single, 
live-gated lymphocytes in peripheral blood (Figure 4-3). BD patients had low percentages 
of circulating NK cells - 5.35 ± 2.31% (Figure 4-4), with CD3-CD56Bright NK cells making 
up 9.86 ± 3.82% of the NK cell compartment. There was no correlation between 
KIR3DL1/S1 allotype and % NK cells (r2 = -0.299, P=0.5456), nor was there a correlation 
between antiproliferative medications and % NK cells (r2 = 0.0126, P=0.7625).  
 
4.5.2 Disease Activity Does Not Affect Natural Killer Cell Percentages 
 
Of the 22 individuals recruited for phenotypic analysis. Twelve (54.5%) individuals were 
inactive at the time of venepuncture and 10 (45.5%) were active in one or more systems. 
There was no difference in levels of circulating NK cells between the active and inactive 
groups (P=0.6524). 
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Figure 4-3. Gating Strategy Used To Identify Natural Killer Cells 
CD56Bright NK cells (CD3-CD56Bright), CD56Dim NK cells (CD3-CD56Dim), KIR3DL1+ 
cells (DX9+) and KIR3DS1+ cells (REA 618+). Density plots and histograms from a 
representative individual (Sample 14) expressing KIR3DL1/S1. In this individual there 
were 2.14% circulating NK cells. NK - Natural killer cell, Dim - CD56Dim, Bright - 
CD56Bright, CD8 T cell - CD3+CD8+ T cell. 
 
 
 154 
 
 
 
 155 
Figure 4-4. (a.) Percentage Of Circulating CD3-CD56+ Cells In Individuals With Known 
KIR3DL1/S1 Allotypes. (b.) Medications Taken By Individuals At The Time Of 
Venepuncture 
(a.) Low percentages of circulating NK cells were found in the BD patients. 
Measurements were repeated an average of 3 times using frozen aliquots of PBMC. (b.) 
Subjects’ research numbers are shown next to their KIR3DL1/S1 allotypes Medications 
taken at the time of venepunture. Col – colchicine, Pred – prednisolone, AZA – 
azathioprine, MMF – mycophenolate mofetil, HCQ – hydroxychloroquine, INF – 
infliximab, ADA – adalimumab  
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4.5.3 KIR3DL1/S1 Is Variably Expressed On Circulating Natural Killer Cells  
 
Peripheral blood mononuclear cells were labelled with an anti-KIR3DL1 antibody (DX9 
clone – henceforth DX9), which recognises KIR3DL1, but not KIR3DS1 and an anti-
KIR3DL1/S1 antibody (REA 618 clone, henceforth REA 618). Using this combination 
of antibodies, KIR3DS1 populations can be identified.  
 
Levels of DX9 binding are known to vary between individuals, a phenomenon attributed 
partly to KIR3DL1 allelic variation and the presence of self-ligands for KIR3DL1  (Burian 
et al., 2016; Trundley et al., 2007). I found the majority of donors’ NK cells bound DX9 
and REA 618 weakly. Eleven (50%) individuals expressed <1% of KIR3DL1 on their 
surface. Four (18%) expressed 1-5% and 7 (32%) expressed >5% KIR3DL1. Overall, 
KIR3DL1 was expressed in 5.22 ± 3.02% of NK cells. Seven individuals (32%) possessed 
a KIR3DS1 allotype. Expression of KIR3DS1 was found to be low in the individuals 
analysed. Five (71%) expressed <1% KIR3DS1 (Figure 4-5).  
 
The presence/absence of Bw4 was analysed to determine whether possession of the ligand 
for KIR3DL1 increased its expression in circulating NK cells. No differences were 
identified between those bearing Bw4 and those without it (P=0.0725).  
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Figure 4-5. Heatmap Showing The Percentage KIR3DL1/S1 Expression On Natural 
Killer Cells  
 
Surface expression of KIR3DL1 and KIR3DS1 were strongly correlated, however both 
receptors were expressed at low levels. Each individual’s HLA-A and –B type is shown in 
low-resolution and colour coded grey if the allele encodes Bw4. P<0.05 was considered 
significant. NK – Natural killer, A – Active, I - Inactive 
 
 
 
 
 
 
4.5.4 Circulating CD8 T Cells Minimally Express KIR3DL1/S1 On The Cell Surface 
 
CD8 T cells also express KIR. Previous work has suggested that CD8 T cells may express 
different KIRs to NK cells and that epistatic interaction between HLA ligands and KIR 
may not affect T cell cytotoxicity in the same way as NK cells (Bjorkstrom et al., 2012). 
To examine the CD8 T cell compartment, CD3+CD56-CD8+ T cells were identified and 
KIR3DL1/S1 expression analysed. CD8 T cells made up 22.82 ± 3.10% of circulating 
r2 =0.986, P=0.0006
Sample Active / 
Inactive
KIR3DL1/S1 
Allele 1
KIR3DL1/S1 
Allele 2 HLA-A 
Allele 1
HLA-A 
Allele 2
HLA-B 
Allele 1
HLA-B 
Allele 2
% NK 
KIR3DL1 
Expression
% NK 
KIR3DS1 
Expression
1 A *0150201 *0010101 A*02 A*11 B*39 B*39 1.66 NA
2 I *052 *0010101 A*03 A*32 B*07 B*35 5.00 NA
3 A *008 *0010101 A*01 A*03 B*51 B*52 2.00 NA
4 A *002 *0010101 A*01 A*03 B*08 B*18 13.00 NA
5 I *002 *0010101 A*01 A*32 B*08 B*08 22.00 NA
6 I *0150201 *0010101 A*02 A*03 B*35 B*35 4.00 NA
7 I *008 *0010101 A*24 A*11 B*51 B*08 17.00 NA
8 A *0050101 *0010101 A*03 A*29 B*08 B*41 16.00 NA
9 I *0050101 *0010101 A*01 A*02 B*52 B*53 0.00 NA
10 A *0050101 *0150201 A*03 A*08 B*35 B*18 0.00 NA
11 I *0050101 *0150201 A*02 A*11 B*08 B*40 0.00 NA
12 I *0050101 *0010101 A*02 A*34 B*08 B*14 0.00 NA
13 A *00401 *0010101 A*03 A*74 B*18 B*42 3.00 NA
14 I *00401 *0050101 A*01 A*68 B*27 B*44 10.00 NA
15 A *00402 *0050101 A*02 A*11 B*13 B*51 3.00 NA
16 A *00402 *0050101 A*02 A*03 B*07 B*15 2.00 NA
17 I *00401 *0050101 A*24 A*31 B*40 B*51 2.00 NA
18 I *0050101 KIR3DS1 A*02 A*30 B*08 B*35 19.00 5
19 I *0050101 KIR3DS1 A*01 A*02 B*56 B*57 2.00 1
20 A *0050101 KIR3DS1 A*01 A*03 B*40 B*51 3.00 2
21 I *0050101 KIR3DS1 A*02 A*02 B*40 B*51 4.00 2
22 A *008 KIR3DS1 A*02 A*68 B*08 B*51 3.00 1
=Bw4
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lymphocytes in the 22 individuals sampled (Figure 4-6a). KIR3DL1/S1 was measured on 
circulating T cells using anti-KIR3DL1/S1 antibodies (DX9 and REA 618). No REA 618 
and minimal DX9 (0.8 ± 0.71%) bound to circulating CD8 T cells (Figure 4-6b). There 
was a low-moderate correllation between individuals expressing KIR3DL1 on NK and T 
cells (r2 = 0.49, P=0.027).  
 
Figure 4-6. Percentage Of Circulating CD8 T Cells In Individuals With Known 
KIR3DL1/S1 Allotypes And Expression Of KIR3DL1 On CD8 T Cells 
(a.) Percentage of circulating CD8 T cells in patients with BD and (b.) DX9+ CD8 T cells. 
Measurements were repeated an average of 3 times from frozen aliquots of PBMC. 
Subjects’ research numbers are shown next to their KIR3DL1 allotypes as well as their 
disease state at the time of venepuncture. 
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4.6 Creation Of A Functional System To Test KIR3DL1/S1 Allotypes 
 
Previous work by Shafi et al (Figure 1-6) indicated that PBMC from individuals with BD 
had variable degranulation responses when presented with target cells (CHO-cells) 
expressing HLA-B*51. This phenomenon was not observed when the same PBMC were 
presented with HLA-B*52+ target cells. Possible explanations for this variation include: 
 
1. KIR3DL1/S1 allotypic variation between patient samples. NK cells from an 
individual with a KIR3DL1/S1 genotype consistent with strong inhibition (e.g. 
KIR3DL1*001/KIR3DL1*01501) should exhibit less cytotoxic activity on contact 
with its Bw4 ligand than NK cells with a genotype consistent with weak inhibition 
(e.g. KIR3DL1*005/KIR3DL1*007).  
2. NK cells from donors with reduced levels of cytotoxicity may have been 
previously educated to HLA-B*51 (donor HLA status was not defined in this 
study). 
3. Target cells may have had unstable expression of HLA-B constructs over time (no 
attempt was made to re-sort target cells over time to maintain an HLA-B -rich 
population). Furthermore, HLA-B and B2M constructs were cloned into 
pcDNA3.1(+) plasmids with the same antibiotic resistance gene (neomycin), thus 
making it impossible to select cells with media enriched with antibiotics.  
4. Donors may have been exposed to different medications affecting their 
lymphocyte function (medication was not reported). 
To avoid the above pitfalls, I had the option to remake the CHO target cells either by 
transfecting the three constructs (MICA*009, HLA-B, B2M) in separate plasmids with 
three antibiotic resistance genes, or by cloning the three constructs into one larger plasmid 
with separate promoter sequences to ensure equal expression. 
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I elected to transfect constructs into one larger pcDNA5-FRT plasmid (Chapter 2.8.1). In 
addition to HLA-B*51 and B*52, I also chose to transfect HLA-B*35 as a Bw6 control. 
Instead of cloning the HLA constructs from patients or healthy controls, I synthesised our 
HLA-B and MICA constructs to ensure accuracy and obtained the shorter and 
oligomorphic B2M sequence from a healthy control. To reduce the size of the plasmid, I 
introduced an internal ribosome entry site (IRES) between the B2M and HLA-B 
constructs. IRES are useful short sequences that allow a ribosome to remain attached to 
mRNA and start transcribing the next coding sequence without the need for another 
(larger) promoter region. The three constructs were then assembled using Gibson 
assembly in a pcDNA5-FRT high copy number plasmid with a hygromycin resistance 
gene (Figure 4-7). 
 
The plasmids were then amplified in chemically competent NEB 5a E. Coli overnight and 
purified on an agarose gel to ensure the correct size product. The plasmid was digested 
with restriction enzymes to ensure the correct products were present (Figure 4-8). The 
insert was then sent for Sanger sequencing to confirm no errors had occurred in the 
sequence during the cloning procedure.  
 
The pcDNA5-FRT vector contains a hygromycin resistance gene which lacks a start 
codon, downstream of a homologous FRT site and upstream of the multiple cloning site 
(MCS), into which our genes of interest (GOI) were inserted. The pcDNA5-FRT vector 
containing the triple construct was transfected into CHO-FRT cells, which resulted in a 
homologous recombination event between the FRT sites on the plasmid and in the cell 
line. 
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Figure 4-7. pcDNA5-FRT Plasmid With Triple Construct And Hygromycin Resistance 
Gene.  
Expression of the B2M gene is driven by a CMV promoter. The stop codon of the B2M 
gene was removed to allow an IRES to be entered immediately downstream. This was 
followed by the HLA-B gene. Another CMV promoter region was added after this to drive 
expression of MICA*009. CMV – cytomegalovirus, B2M – Beta 2 Microglobulin, HLA- 
Human Leukocyte Antigen, MICA – MHC Class I polypeptide-related sequence A. FRT – 
Flp recombinase target, AmpR – ampicillin resistance gene. 
 
 
This process has the advantage of integrating the GOI into the CHO-cell genome 
downstream of a CMV promoter. It also disrupts the zeocin resistance gene present in the 
CHO-FRT cells and provides a start codon for the hygromycin resistance gene present in 
the pcDNA5-FRT vector. Positive cells expressing the GOI are then selected for 
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hygromycin resistance by enriching the media with hygromycin, thus killing all non-
transfected cells that retained their functional zeocin resistance gene.  
 
Figure 4-8. Enzyme Digest To Ensure MICA*009, HLA-B*51 And B2M Were All Present 
In The pcDNA5-FRT/B2M/HLA-B*51/MICA*009/Hygromycin Vector 
Fragments containing the GOI were digested and amplified with specific primers and run 
on an agarose gel with 100bp ladder. All three constructs were successfully incorporated 
into the pcDNA5 vector.  
 
 
 
The CHO-cells were then cultured in T175 plates until 80% confluent. Accutase was used 
to detach the cells, which were then stained with antibodies against HLA-Class I (clone 
W6/32), MICA and B2M. Unfortunately, HLA-B was not expressed despite multiple 
attempts to enrich the HLA-B+ population using FACS-sorting (Figure 4-9). This lack of 
expression may have been due to the IRES not functioning as expected.  
 
 
 
 
 
MICA9 HLA-B51 B2M 100bp	
ladder
Triple	Transfect	CHO	–
Hygromycin and	
Neomycin	Resistant
All	genes	present
500bp
1000bp
 163 
Figure 4-9. No Expression Of HLA-B (APC) In CHO Cells Transfected With pcDNA5-
MICA*009/HLA-B/B2M 
 
Transfected CHO-cells were stained with PE (MICA), FITC (B2M) and APC (HLA-Class 
I). After gating on cells and excluding doublets, less than 0.1% of cells were APC+. (a) 
CHO-cells gated, (b.) singlets gated, (c.) 67% expression of MICA but no expression of 
HLA-B, (d.) 53% expression of B2M, but no expression of HLA-B. 
 
 
 
I then opted to create three separate plasmids with three antibiotic resistance genes. First, 
the CHO-FRT cells were transfected with the pcDNA5-FRT vector with MICA*009 
cloned into the MCS, conferring hygromycin resistance (and disrupting zeocin 
resistance). The CHO-cells were then cultured for a week in media supplemented with 
hygromycin to ensure all the non-transfected cells were dead. The CHO-MICA*009 cell 
line was then transfected with a pcDNA3.1(+) plasmid into which a zeocin resistance 
gene had been inserted, as well as B2M. Unlike the pcDNA5-FRT vector, transfection 
with pcDNA3.1(+) does not stably integrate into the cell genome, so antibiotic selection 
was applied for 8 weeks and flow sorted to ensure the CHO-cells expressed both 
MICA*009 and B2M. Finally, HLA-B*51, B*52 and B*35 were separately cloned into 
a. 
d. 
b. 
c. 
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the pcDNA3.1(+) vector along with a neomycin resistance gene. A neomycin vector 
control was also produced as an HLA-Null control cell line. These were then transfected 
into the CHO-MICA*009/B2M cells and the lines were maintained in media 
supplemented with hygromycin, G418 and zeocin for the remainder of the experiments. 
Figure 4-10 shows the cells growing well under triple selection.  
 
To ensure the CHO-cells maintained expression of all three constructs the cell lines were 
periodically flow-sorted. Figure 4-11 shows the four cell lines after flow-sorting. As can 
be seen, the HLA-Null CHO-cell line expressed over 95% B2M and MICA*009, but <1% 
HLA. The HLA-B*51, B*52 and B*35+ cell lines all expressed over 90% HLA after flow-
sorting.  
 
Figure 4-10. Triple Transfected CHO Cells Grow Well Under Multiple Drug Selection 
 
(a.) Normal morphology of CHO-FRT cells with no antibiotic supplementation. (b.) 
Morphology of CHO-MICA*009/B2M/HLA-B cells with hygromycin 200ug/ml, G418 
650ug/ml and zeocin 100ug/ml 
 
 
.                        
 
 
 
 
 
 
a. b. 
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Figure 4-11. Expression Of Constructs In Triple Transfected CHO-Cell Line. 
After one week of triple drug selection and flow sorting on MICA+B2M+HLA-B+ cells, 
there was good expression of all constructs. (a). 97% MICA*009, 99% B2M, 0% HLA-B 
expression in the double transfectant HLA-Null cell line. (b.) 97% MICA*009, 99% B2M, 
95% HLA-B expression in the CHO-MICA*009/B2M/HLA-B*51 cells. (c.) 97% 
MICA*009, 99% B2M, 93% HLA-B expression in the CHO-MICA*009/B2M/HLA-B*52 
cells. (d.) 96% MICA*009, 99% B2M, 97% HLA-B expression in the CHO-
MICA*009/B2M/HLA-B*35 cells. CHO – Chinese Hamster Ovary, HLA – Human 
Leukocyte Antigen, SSC – Side Scatter, FSC – Forward Scatter, H – Height, A -Area 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
c. 
d. 
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4.6.1 MICA*009 And HLA-B Expression In The CHO-Cell Line Reduces Over Time. 
 
Despite culturing in medium with antibiotic supplementation, the CHO-cell lines began 
to lose expression of the constructs (Figure 4-12). Over 50% of MICA*009 expression 
and 15-35% of HLA-B expression was lost within 4 weeks.  
 
The cells were therefore re-sorted to achieve over 90% expression of all constructs. I then 
used three healthy control PBMC with known KIR3DL1/S1 allotypes to test how 
effective the CHO-cells were at producing a degranulating response. This was measured 
using CD107a (LAMP-1) expression on the cell surface. CD107a is released as a result 
of exocytosis of the cytolytic granules following activation of immune cells. 
Degranulation was inferred from the percentage of CD107a+ cells.  
 
CHO target cells were co-cultured with PBMC and stained with anti-CD107a antibody at 
the start of the experiment. Initially, I used a protocol co-culturing 1x105 target cells with 
1x105 NK cells (the number of NK cells present in donors’ PBMC was established prior 
to, but on the same day as, the degranulation assay). Target cells and PBMC were co-
cultured in a 5ml polystyrene tube in the presence of anti-CD107a at 37°C with 5% CO2 
(with monensin added one hour into the experiment) for 5 hours, before washing and 
staining. Using this protocol, the CHO-cell constructs failed to provoke degranulation in 
the PBMCs. In order to understand why this was not working, I used CFSE, a dye which 
is rapidly internalised by cells and retained intracellularly to stain the CHO-cells prior to 
incubation with anti-CD107a antibody. A reduction in CFSE MFI relates to a loss in cell 
viability (Figure 4-13a). To ensure that this loss of viability was not due to the constructs 
transfected into the cells,  I ran the same assay with the untransfected CHO-FRT cells and 
found a similar, but less pronounced loss of viability (Figure 4-13b). 
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Figure 4-12. Effect Of Time In Cell Culture On Expression Of Constructs In The Double 
And Triple Transfected CHO-Cells Despite Continuous Drug Selection.  
Representative FACS plots taken 4 weeks after flow sorting to >90% purity of all 
constructs. The HLA-Null double transfectant shows loss of MICA*009, but not B2M over 
time. Triple transfectants show loss of MICA*009 and HLA-B, but not B2M over time. 
(a). 46% MICA*009, 99% B2M, 0% HLA-B expression in the double transfectant HLA-
Null cell line. (b.) 49% MICA*009, 99% B2M, 65% HLA-B expression in the CHO-
MICA*009/B2M/HLA-B*51 cells. (c.) 49% MICA*009, 99% B2M, 84% HLA-B 
expression in the CHO-MICA*009/B2M/HLA-B*52 cells. (d.) 50% MICA*009, 99% 
B2M, 85% HLA-B expression in the CHO-MICA*009/B2M/HLA-B*35 cells. CHO – 
Chinese Hamster Ovary, HLA – Human Leukocyte Antigen, SSC – Side Scatter, FSC – 
Forward Scatter, H – Height, A -Area 
 
 
d. 
c. 
b. 
a. 
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Figure 4-13. Loss Of Expression Of Constructs Over Time In Culture. 
(a.) CHO-MICA*009/B2M/HLA-B cells and (b.) CHO-FRT cells lose viability in less than 
three hours of co-culture in a sterile 5ml polystyrene tube. This was thought to be due to 
the CHO-cells failing to adhere to the coated FACS tubes and resulting a loss of viability. 
 
a. 
 
b. 
 
 
This loss of viability was likely to be due to CHO-cells failing to attach to the polystyrene 
FACS tube, while this is not normally a problem for 1 hour at 4C whilst staining with 
antibodies prior to FACS work, 5 hours at 37C appeared to be too long for the CHO-cells 
to remain unbound and thus likely resulted in cell death (although this was not tested 
directly). An alternative method was therefore adopted. The triple transfectant CHO-cells 
were seeded in 96 well plates and allowed to grow to near confluence. This allowed 5,000 
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cells to grow per well. I tested this protocol using PBMC from three healthy controls with 
known KIR3DL1/S1 allotypes. I then added PBMC containing 5,000 NK cells (to 
maintain a 1:1 ratio) to the well in the presence of anti-CD107a antibody and monensin 
(after 1 hour). The experiment was run in triplicate (to increase the number of events to 
15,000) with three experimental repeats on different dates (using frozen aliquots of 
PBMC). The cells were then detached, washed and stained for analysis.  
 
Using this protocol, I found that there was measureable degranulation (55%) in PBMCs 
exposed to the positive control (PMA and ionomycin) but a much smaller response to the 
MICA*009 control (5%). The triple transfectants (1-2%) provoked minimal CD107a 
expression as did the negative control (1%) (Figure 4-14a). This level of CD107a 
expression is far below that reported using non-adherent cells to provoke degranulation. 
I then attempted to see whether a longer incubation time could improve the response 
(Figure 4-14b). While there was a small increase in CD107a expression up to 8hrs, the 
results remained disappointing.  
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Figure 4-14. CD107a Expression on Peripheral Blood Mononuclear Cells From Three 
Healthy Control Individuals Following Co-Culture CHO-Cell Transfectants.  
 
(a.) There is good CD107a expression on PBMCs co-cultured with the positive control 
(PMA + ionomycin), but much less when co-cultured with the HLA-Null cells. The HLA-
B triple transfectants and negative control provoked minimal, but similar levels of 
CD107a expression on the PBMCs. (b.) There was a small increase in CD107a expression 
if the assay was run for a longer period of time, peaking at 8 hrs. This experiment used 
PBMC from HC 1  
a. 
 
b. 
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4.7 Creation Of 721.221 B Cell Target Cell Line 
 
The purpose of creating target cell lines expressing different HLA constructs was to allow 
differentiation between the inhibitory potentials of various HLA-B-KIR3DL1 
combinations. In my hands, the CHO-cell line did not provoke high enough levels of 
CD107a to make meaningful observations between the constructs.  
 
One possible reason for the poor degranulating response from the CHO-cell line could be 
a consequence of its adherent nature. Traditionally, CD107a assays are carried out using 
a non-adherent cell line, allowing cytotoxic cells 360° access to the target cell. As an 
alternative, I obtained the HLA-null 721.221 cell line (courtesy of the Moffett laboratory, 
Cambridge, UK) and cloned in HLA-B constructs to use as target cells. The 721.221 
(henceforth 221) cell line was formed by Epstein-Barr virus (EBV) transformation of a 
lymphoblastoid cell line. It is HLA-Class I null, but expresses activating NK receptors, 
so unlike the CHO-cell line (which required MICA*009 to trigger a degranulating event), 
there was no need to transfect the MICA construct. Furthermore, there was no need to 
transfect B2M as 221-cells are human in origin and constitutively express B2M.  
 
I used the pcDNA3.1(+) neomycin vectors with HLA-B*51, B*52, B*35 as well as the 
vector control to transfect naïve 221-cells. Transfecting B cells is more challenging that 
CHO-cells and traditional lipid-based transfection methods did not work. I therefore used 
electroporation to ensure the plasmids were taken up by the 221-cells. After 2 days of 
recovery, the cells were flow sorted. Figure 4-15 shows the level of HLA expression on 
221-cells four weeks after flow sorting. As can be seen, the 221-cells also lose HLA-
expression over time, despite continuous antibiotic selection. For this reason, the cells 
were checked for HLA expression and flow sorted to >90% expression prior to functional 
assays.  
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Figure 4-15. Expression Of Genes Of Interest In 221 Cell Constructs Four Weeks After 
Flow Sorting.  
In each row, cells are gated firstly on 221-cells using FSC and SSC, then on singlets using 
SSC-H and SSC-A and finally histograms of HLA-Class I staining are shown. (a.) HLA-
Null cells have 0% HLA expression. (b.) HLA-B*51 cells express 55.7% HLA-B. (c.) HLA-
B*52 express 57% HLA-B. (d.)  HLA-B*35 express 85% HLA-B. HLA – Human 
Leukocyte Antigen, SSC – Side Scatter, FSC – Forward Scatter, H – Height, A -Area 
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4.7.1 721.221 Cell Transfectants Provoke A More Profound Degranulation Response 
Than CHO-Cell Transfectants 
 
 
To test how effective the 221-cells were at provoking a degranulating response, I used 
the same healthy control individuals with known KIR3DL1/S1 allotypes to test the cell 
lines. 1 x105 221-cells were co-cultured in a 1:1 ratio with PBMC containing 1x105 NK 
cells (as previously described), Figure 4-16 shows the level of degranulation observed 
after 5 hours of co-culture. 
 
In addition to provoking a more robust CD107a response from PBMC, the 221 cell line 
was also easier to use in the assay as the co-culture could take place in a capped 5ml 
polystyrene tube, which could then be used in downstream cytometric assays. Growing 
the CHO-cells in 96 well plates until 80-90% confluent was challenging as not all the cell 
lines grew at the same rate and if they were grown too densely, the assay could not be 
carried out. In contrast, the 221-cells could be counted and aliquoted on the day of the 
assay.  
 
4.7.2 Confirming Transfected Constructs Within 721.221 Cells 
 
The antibody used to detect HLA-B throughout this thesis is a W6/36 clone. This clone 
is unable to differentiate between different HLA-B allotypes. To help ensure that the 
samples did not become contaminated during passages, they were periodically tested for 
each HLA-B construct. Primers were designed to amplify unique regions within HLA-
B*51, B*52 and B*35. On a monthly basis, DNA was extracted from 221 cell 
transfectants and screened for contamination. Figure 4-17 shows the size of the amplified 
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products from each primer pair. Primers were based on Bunce et al. (Bunce et al., 1995) 
and are used routinely in clinical transplantation laboratories for HLA typing. 
 
Figure 4-16. CD107a Expression On PBMC From Three Healthy Control Individuals 
Following Co-Culture With 221-Cell Transfectants For 5 Hours 
There is robust CD107a expression in PBMCs co-cultured with the positive control and 
HLA-Null controls. The HLA-B transfectants provoke less CD107a expression on PBMC 
than their positive control counterparts and negative controls provoke low levels of 
CD107a expression. Dotted line separates the positive and negative controls from the 
HLA transfectants. Each experiment was repeated three times. 
 
 
 
Figure 4-17. Testing For Contamination Of HLA-B Transfectants 
DNA from each transfectant is amplified in the presence of primer pairs 1-(HLA-B*51), 
2-(HLA-B*52) and 3-(HLA-B*35). If more than one product was detected when run on 
an agarose gel, the sample was considered contaminated. In this gel, all three products 
are shown as well as a vector control. 
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4.8 CD107a Expression After Co-Culture With 721.221 Cell Transfectants 
 
4.8.1 CD107a Expression On Natural Killer Cells  
 
Degranulation assays were carried out on nine donor PBMC with the 221 cell line 
constructs. Experimental repeats were carried out an average of three times (range 2-9) 
when enough PBMC were available. The percentage of CD107a expressed was adjusted 
according to the negative control for each sample (Figure 4-18). 
 
The HLA-B*51 cell line appeared to inhibit degranulation more than the HLA-B*52 and 
B*35 cell lines, however, there were no significant differences in the levels of CD107a 
expressed by NK cells between the four cell lines (P=0.0736).  
 
4.8.2 CD107a Expression On CD8 T Cells 
 
CD107a expression was examined in the T cell compartment to establish whether CD8 T 
cells may have an effect in early target cell lysis. Figure 4-19 shows the level of 
degranulation in CD8 T cells. There was very little CD107a expression in the CD8 T cell 
compartment. This low level CD107a expression was also seen in the positive control 
(PMA + ionomycin), with 3.12 ± 1.45 % cells expressing CD107a.  
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Figure 4-18. Natural Killer Cell CD107a Expression In The HLA-Null, HLA-B*51+, 
HLA-B*52+ And HLA-B*35+ 721.221 Cell Lines.  
There was no significant difference in CD107a expression on NK cells co-cultured with 
the three HLA-B transfected cell lines. Expression levels were normalised against a 
negative control prior to comparison. ns – not significant. Each experiment was repeated 
three times. 
 
 
 
 
Figure 4-19. CD8 T Cell CD107a Expression In The HLA-Null, HLA-B*51+, HLA-
B*52+ And HLA-B*35+ 721.221 Cell Lines  
There was no significant difference in CD107a expression on CD8 T cells co-cultured 
with the three HLA-B transfected cell lines. Expression levels were normalised against a 
negative control prior to comparison. ns – not significant. Each experiment was repeated 
three times. 
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4.9 Discussion Of Findings 
 
There have been two attempts in the past to establish a link between KIR3DL1/S1 and 
BD. In 2007, Middleton et al. examined 93 Turkish cases and 43 controls for the 
presence/absence of KIR3DL1/S1, but did not find any association when controlling for 
the effects of HLA-B*51 (Middleton et al., 2007). Recently, Erer et al. used a large and 
carefully complied dataset of 1,799 Turkish BD cases and 1,710 matched controls to 
examine the effects of KIR3DL1/S1 in BD. They found an association between presence 
of KIR3DS1 and ocular disease, but no effect of KIR3DL1/S1 overall on disease-risk (Erer 
et al., 2016). Our data reflected some of these findings but did not confirm the association 
between KIR3DS1 and ophthalmic disease. This may be due to very low power (14%) 
resulting in a type II error, as there was minimal difference between the BD and HC 
groups. I found KIR3DL1 to be present in 96% of BD cases in the UK cohort and 97% in 
the European Subgroup, whereas KIR3DS1 was present in 42% of the UK cohort and 45% 
of the European Subgroup. The lower frequency of KIR3DS1 may have reduced the power 
of the study enough to miss an association between ophthalmic disease and KIR3DS1. It 
is also possible that the ophthalmic disease referenced in the paper by Erer et al. may have 
been phenotypically different that found in the UK cohort (further discussed in Chapter 
5).  
 
I did not find any specific allele to increase or decrease the risk of developing BD. Nor 
did I find an association when alleles were grouped by their inhibitory-potential. The 
combination of a low-expressing KIR3DL1 allele and an activating allele 
(KIR3DL1LOW/KIR3DS1) was associated with increasing the risk of BD (OR 2.47 in UK 
cohort and 2.35 in European subgroup). This association survived correction for multiple 
testing reducing the risk of a type I error and was well powered to avoid a type II error 
(93%). Of the low-expressing KIR3DL1 alleles, KIR3DL1*00501 was the most frequent 
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(possessed by 82.18% of individuals with BD and 70.78% of HCs in the UK cohort) 
followed by KIR3DL1*00701 (possessed by 17.82% of individuals with BD and 25.32% 
of HCs in the UK cohort). KIR3DS1 was not found to be polymorphic and only 
KIR3DS1*013 was identified in those individuals analysed.  
 
A combination of the high-expressing KIR3DL1 allele and a null KIR3DL1 allele 
(KIR3DL1HIGH/KIR3DL1NULL) was associated with decreased risk of BD (OR=0.53 in UK 
cohort and 0.36 in European subgroup). This association survived correction for multiple 
testing reducing the risk of a type I error and was well powered to avoid a type II error 
(92%).  Of the high-expressing KIR3DL1 alleles, KIR3DL1*0010101 was the only allele 
implicated in protection from disease and was present in 14.77% of individuals with BD 
and 16.38% of HCs.  
 
It is possible to explain the increased risk conferred by the KIR3DL1LOW/KIR3DS1 
genotype in two ways (Figure 4-20). Firstly, the presence of the conserved KIR3DS1*013 
may increase the activation of innate immune cells and drive persistent inflammation. 
When combined with a weakly inhibitory KIR3DL1LOW allele there may be insufficient 
inhibition to ‘turn off’ the inflammatory response. Thus, an individual remains in a pro-
inflammatory state, which could be easily exacerbated by a trigger such as a viral 
infection, trauma or stress causing downregulation of cell-surface HLA and increased 
cell-mediated cytotoxicity. Similarly, the protective KIR3DL1HIGH/KIR3DL1NULL 
genotype lacks KIR3DS1 and relies on other activating receptors to initiate degranulation, 
although why KIR3DL1HIGH/KIR3DL1NULL should result in protection from disease, while 
the KIR3DL1HIGH/KIR3DL1HIGH genotype is not implicated in protection, is unclear. It 
may be that KIR3DL1NULL provides sufficient inhibition during NK cell licencing for other 
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inhibitory KIRs to be expressed in the presence of their ligand. The role of KIR3DL1*004 
is discussed further below.  
 
Figure 4-20. Possible Rationales Of KIR3DL/S1 ‘Functional Genotypes’ In (a.) Risk And 
(b.) Protection From Behçet’s Disease.  
(a.) The effects from the activating KIR3DS1 outweighs the inhibitory KIR3DL1 signal. 
This, combined with potential downregulation of self-HLA in viral infections, leads to 
degranulation of NK cells and target cell lysis. Uncontrolled and unopposed NK cell 
activation results in chronic inflammation and local tissue damage. (b.) A strong 
inhibitory KIR3DL1 signal prevents NK degranulation, thus there is no local 
inflammation or tissue destruction. This model does not fully explain why individuals who 
are KIR3DS1 or KIR3DL1HIGH homozygous should not be affected by the same risk and 
protection effects. It may be that the balancing effect of another KIR3DL/S1 allele is 
implicated in NK cell education and disease progression. 
 
 
 
 
 
4.9.1 KIR3DL1*004 
 
The role of KIR3DL1*004 in disease is of current interest. If the protein is retained 
intracellularly and therefore is truly ‘null’, why would it be maintained by natural 
selection, and be present in ~20% Caucasians? (Martin et al., 2007). Historically, 
KIR3DL1*004 has been thought to reside intracellularly due to two amino acid 
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substitutions in the D0 and D1 Ig-like domains (Pando et al., 2003). More recently, Taner 
et al. published work showing that, while the majority of KIR3DL1*004 is retained 
intracellularly, a small proportion is correctly folded and expressed on the cell surface 
(Taner et al., 2011). This data, complied with evidence that possession of Bw4 and 
KIR3DL1*004 slows progression of human immunodeficiency virus (HIV) infection to 
acquired immunodeficiency syndrome (AIDS) (Martin et al., 2007), make it tempting to 
hypothesize that KIR3DL1*004 confers some level of inhibitory potential to NK cells 
that express it. If this is the case, then low surface levels of KIR3DL1*004 could modulate 
NK cell function in the same way as the KIR3DL1LOW receptor KIR3DL1*005, which is 
expressed at low levels, but confers robust inhibition to degranulation (Yawata et al., 
2006). If KIR3DL1*004 is interacting with Bw4, then it is likely to play a role in 
educating NK cells and indirectly influencing the proportion of KIR3DL1/S1+ NK cells 
(Morvan et al., 2009). 
 
4.9.2 KIR3DL1*005 And *007 
 
Two low-expressing KIR alleles were found to confer risk in combination with KIR3DS1 
(*00501 and 00701) in this study. In the MC group, there was no effect from 
KIR3DL1*00501, whereas in the ophthalmic group both alleles contributed to disease 
susceptibility. KIR3DL1*00701 was found less frequently in both groups, but its effect 
size was between 5-10x greater than KIR3DL1*005. KIR3DL1 is broadly represented by 
three ancestral lineages; KIR3DS1*01301, KIR3DL1*005 and KIR3DL1*015 (Parham et 
al., 2011). From these lineages, selection pressures have encouraged an abundance of 
KIR3DL1 allotypes to form. The KIR3DL1*015 lineage is most diverse amongst Africans, 
whereas the KIR3DL1*005 lineage is more common in Caucasians (Norman et al., 
2007a). While KIR3DL1*005 has remained stable for more than three million years, 
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KIR3DL1*007 segregated as a clade from KIR3DL1*015 more recently (Parham et al., 
2011). It is notable in our cohort that KIR3DL1*015 was not associated with BD, whereas 
KIR3DL1*007 with its narrow binding pattern and KIR3DL1*005 with its broader 
specificity are. Despite these biological differences, both receptors are expressed at low 
levels on the cell surface with KIR3DL1*005 contributing a strong inhibitory response 
and KIR3DL1*007 a much weaker response (Gumperz et al., 1997; Gumperz et al., 1996; 
Yawata et al., 2006).  
 
4.9.3 KIR3DS1 
 
KIR3DS1 was found to increase the risk of developing BD in conjunction with 
KIR3DL1LOW alleles. KIR3DS1 appeared to be monomorphic in our cohort; 
KIR3DS1*01301 being the only allele identified. KIR3DS1*01301 is thought to be the 
prototypic KIR3DS1 allele and is found in all studies populations.  
 
Despite many structural similarities between KIR3DL1 and KIR3DS1, it remains 
contentious as to whether Bw4 is a ligand for KIR3DS1. There has been one report of 
KIR3DS1 binding HLA-B*57 (O'Connor et al., 2015) in the context of HIV-1 infection. 
However, in 2016, HLA-F was identified as a high-affinity ligand for KIR3DS1 (Garcia-
Beltran et al., 2016). HLA-F is thought to be the ancestral progenitor of the stress-induced 
ligand – MICA. Like MICA, HLA-F does not bind peptide, nor require B2M to stably 
fold and is upregulated during cell-stress (Cerboni et al., 2007; Goodridge et al., 2010). 
 
HLA-F also binds other allotypes of KIR3DL1, but at a lower affinity. In BD, KIR3DS1 
may be recognising HLA-F, which has been upregulated due to cell-stress (N. Lee et al., 
2010). Our data suggests that this, in conjunction with a KIR3DL1LOW allotype, results in 
NK cells that are more likely to degranulate than those without an inhibitory KIR3DL1 
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(i.e. KIR3DS1/KIR3DS1), or indeed an activating receptor (i.e. 
KIR3DL1LOW/KIR3DL1LOW). KIR3DS1 has also been linked to a number of other 
diseases without an HLA-Bw4 association (Besson et al., 2007; Trydzenskaya et al., 
2013; Venstrom et al., 2010), suggesting that the effects of KIR3DS1 may be independent 
of Bw4. This is relevant to this study as the KIR3DL1LOW/KIR3DS1 ‘functional genotype’ 
was found to be significant in the Bw6 subgroup as well as the Bw4 subgroup in the UK 
cohort. However, in the European subgroup the Bw4 group lost its association (Figure 
4-1). Suggesting that the ‘risk genotype’ may be partially (or completely) mediated by 
mechanisms other than Bw4 interaction. By comparison, the protective 
KIR3DL1HIGH/KIR3DL1NULL genotype was associated with Bw4 in both the UK cohort 
and the European subgroup.  
 
In 2017, Carlomagno et al. published findings suggesting that KIR3DS1 may play a role 
in NK cell education in the same way as KIR3DL1. The authors found that KIR3DS1+ 
NK cell clones could recognize HLA-B*51 when transfected into Bw4- target cells, but 
not in Bw4+ cells. Thus, implying that exposure of KIR3DS1 to Bw4 during early 
development reduces binding to self-targets later in life.  
 
4.9.4 Expression Of KIR3DL1/S1 In Behçet’s Disease  
 
This project aimed to determine KIR3DL1/S1 allelic variation in BD and to establish 
whether this variation could explain the role of HLA-B*51 in disease pathogenesis. To 
do this, a large cohort of individuals with BD and demographically matched HCs were 
genotyped. Using the data generated, I approached individuals with specific KIR3DL1/S1 
genotypes to donate PBMC for phenotypic and functional analysis. Over a 16-month 
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period, PBMC from only 22 individuals were collected. There are a number of reasons 
for this: 
 
1. Individuals who are clinically stable were only returning to clinic on an annual 
basis. 
2. Individuals often required a large number of clinical samples to be taken 
during their visit and were reluctant to have additional research samples taken, 
despite donating blood previously. 
3. Individuals may not attend clinic or be lost to follow-up.  
 
Of the 22 individuals phenotyped, NK cells made up 5.35% ± 2.31 of circulating 
lymphocytes. In the past, circulating NK cells in BD have been reported as being raised 
(F. Kaneko et al., 1985; Suzuki et al., 1992), unchanged (Eksioglu-Demiralp et al., 1999; 
Saruhan-Direskeneli et al., 2004) and reduced (Hamzaoui et al., 1988; Hasan et al., 2017). 
However, many of these reports are not comparable due to heterogeneous patient groups, 
disease activity status, concurrent medications and methodological discrepancies. In 
2017, Hasan et al. described reduced numbers of circulating NK cells in the same patient 
population as that studied here. The authors also found a slight shift toward CD56Bright 
NK cells compared to healthy controls. Of interest, NK cell percentages were lowest 
amongst BD cases with active disease and those taking the DMARD azathioprine. 
Although it did not appear to have a marked impact in the patients studied in our cohort, 
azathioprine has been previously identified as cause for NK cell depletion (Cseuz et al., 
1990; Mellado et al., 2012; Orandi et al., 2017; Pedersen et al., 1986; Prince et al., 1984; 
Shih et al., 1982). Similarly, our data did not support the finding that there is a significant 
difference between circulating NK cells in active and quiescent BD.  
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It is possible that circulating NK cells are being actively recruited to inflamed tissues in 
BD (particularly during a flare). However, there is no published data specifically 
investigating the presence of NK cells in BD-lesions. Reduced NK cells in peripheral 
blood have been described in other diseases, such as type-1 diabetes mellitus (Rodacki et 
al., 2006), systemic lupus erythematosus (Yabuhara et al., 1996), rheumatoid arthritis 
(Dalbeth et al., 2002) and psoriasis (Ottaviani et al., 2006). There is further data from the 
diabetes literature that suggests that NK cells are increased in pancreatic islet cells, thus 
reinforcing the concept that peripheral NK depletion is coupled with NK cell tissue-
aggregation (Gur et al., 2010). Another interpretation of this finding could be that NK 
cells are depleted in all compartments as a result of BD, or indeed, that a state of NK 
depletion contributes to BD development. At present, there is insufficient data to discount 
the hypothesis that NK cells are recruited to inflamed tissues in BD.  
 
KIR3DL1/S1 was labelled with an antibody that recognizes only KIR3DL1 (DX9) and 
another which recognizes both KIR3DL1 and KIR3DS1 (REA 618). Traditionally, the 
Z27 antibody clone is used to label KIR3DL1 and KIR3DS1. However, for manufacturing 
reasons it was not available at the time these experiments were carried out. Low levels of 
KIR3DL1 were identified on NK cells and practically none on CD8 T cells. Much of the 
previously published data examining KIR3DL1/S1 allotype binding profiles was carried 
out on transfected cell lines, so the normal-range of DX9 binding in health and disease is 
not extensively described and has never been carried out in a cohort of BD patients from 
the UK before. In 2016, Boudreau et al. published data based on 135 healthy controls and 
found that the expression level (Low, High or Null) was proportionate to the percentage 
of NK cells expressing KIR3DL1 (Figure 1-8) (Boudreau et al., 2016). Based on this, it 
was expected that KIR3DL1LOW homozygotes would have a lower percentage of NK cells 
expressing KIR3DL1 than KIR3DL1HIGH homozygotes. However, the DX9 binding data 
 185 
shown here did not correlate with the expected binding. For example, 22% NK cells 
expressed KIR3DL1 in sample 5 (KIR3DL1HIGH homozygote), whereas less than 5% of 
NK cells expressed KIR3DL1 in samples 1, 2, 3 and 7 (also KIR3DL1HIGH homozygotes). 
This finding was not dependent on the presence or absence of Bw4 and there did not 
appear to be a significant effect from medication or disease activity. Similarly, samples 
9, 10, 11 and 12 (KIR3DL1HIGH/KIR3DL1LOW) did not express any KIR3DL1 at the time 
of testing.  
 
A study in 2017, examined KIR3DS1 expression on NK cells of 27 HC donors (Figure 
4-21). The authors found that KIR3DS1 was present on ~40% of NK cells using the same 
staining strategy as that used in this study (Figure 4-22A). They also found no difference 
in KIR3DS1 expression on cells expressing Bw4I80, T80 or Bw6 (Figure 4-22B). By 
comparison, I found negligible KIR3DS1 expressed on NK cells in the five individuals 
possessing KIR3DS1 (Carlomagno et al., 2017).  
 
CD8 T cells also express KIR. Currently available data suggests that this occurs at a lower 
level and with less variability than their NK cell counterparts (Bjorkstrom et al., 2012; 
Ugolini et al., 2001) (Figure 4-22). Furthermore, CD8 T cells appear to frequently express 
different KIR than NK cells, which may or may not have a self-ligand present. In this 
project, I determined that expression of KIR3DL1/S1 on CD8 T cells was not correlated 
to expression in NK cells. However, given the low levels of expression detected, it is 
difficult to draw any conclusions regarding differences between the individuals tested. 
The percentage of CD8 T cells expressing KIR3DL1 has been found to vary considerably 
in different individuals. In 2012, Bjorkstrom et al. examined the expression of KIR3DL1 
in 43 individuals and found that KIR3DL1 was expressed on 22.5% NK cells compared 
to 4% of CD8 T cells; a level of expression comparable to our cohort.  
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Finally, these results could be compared to those published by Takeno et al, 2004 (Takeno 
et al., 2004). The authors investigated KIR3DL1 expression (in the absence of data 
regarding the KIR3DL1 alleles present) in a group of 40 individuals with BD. The 
majority (60%) of patients had ophthalmic disease and of the remaining 40% who did not 
have ocular manifestations, 90% had either neuro-BD or gastrointestinal involvement. 
The authors also found that KIR3DL1 was reduced on circulating NK cells in BD, but to 
a lesser extent that in this study (12.99 ± 12.49%). This could be explained due to the 
severity of BD in the two groups (severe vs less severe), ethnicity or medication. It is also 
possible that the KIR3DL1 antibody used had a different binding pattern to that used in 
this study.  
 
Figure 4-21. Gating Strategy For Selecting KIR3DS1+ NK Cell Subsets 
KIR3DS1+ NK cells (CD3-CD56+KIR3DS1+KIR3DL1-) in PBMC from healthy controls 
(A). KIR3DS1 surface expression was evaluated on NK cells from HLA-B Bw4-I80 (n = 
12, full squares), Bw4-T80 (n = 7, full circles), or Bw4- (n = 8, full triangles) healthy 
donors and found to be equivocal across all groups (B). Reproduced with permission from 
(Carlomagno et al., 2017) 
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Figure 4-22. Frequency Of KIR3DL1 Expression On NK And CD8 T Cells In 43 Healthy 
Control Individuals 
The authors found KIR3DL1 to be expressed on 40% of NK cells in an HC population. 
This contrasts with the findings in the project, where KIR3DL1 was expressed on less 
than 10% of cells in patients with Behçet’s Disease. Reproduced with permission from 
(Bjorkstrom et al., 2012). 
 
 
4.9.5 Degranulation Assays  
 
HLA-null, 221 target cells were used to create HLA-B*51, HLA-B*52 and HLA-B*35+ 
cell lines. These cell lines did not induce significantly different levels of degranulation in 
NK cells from KIR3DL1/S1-typed donors. I was only able to test a small proportion of 
the overall number of patients genotyped and I was unable to compare healthy controls 
with matched KIR3DL1/S1 genotypes. There may have been a trend to suggest that HLA-
B*51 provoked less CD107a expression than the HLA-B*52 and B*35 cell lines (Figure 
4-18), however, more samples would need to be run to confirm this trend.  
 
4.9.6 Chapter Summary 
 
Behçet’s Disease is a heterogeneous condition. Many patients will only ever experience 
orogenital ulceration, while others go on to develop blinding uveitis or inflammatory brain 
disease causing long-standing neurological deficit.  
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This is the first study to examine KIR3DL1/S1 alleles in BD. I found that a 
KIR3DL1LOW/KIR3DS1 genotype was associated with an increased risk of developing 
BD, whereas a KIR3DL1HIGH/KIR3DL1NULL genotype was associated with protection from 
disease. My findings correlate with published data in other inflammatory diseases. In 
2016, Ahn et al. examined the frequency of KIR3DL1/S1 allotypes in 203 patients with 
psoriasis and 111 healthy controls of European descent. Their results suggested that 
presence of a weakly inhibitory KIR3DL1 allele increased the risk of developing psoriasis, 
whereas KIR3DL1*004 was protective (Ahn et al., 2016). Similarly, Diaz-Pena et al. 
found that the combination of KIR3DS1*013 and KIR3DL1*004 was protective in 
ankylosing spondylitis (Diaz-Pena et al., 2010). In 2016, a large cohort of African-
Americans with multiple sclerosis were tested for any KIR associations. The authors 
found that presence of KIR3DL1 in conjunction with Bw4 lead to protection from disease, 
however, these benevolent effects were overridden by the risk attributed from HLA-
DRB1*15:01 (Hollenbach et al., 2016). There are still relatively few disease-association 
studies investigating the effects of KIR allelic variation. The findings from this project 
need to be repeated in other BD cohorts to confirm their validity. 
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5 A Prospective Survey of the United Kingdom To Identify 
The Incidence Of Ophthalmic Manifestations In Behçet’s 
Disease 
 
There is no published data exploring the ocular manifestations of BD in the UK. Nor are 
there robust statistics available to inform clinicians and patients of the incidence of 
ophthalmic BD. Knowledge of the incidence of eye disease within the UK is important to 
better inform patients of their prognosis. Given the heterogeneity of BD across the globe; 
it is not adequate to counsel patients based on data from another population (Mahr et al., 
2008). This information is also important for planning clinical trials, calculating costs to 
the health service and determining best management strategies.  
 
The ophthalmic complications of BD can be particularly challenging to manage. It has 
been reported that up to 90% of patients who are not treated will lose all vision in both 
eyes within four years (BenEzra et al., 1978). As previously mentioned, it is likely that 
the prevalence of BD in the UK is approximately 2 per 100,000, based on unpublished 
data collected by the Behçet’s Disease Centres of Excellence. The incidence of 
ophthalmic disease varies across the world from 10-80% (Barra et al., 1991; Chamberlain, 
1977; González-Gay et al., 2000; Papoutsis et al., 2006; P. Yang et al., 2008; Zouboulis, 
1999; Zouboulis et al., 1997). A study from 1977 carried out in Yorkshire, UK suggested 
that ocular complications of BD were present in 25% of individuals affected. However, 
the study involved small numbers and was retrospective in design.  
 
In order to collect incidence data, I approached the British Ophthalmic Surveillance 
Unit (BOSU). BOSU is part of the Royal College of Ophthalmology and was 
established to survey the incidence of rare ocular conditions.  
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5.1 Incidence Of Ophthalmic Manifestations Of Behçet’s Disease 
 
Behçet’s Disease is known to be most common across the ancient Silk Route and most of 
the epidemiological data has come from countries that are most affected. In 2001, Bang et 
al. reported a BD prevalence of 3.2 per 100,000 in South Korea. Of these, 50% (n=320) had 
eye disease (Bang et al., 2001). Data from Germany suggested that the prevalence of BD in 
1997 was 1.68 per 100,000 with between 48%-66% (n=150-210) having BD-related eye 
disease (Zouboulis et al., 1997). A smaller survey reported the incidence in northwest Spain 
at 0.66 per 100,000 with 30% having eye disease (n=34 over 5 years) (González-Gay et al., 
2000).  
 
5.2 Case Definition 
 
 
Patients eligible for the study must have had ocular pathology consistent with BD. 
Typically, this includes; anterior uveitis, vitritis, vascular occlusion and retinal infiltrates. 
Rarely, patients may present with episcleritis, scleritis, optic neuritis and ocular surface 
inflammation.  
 
A retinal infiltrate is a creamy-white lesion, usually larger than a cotton-wool spot and 
can be found in the posterior pole or periphery. They represent areas of intraretinal 
neutrophilic aggregation. Figure 5-1 shows a retinal infiltrate at the posterior pole of the 
left eye.  
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Figure 5-1. Example Of A Retinal Infiltrate Secondary To Behçet’s Disease  
Colour fundus photograph of the left eye – there is a retinal infiltrate at the macula with 
1+ vitreous haze.  
 
 
5.3 Reported Cases 
 
Reporting methodology can be found in Chapter 2. Cases were surveyed for 12 months 
between November 2016 and October 2017. During that time 31 cases were reported via 
the BOSU yellow-card system. Figure 5-2 details the number of reported cases, correct 
diagnoses and cases analysed. The study was granted an extension from BOSU in October 
2017 to allow a second year of data collection, due to end in November 2018. The results 
in this Thesis do not reflect those collected during the second year of data collection.  
 
5.4 Incidence Of Ophthalmic Manifestations Of Behçet’s Disease 
 
A total of 33 cases of ophthalmic manifestations of BD were reported between October 
2016 and October 2017. The location of reporting sites can be seen in (Figure 5-3). There 
was a good spread of reporting from across the UK, with the exception of the North-East 
and North-West of England and East Anglia, where no cases were reported.  
 192 
Figure 5-2. Flow Chart Illustrating The Number Of Cases Reported To The British 
Ophthalmic Surveillance Unit And The Number Finally Analysed. 
Thirty-three cases were reported via BOSU, 29 complete questionnaires were returned 
and of these, 23 fulfilled inclusion criteria for the study. 
 
 
 
 
Figure 5-3. Heat-Map Indicating The Locations Of Reported Cases Of Ophthalmic 
Behçet’s Disease 
The first-half of patients’ post code was collected as demographic data. This was 
geomapped onto a map of the United Kingdom and shows that most of the reported cases 
come from areas of high population density.   
 
 
 
 
 
Cases Reported  n=33
Questionnaires Returned n=29
Cases Excluded n=6 
• Incorrect Diagnosis n=1 
• Reporting Error n=5
Cases Analysed n=23
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Questionnaires were not returned for four cases; five cases were a reporting error (not the 
first episode of uveitis) and one case was a misdiagnosis. Over the surveillance period, 23 
cases met the inclusion criteria. This gives an estimated annual incidence of ophthalmic 
manifestations in BD of 0.04 (95% CI 0.02-0.05) per 100,000. In total, 27 eyes were 
affected. The age, gender, laterality and ethnicity are reported in Figure 5-4. The median 
age of reported cases was 37±11.1 years (range 15-55 years). There was no predilection 
for gender, with females making up 52% of cases and males 48%. Fifty per cent of cases 
had bilateral involvement and 50% unilateral (38% right eye, 12% left eye. The majority 
of cases were of Northern European ethnicity (72%) followed by Middle Eastern (19%) 
and North African (9%). 
 
Figure 5-4. Demographics Of Individuals Reported  
The age of reported (a.) cases, (b.) gender, (c.) laterality and (d.) ethnicity. 
 
a. Of the cases reported, there was two peaks around ages 25 and 40yrs.  
b. There was no gender predominance in those patients with ocular involvement.  
c. Half of the cases were bilateral. 
d. The majority of cases described were of Northern European ancestry. 
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5.5 Clinical Presentation Of Ophthalmic Behçet’s Disease 
 
Fifty-two percent (n=12) of individuals were diagnosed with BD at the time they 
presented with ocular inflammation. The remaining 48% (n=11) of reported cases 
presented with an ocular inflammatory event after they had a diagnosis of BD (Figure 
5-5). Seventy-three percent (n=8) of individuals in this group were taking systemic 
immunosuppression at the time of their ocular event.  
 
Figure 5-5. Percentage Of Patients With A Previous Diagnosis Of Behçet’s Disease  
The percentage of patients given immunosuppression is shown along with the median ± 
SD time until onset of eye-disease. Fifty-two percent of patients did not have an 
underlying diagnosis of BD, however 48% did, the majority of these were being treated 
with systemic immunotherapy prior to the onset of eye disease. 
 
 
5.5.1 Systemic Manifestations Of Behçet’s Disease 
 
Ninety percent (n=21) of cases had recurrent oral aphthous ulcers, 55% (n=12) reported 
genital ulceration, 50% (n=11) skin lesions, 10% (n=2) systemic vascular occlusion and 
5% (n=1) inflammatory arthritis.  
 
Median (±SD) time until onset of 
eye-disease after diagnosis of BD - 
73±75 days
35% Previous diagnosis of BD - On systemic immunosupression
13% Previous diagnosis of BD - Not immunosupressed
52% No previous diagnosis of BD
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5.5.2 Ophthalmic Manifestations Of Behçet’s Disease 
 
 
All eyes had intraocular inflammation. There were no reported cases of episcleritis, 
scleritis, optic nerve pathology or ocular surface disease. Anterior uveitis alone was 
present in 26% (n=5) and in conjunction with a hypopyon in 5% (n=1). Vitritis was 
reported in 42% (n=8) and panuveitis in 26% (n=5). Cystoid macula oedema (CMO) was 
present in 40% (n=9) of individuals and retinal infiltrates in 35% (n=12). Inflammatory 
retinal vascular occlusion was reported in 35% (n=9). Retinal vasculitis was present in 
10% (n=2). Ocular Manifestations can be seen in Figure 5-6.  
 
Figure 5-6. Ophthalmic Phenotype At Presentation 
The most common ocular manifestations were vitritis, macular oedema, retinal 
infiltrates and vascular occlusions. 
 
 
 
Respondents were asked to specify the cause of visual loss (if relevant). Figure 5-7 shows 
the top three causes of visual loss (CMO, retinal ischaemia and vitritis). The greatest 
visual morbidity in BD was caused by CMO (P=0.0102). The mean LogMAR best-
corrected visual acuity (BCVA) for those presenting with CMO was 1.1±0.58. This was 
followed by retinal ischaemia (mean LogMAR BCVA of 0.33±0.12) and vitritis (mean 
LogMAR BCVA 0.20±0.16). In order to analyse mild and severe ocular inflammation, I 
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scored ophthalmic manifestations depending on severity and potential threat to vision 
(Table 5-1). I found no difference between males and females with regard to disease 
severity (P=0.6698). Patients taking corticosteroids alone or one DMARD plus a 
corticosteroid had more severe ocular manifestations that those taking multiple DMARDs 
or a biologic medication (P=0.0357). 
 
Table 5-1. Scoring Severity Of Ophthalmic Disease 
A score 1 was given to intraocular inflammation alone. Any macula oedema, retinal 
infiltrate or vein occlusion scored 2 due to the increased severity and increased risk of 
visual loss. 
 
Ophthalmic Manifestation Score 
Anterior Uveitis 1 
Vitritis 1 
Panuveitis 1 
  
Retinal Infiltrate 2 
Vascular Occlusion 2 
Macula Oedema 2 
 
Figure 5-7. Top Three Identified Causes Of Low Vision 
Individuals with macula oedema presented with significantly worse vision than those with 
vitritis alone. The mean ± standard deviation LogMAR best corrected visual acuity 
(BCVA). *P<0.05 
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5.5.3 Medical Management Of Patients Prior To Onset Of Ophthalmic Behçet’s Disease 
 
Thirty-five percent (n=8) were treated for BD prior to developing eye disease. Of these, 
38% (n=3) were taking oral corticosteroids alone, 38% (n=3) were taking oral 
corticosteroids plus one disease modifying anti-rheumatic drug (DMARD), 4% (n=1) 
were taking multiple DMARDs and 4% (n=1) were taking an anti-TNFα medication. 
Figure 5-8 shows a breakdown of ocular manifestations by medication 
 
Figure 5-8. Ocular Manifestations Of Behçet’s Disease Occurring In Those Patients 
Already Taking Immunosuppression 
 
Eight patients were already being treated with a systemic therapy prior to onset of eye 
disease. Of these, one patient was taking an anti-TNF α monoclonal antibody and one 
was taking two DMARDs.  DMARD – Disease modifying anti-rheumatic drug, TNFa – 
tumour necrosis factor α. 
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5.5.4 First Line Therapy For Ocular Manifestations Of Behçet’s Disease 
 
I asked respondents to state which first-line therapy was given to the patients. Figure 5-9 
shows medications prescribed for each indication by percentage. Over half (56%, n=15) 
of eyes were prescribed topical corticosteroids for both mild and severe disease (see Table 
5-1). Twenty-six percent (n=7) of eyes were prescribed oral corticosteroids, 7% (n=2) 
were prescribed intravitreal corticosteroids, 7% (n=2) were prescribed a DMARD and 4% 
(n=1) were prescribed intravenous corticosteroids. 
 
Figure 5-9. First-Line Medication Given To Patients With Differing Ocular Inflammation 
 
There was no clear pattern in management of eye disease. Patients with sight-threatening 
disease were topical steroids and patients with mild anterior uveitis were started on 
DMARDs. Only three patients were started on a DMARD at the time of presentation, 
despite EULAR guidelines, 2016. DMARD – Disease modifying anti-rheumatic drug. 
EULAR – European League Against Rheumatism. 
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5.6 Discussion Of Findings 
 
Prospective surveillance studies rely on accurate and reliable reporting. There are 
currently 1420 consultants and associate specialists receiving BOSU reporting cards 
(personal communication, RCOphth). Typically, 70-75% of cards are returned each 
month (either to report a case or to indicate that there is ‘nothing to report’). Furthermore, 
85-90% of individuals will return their reporting cards 6 or more times a year. However, 
despite good return rates, missing a few cases per year can significantly impact an 
incidence calculation. A case may be missed, if the patient was managed by a non-
consultant or associate-specialist grade doctor (who do not receive reporting cards), or if 
the reporting doctor was unable to remember seeing a patient at the end of a clinic. There 
is also the phenomenon of ‘reporting fatigue’. This can happen in busy centres where 
many cases are being surveyed. In this scenario, reporting physicians can be overwhelmed 
by the number of conditions they are supposed to report and cases can be missed.  
 
It is important that questionnaires are sent out to reporting clinicians as quickly as 
possible, so clinical notes are available and accurate information is obtained. In this study, 
all questionnaires were sent within a week of notification. If no reply was received after 
two weeks, a reminder was sent, followed by a phone call 1 month later. Four 
questionnaires were not returned despite our best efforts to obtain the data. These were 
all from the same centre. 
 
Over-reporting of cases can occur if there is duplicate reporting. This may be due to a 
patient being referred from a district general hospital to a tertiary referral centre and the 
case being reported twice.  
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I did not receive any duplicate reports in this study. There was unequal reporting across 
the UK. No cases were reported from the North-East, the North-West of England or East 
Anglia. The last ethnicity data collected by the office of national statistics (ONS) in 2011 
found that these areas had relatively few individuals who identified as non-White, which 
may have contributed to low reporting (ONS, 2011) (Figure 5-10). These regions also 
have an older population (see below). 
 
Figure 5-10. Self-Reported Ethnicity Data From The National Census Collected In 
England And Wales, 2011 (ONS, 2011).  
Outside of London, over 80% of individuals self-report as ‘White’. The three regions on 
the left did not report any cases via BOSU. The regions on the right of the graph all had 
at least one case reported.  
 
 
Finally, the denominator used for incidence studies is typically the population of the 
region surveyed. In this case, the population of the UK is 65.5 million. However, BD-
related eye disease is very unlikely to occur in patients over the age of 50 years. The ONS 
has estimated that in 2016, 63.1% of the UK population was between 16-64 years. This 
would reduce the denominator down to 41.3 million and the increase the incidence to 
0.056 per 100,000 individuals.  
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There are a number of problems with this figure. Firstly, in order to be comparable to 
other populations, it is important that the denominator remains a predictable figure (i.e. 
the population). Secondly, the proportion of individuals under 16 years or over 64 years 
varies depending on location (Figure 5-11). For example, in 2016, 31% of the population 
of North Norfolk was over 64 years, compared to 6% in Tower Hamlets. It is also notable 
that the areas of the UK with 20-40% of the population over 64 years, such as the North 
East of England and East Anglia, reported no cases. While ethnicity is important in the 
pathophysiology of BD; the number of individuals presenting with ocular involvement is 
small. It is therefore likely that reported cases are coming from areas of high population 
density and can be described by the Poisson distribution. 
 
This is the first study to prospectively survey the incidence and manifestations of 
ophthalmic BD in the UK. The data indicate that the incidence of ocular inflammatory 
disease in BD is 0.04 per 100,000 individuals. There is no published data to directly 
compare our findings against because previous studies examining the incidence of BD 
have used a retrospective methodology to capture all the cases reported within a certain 
area in a specific time-frame. Similarly, no previous study has examined the incidence of 
BD-related eye disease.  
 
The incidence of ophthalmic disease in other populations can be calculated using the local 
incidence of BD and estimating the percentage likely to have ocular involvement. There 
is incidence data available from Sweden (0.2/100,000) (Mohammad et al., 2013), Italy 
(0.24/100,000) (Salvarani et al., 2007), the USA (0.38,100,000) (Calamia et al., 2009), 
Germany (1.0/100,000) (Altenburg et al., 2006) and Korea (2.6/100,000) (Y. B. Lee et 
al., 2017). Ophthalmic disease occurs in 20-50% of patients with BD, depending on 
ethnicity (Bang et al., 2001; González-Gay et al., 2000; Zouboulis et al., 1997). 
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Figure 5-11. United Kingdom Population Aged 65 And Over And The Old Age 
Dependency Ratio By Local Authority, 2016. (ONS, 2017) 
Regions with the highest proportions of individuals over the age of 65 were concentrated 
around the coast in Lincolnshire, East Anglia, Sussex, Hampshire, Dorset and Devon. 
These areas reported few cases. 
 
Data exported from ONS, 2017 interim census. 
www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationest
imates/bulletins/annualmidyearpopulationestimates/mid2017. 
 
 
 
The incidence of ocular disease would, therefore be 0.04-1.3/100,000 in these 
populations: higher than that found in the UK in this study.  
 
Twenty-six percent of individuals identified in this study were either Middle Eastern or 
North African. In the last national census, 8.8% of the UK identified as ‘Black/ 
African/Black-British/Caribbean’ or ‘Asian/Asian-British’ (ONS, 2017). I found three 
times more non-‘White British’ individuals than one would expect from the population of 
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the UK. This is not a surprising finding, given the increase in frequency of BD across 
Central Asia, the Middle East and North Africa.  
 
The literature suggests that ophthalmic disease is more common in males and is associated 
with a more severe disease course (Yazici et al., 1984). I found no difference between 
males and females in incidence or severity of uveitis. Fifty-two percent of reported cases 
were diagnosed with BD at the time of presentation. Forty-eight percent already carried a 
diagnosis of BD and presented with an ophthalmic manifestation between 2-148 days 
after the diagnosis was made.  
 
I analysed the systemic medication taken by 73% of individuals already carrying a 
diagnosis of BD. Of note, 38% of individuals were taking oral corticosteroids alone, a 
further 38% were taking a DMARD as well as corticosteroids, one individual was taking 
multiple DMARDs and one was taking infliximab (an anti-TNF monoclonal antibody). 
The patients taking infliximab and multiple DMARDs presented with less severe disease 
than those taking one DMARD or corticosteroids alone.  
 
Respondents were asked to identify the major cause of visual morbidity in patients with 
poor vision. Macula oedema was significantly more likely to cause poor vision than 
vitritis, but not retinal ischaemia. Identifying the major cause of visual morbidity is 
important for focussing treatment strategies. However, it can be challenging, as more 
often than not, there are multiple causes for poor vision and the components of ocular 
inflammation do not occur in isolation. For example, retinal ischaemia may lead to macula 
oedema. In this situation, it is challenging to identify the major cause of visual loss as 
both pathologies will be contributory.  
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Finally, I analysed the first-line treatment given for the reported cases. Topical and oral 
corticosteroids were the mainstay of treatment for all manifestations. Intravenous 
corticosteroids were given to one patient with a retinal infiltrate and panuveitis. 
Intravitreal corticosteroids were given to three eyes of two patients. One patient had 
bilateral injections for retinal vasculitis and panuveitis and one patient had a unilateral 
injection for macula oedema. Disease modifying anti-rheumatic drugs were started in two 
patients. One with bilateral anterior uveitis and one with a retinal infiltrate. The EULAR 
guidance, published in 2008, was updated in 2016 and is awaiting formal publication. The 
guidance recommends that all patients with ophthalmic disease are started on azathioprine 
in combination with corticosteroids. If this does not control the inflammation, patients 
should be escalated to infliximab, interferon α or ciclosporin (Hatemi et al., 2008). Two 
individuals were started on a DMARD with corticosteroids as a result of their eye disease. 
A further 5 were already immunosuppressed, leaving 75% of patients who (n=16) may 
not have been managed in accordance to these guidelines. There are a number of possible 
explanations for this. Firstly, respondents were asked for their first-line treatment – it is 
reasonable to assume that starting a DMARD would not be considered ‘first-line’ by many 
clinicians. Secondly, reporting ophthalmologists may have been waiting for a medical 
opinion before starting immunosuppression or the questionnaire may have been filled in 
before this had occurred. Finally, patients may have been unable to take azathioprine due 
to a low thiopurine-methyltransferase level and were either due to start another second 
line agent or were waiting to be referred to the BD-centres of excellence for a biologic 
medication.  
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5.6.1 Chapter Summary 
 
 
 
This is the first prospective study to analyse the incidence of ophthalmic involvement in 
BD. I found the incidence of BD-related ophthalmic disease to be is 0.04 (95%CI 0.02-
0.05) per 100,000. Knowledge of incidence and the affected demographics is helpful for 
clinicians working with BD patients in the UK as it allows us to offer patients a more 
informed prognosis as well as inform recruitment to future clinical trials.  
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6 Discussion, Limitations and Further Work 
6.1 Discussion Of Thesis 
 
In this PhD, I investigated the genetic associations in a cohort of individuals with BD 
from the UK. I was able to confirm HLA-B*51 as a risk factor in this group. MICA*009 
was also associated with BD in this cohort. Of note, I did not find an association between 
the MICA A6 triplet repeat, a finding that has been confirmed in a number of other 
populations.  
 
A putative mechanism by which HLA-B*51 may function to influence disease is via its 
interaction with KIR3DL1.  To investigate this, I used sequence-based typing to analyse 
KIR3DL1/S1 allelic variation in BD and HC groups. I did not find any specific 
KIR3DL1/S1 allele to be associated with BD, however, when ‘functional genotypes’ were 
constructed, I found a strong association between possession of a KIR3DL1LOW/KIR3DS1 
genotype and risk of developing BD. Similarly, I found a protective effect from 
possessing a KIR3DL1HIGH/KIR3DL1NULL genotype. It appears that these effects are not 
entirely mediated via Bw4, as the ‘functional genotypes’ were also found in those lacking 
Bw4. It may be that there is a partial effect from Bw4 and that presence of the HLA-F OC 
(which was not examined in this project as it was only confirmed as a ligand for KIR3DS1 
in 2016) plays an important role in the KIR3DL1LOW/KIR3DS1 risk genotype.  
 
In the UK cohort, both the risk and protective genotypes were significant in individuals 
bearing the Bw4 epitope. However, in the European subgroup, the risk effect was not 
statistically significant. The protective effects were significant in the Bw4 subgroups in 
both the UK cohort and European subgroup. Neither KIR3DL1/S1 ‘functional genotype’ 
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was significant in the HLA-B*51+ subgroups, which may have been due to small numbers 
in that particular subgroup.  
 
I then analysed the effects of the risk and protective genotypes in two different clinical 
manifestations of BD: mucocutaneous disease alone and mucocutaneous disease with 
ophthalmic involvement. I found that the risk genotype was only significant in the 
ophthalmic group, whereas the protective genotype was only significant in the MC group. 
Behçet’s disease is a heterogenous condition made up of a constellation of clinical 
manifestations. There have been reports suggesting that individuals with ophthalmic 
disease have a more severe disease form than those with MC disease alone (Gul et al., 
2012; Yazici et al., 1990). This issue remains contentious. However, if ophthalmic disease 
represents one end of the disease spectrum, then it may explain why different 
KIR3DL1/S1 genotypes are associated with this pathology. A similar rationale has been 
used to explain the increased prevalence of HLA-B*51 in patients with ophthalmic disease 
vs non-ophthalmic disease in the past (L. Krause et al., 2009; Sant et al., 1998), although 
this is also disputed. In 2001, Gul et al. reported a series of Turkish individuals with BD. 
The authors used a modified version of the BD total activity index (Yazici et al., 1984) to 
score disease severity. They then examined HLA-B*51 presence/absence and 
heterozygosity/homozygosity in the different groups and found minimal differences 
between individuals with mild, moderate and severe disease (Gul et al., 2001). Whether 
these findings can be extrapolated to a UK population in which HLA-B*51 is less 
frequently possessed remains unclear. 
 
This project was designed in 2014. The emphasis was to investigate the KIR3DL1 - Bw4 
interaction (and by extension the KIR3DL1 - HLA-B*51 interaction) in BD. At that time, 
the primary ligand for KIR3DS1 was unknown (Burian et al., 2016; Garcia-Beltran et al., 
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2016). Similarly, much of the work investigating KIR3DL1 copy number variation was in 
its infancy (Tao et al., 2014; Vendelbosch et al., 2015). It would have been useful to have 
added HLA-F into the NGS panel along with all of the KIRs so copy number variation 
could have been established. This may have allowed more detailed interpretation of the 
KIR3DL1 ‘functional genotypes’ constructed.  
 
In order to create a more homogeneous group of patients, I aimed to control for ethnicity 
as much as possible. In addition to taking a detailed family history, I ran a panel of AIMs 
specific for European ancestry. This panel enabled us to create a subgroup of individuals 
of European extraction who could then be used to confirm genetic associations found in 
the whole UK cohort. Using this methodology, I have reduced some of the error 
introduced to population-based studies, caused by admixture (Abi-Rached et al., 2011; 
Skotte et al., 2013). The AIMs panel used was concise and only allowed differentiation 
between European and non-European populations. There are other, more detailed ancestry 
panels which would have allowed more elaborate analysis and enabled us to create a 
geographically smaller subgroup (such as the United Kingdom or Northern Europe). 
There would have been benefits to this; a European subgroup includes individuals from 
Southern Europe and the Mediterranean – these populations share much of their genome 
with individuals from the Middle East and Northern Africa. It could be argued that 
including Italians in the same group as British individuals makes less sense than grouping 
Italians with Turkish individuals. This argument has merit. However, the smaller the 
geographic region analysed, the larger the overall dataset would need to be. In this project, 
I was limited to patients from the UK and therefore the pool of potential patients was 
relatively small. For this reason, the UK cohort has been treated as a single group 
throughout this thesis with reference and confirmation to the European subgroup where 
relevant. From a clinical perspective, it is not useful to be able to sub-categori
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factors that are applicable to individuals of one small geographic region as this kind of 
information is not readily available in a clinical setting. 
 
Prior to investigating the effects of the KIR3DL1/S1 ‘functional genotypes’, NK and CD8 
T cell subsets were examined for presence of KIR3DL1/S1 in the BD group. Peripheral 
blood mononuclear cells were collected from 22 individuals with known KIR3DL1/S1 
alleles. I confirmed low percentages of circulating NK cells in our BD cohort, in line with 
previous data from our UK cohort (Hasan et al., 2017). I was unable to demonstrate any 
differences between active and inactive disease, or in those on disease-modifying therapy, 
although the sample size was small and meaningful differences cannot be excluded on the 
basis of this data. 
 
Overall, KIR3DL1 was expressed on 5.22 ± 3.02% of NK cells, with the majority of 
individuals expressing less than 5% KIR3DL1. KIR3DL1 was present on the surface of 
CD8 T cells in 22.72% (n=5) of individuals tested and only at very low levels.  
 
KIR3DS1 was possessed by 22.72% (n=5) of individuals tested and expressed on 1-5% 
of circulating NK cells. This is in contrast to work by Li et al., who suggested that in 
individuals with one copy of KIR3DS1 20-50% of NK cells express KIR3DS1, whereas 
in individuals with two copies, more than 60% of NK cells express the receptor (Li et al., 
2008).  
 
The target cells used for CD107a assays were 721.221 B lymphoblastoid cells, which 
were thought to be HLA-F null, however in 2018, Kiani et al recently demonstrated that 
221-cells do indeed express HLA-F (Kiani et al., 2018). HLA-F OC are ligands for 
KIR3DS1 and therefore findings from assays involving KIR3DS1+ cells should be treated 
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with caution. However, in samples analysed, I found minimal expression of KIR3DS1 
and its overall effect on CD107a expression is likely to be minimal.  
 
Low expression of KIR3DL1/S1 is an important finding from this project, but also colours 
interpretation of CD107a assays subsequently carried out. I did not find any significant 
variation in CD107a expression in the individuals tested. However, this may reflect the 
relative paucity of KIR3DL1/S1 on the surface of cells tested. Much of the published data 
examining KIR3DL1-Bw4 interaction has been carried out using tetramer binding to 
characterise the binding patterns of KIR3DL1 to its ligand. This data may not be 
representative in BD. Low numbers of circulating NK cells could also be explained by 
the sequestration of KIR3DL1/S1-bearing NK cells in tissues, resulting in a depleted 
circulating population. Whether low expression of KIR3DL1/S1 is associated with 
disease pathogenesis or a secondary effect of depleted NK cells remains to be seen. 
 
Finally, I sought to define the ophthalmic subset in greater detail by carrying out a 
prospective survey of ophthalmic BD in the UK using the BOSU reporting system. This 
allowed me to calculate incidence of ophthalmic disease in the UK over a period of 12 
months as well as gather data regarding the presenting features of ophthalmic disease, the 
initial management strategy and referral pathways that exist for BD. The incidence of 
ophthalmic BD in the UK is 0.04 per 100,000 individuals, with male patients making up 
52% of all cases reported. The median age at presentation was 37 years. Forty-eight 
percent of reported cases occurred in individuals with a previous diagnosis of BD and of 
these individuals, those concurrently treated with 2 or more DMARDS or a biologic agent 
had less severe ophthalmic disease that those taking corticosteroids alone or 
corticosteroids plus one DMARD. Patients with cystoid macula oedema presented with 
the worse vision than those with vitritis or retinal infiltrates (P=0.0102). Ophthalmic 
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manifestations of BD were treated with oral or topical corticosteroids most commonly, 
with intravenous and intravitreal corticosteroids being used in less than 10% of cases.   
 
6.2 Limitations Of The Project 
 
6.2.1 Clinical Data 
 
It is possible that some of the clinical information collected was inaccurate. The clinical 
data was taken from the clinical records, however, some patients had missing notes and 
were unable to accurately recall the exact clinical manifestations of their disease since 
symptoms began. Furthermore, it is possible that some of the HCs were not truly 
‘healthy’. I relied on history from the unrelated HCs to ensure there was no current or past 
history of BD or any other inflammatory disease. However, patient recall is imperfect, 
and it is possible that some of these individuals had other diseases with HLA, MICA or 
KIR3DL1/S1 associations that they were unaware of. 
 
6.2.2 Genotyping 
 
Despite our best efforts, some DNA was either too dilute for analysis, contaminated, or 
did not amplify during the library preparation. While there was HLA-A data available for 
over 95% of individuals and HLA-B data for 99%, a proportion of data was lost at the 
start. This may be relevant as some of the associations found were present in very low 
number of individuals. For example, the HLA-B*58 association was present in less than 
1% of BD cases.  
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In order to make the project affordable, samples were sequenced to a depth of 10-15x. 
This meant that some of the samples had ambiguous reads and had to be repeated using 
either SSP or SSOP depending on the quantity of DNA available. There were two cases 
from the HC group that were excluded as no DNA was available and the HC was not 
willing to donate more blood.  
 
There are also intrinsic limitations to the data set used to derive the AIMs, which were 
taken from the Wellcome Trust Case Control Consortium 3 anorexia nervosa GWAS, 
which included 2,907 cases from 15 different populations of European origin. The 
samples were collected for clinical use rather than population genetics and details of the 
ancestry of these patients was not always available.  
 
6.2.3 Statistical Analysis 
 
This project was not carried out in conjunction with a statistical geneticist. Although I 
endeavoured where possible to ask opinions at international conferences and from of the 
groups working in the field, I carried out all the analyses myself. The project would have 
benefitted from early planning with a statistical geneticist and collaboration regarding the 
interpretation of results. As mentioned in the Chapter 2.12, I corrected multiple testing 
using Bonferroni-Dunn correction. This is well known to be a very stringent process and 
while it is likely to avoid type I error, it may lead to a number of relevant findings being 
dismissed. 
 
Where relevant, I have calculated post-hoc power to give the results context with regard 
to type II errors. There are a large number of potential sources for type II error in the 
project and these have been highlighted throughout the thesis. Ultimately, a larger sample 
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size would have benefitted the analysis, however, BD is rare in the UK so larger numbers 
of samples were not an option for me.  
  
6.2.4 Small Number Of Samples Available For Phenotypic And Functional Analysis 
 
The low number of individuals with known KIR3DL1/S1 allotypes analysed is a major 
limitation of this project. It would have been preferable to store PBMC from all 
individuals recruited for the genotyping part of the project, thus a library of PBMC would 
have been available for later analysis. However, I did not have ethics approval to create a 
lymphocyte biobank and did not have the liquid nitrogen storage facilities to store 712 
samples of PBMC. Furthermore, it is possible that some participants would have objected 
to donating more than 50 ml of blood at the time of venepuncture.  
 
6.2.5 New Cases Of Ophthalmic Manifestations In The United Kingdom Are Rare 
Events 
 
The British Ophthalmic Surveillance unit is set up to allow the incidence of rare diseases 
to be calculated. In this study, I received 23 reported of new cases over a 12-month period. 
With such small numbers a reporting error or a missed case can have a large impact on 
the overall incidence. In order to increase the confidence of this finding I have decided to 
run the study for a further 12 months.  
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6.3 Further Work 
 
It would be of great use to carry out a large KIR3DL1/S1-phenotyping project in BD. 
Findings from this project have suggested that KIR3DL1/S1 expression is low in patients 
with BD. Future projects would benefit from data from HCs to compare against BD 
KIR3DL1/S1 expression.  
 
This project did not examine KIR3DL1 mRNA transcript levels in our cohort. However, 
given our findings, it would be informative to establish whether low expression of 
KIR3DL1 is due to an upstream transcription abnormality. Previous work investigating 
KIR3DL1 mRNA transcripts in healthy Han Chinese individuals found no difference 
between different KIR3DL1 alleles (Tao et al., 2014). Nonetheless, there has been some 
work carried out investigating KIR transcript levels in HIV-1 infection suggesting that 
increased copy number variation in KIR3DL1, in conjunction with the presence of 
KIR3DS1 may lead to resistance to HIV-1 infection (Pelak et al., 2011).  
 
As with any new genetic finding, the ‘functional genotypes’ elucidated here need to be 
explored in other BD cohorts around the world.  
 
6.4 Summary Of Thesis Findings 
 
This thesis focuses on genetic risk factors and ophthalmic manifestations in a cohort of 
individuals with BD from the UK. There is an established association between BD and 
risk loci within HLA. I analysed HLA-A and -B as well as MICA in cohort of 267 BD 
patients and 445 HC. I confirmed HLA-B*51 (OR 2.13 (1.49-3.06), Pc=0.0009) and 
MICA*009 (OR 1.80 (1.31-2.47), Pc=0.0045) as independent risk factors for BD in a 
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mixed UK cohort and a subgroup of individuals with European ancestry-informative 
markers (with a smaller effect size). I then investigated the associations between 
KIR3DL1/S1 and BD. KIR3DL1/S1 allele-level analysis indicated that low-expressing 
KIR3DL1/S1 alleles in combination with KIR3DS1 increased the risk of developing BD 
(KIR3DL1LOW/KIR3DS1: P=0.0004, Pc=0.0040, OR 2.47, 95% CI 1.43-4.25), whereas 
high-expressing KIR3DL1/S1 alleles in combination with a null-expressing KIR3DL1 
reduced the risk of disease (KIR3DL1HIGH/KIR3DL1NULL: P=0.0035, Pc=0.0350, OR 0.53, 
95% CI 0.33-0.87). Behçet’s Disease can manifest as a purely mucocutaneous disease or 
can involve other organ systems such as the eyes. In the UK cohort studied here, 
KIR3DL1LOW/KIR3DS1 increased the risk of ophthalmic disease (P=1.2x10-5, OR 3.92, 
95% CI 2.06-7.47), whereas KIR3DL1HIGH/KIR3DL1NULL provided protection against 
mucocutaneous disease (P=0.0048, OR 0.45, 95% CI 0.25-0.81). I then investigated 
expression of KIR3DL1/S1 in a genotyped group of individuals, but found only very low 
levels expression (1-5%) in the majority of cases; limiting further functional work. 
Finally, I undertook a prospective study to analyse ophthalmic manifestations BD in the 
UK and found the incidence to be 0.04 (95% CI 0.02-0.05) per 100,000. This is the first 
piece of work to explore both the genetic risk factors in a UK cohort of individuals with 
BD and the incidence of eye-disease in this group of patients.  
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11 Appendix 1 – Primers For PCR SSP HLA-A And HLA-B  
Table 11-1. PCR SSP Primers Used for HLA-A and –B Typing  
 
 
Forward Primer
Primer No. HLA Annealing Position
174 HLA-A 241-259 5' C C G G A G T A T T G G G A C C T G C
187 HLA-B 217-234 5' G C G C C G T G G A T A G A G C A A
188 HLA-B 190-206 5' G C C G C G A G T C C G A G G A C
189 HLA-B 254-272 5' A C C G G A A C A C A C A G A T C T G
192 HLA-B 254-272 5' A C C G G G A G A C A C A G A T C T C
193 HLA-A&B 243-261 5' G G A G T A T T G G G A C C G G A A C
194 HLA-B 268-285 5' A A C A T G A A G G C C T C C G C G
195 HLA-B 253-272 5' G A C C G G A A C A C A C A G A T C T T
197 HLA-B 230-246 5' A G C A G G A G G G G C C G G A A
202 HLA-B 124-141 5' G G G G A G C C C C G C T T C A T T
203 HLA-B 265-283 5' C A G A T C T A C A A G G C C C A G G
205 HLA-B 83-103 5' C C A T G A G G T A T T T C T A C A C C G
206 HLA-B 253-272 5' G A C C G G A A C A C A C A G A T C T A
207 HLA-B 294-311 5' C C G A G A G A G C C T G C G G A A
208 HLA-A&B 293-311 5' A C C G A G A G A A C C T G C G G A T
209 HLA-B 189-206 5' C G C C G C G A G T C C G A G A G A
239 HLA-A 406-423 5' G G G T A C C A G C A G G A C G C T
240 HLA-B 259-278 5' G A G A C A C A G A A G T A C A A G C G
242 HLA-B 295-312 5' C G A G A G A G C C T G C G G A A C
243 HLA-B 192-209 5' C G C G A G T C C G A G G A T G G C
246 HLA-B 78-97 5' C C A C T C C A T G A G G T A T T T C C
271 HLA-B 125-142 5' G G G A G C C C C G C T T C A T C T
272 HLA-B 189-206 5' C G C C A C G A G T C C G A G G A A
280 HLA-B 149-167 5' G C T A C G T G G A C G A C A C G C T
284 HLA-A 247-265 5' T A T T G G G A C G A G G A G A C A G
286 HLA-A 186-203 5' C G A C G C C G C G A G C C A G A A
288 HLA-A 283-302 5' T C A C A G A C T G A C C G A G C G A A
290 HLA-A 264-282 5' A C G G A A T G T G A A G G C C C A G
291 HLA-A 184-200 5' A G C G A C G C C G C G A G C C A
292 HLA-A 239-257 5' G G C C G G A G T A T T G G G A C G A
294 HLA-A&B 283-302 5' T C A C A G A C T G A C C G A G A G A G
295 HLA-A 110-126 5' C C C G G C C C G G C A G T G G A
296 HLA-A 222-240 5' G T G G A T A G A G C A G G A G G G T
368 HLA-B 284-302 5' C A C A G A C T G A C C G A G T G A G
371 HLA-A 78-98 5' C C A C T C C A T G A G G T A T T T C T C
434 HLA-A 78-98 5' C C A C T C C A T G A G G T A T T T C A C
435 HLA-B 303-319 5' C C T G C G C A C C G C G C T C C
451 HLA-A 406-423 5' G G G T A C C G G C A G G A C G C T
475 HLA-A 264-282 5' A C G G A A A G T G A A G G C C C A G
493 HLA-A 161-180 5' C A C G C A G T T C G T G C G G T T T
395 HLA-B 190-206 5' G C C G C G A G T T C G A G A G G
Reverse Primer 
Primer No. HLA Annealing Position
127 HLA-B 361-379 5' G G T C G C A G C C A T A C A T C C A
145 HLA-A&B 559-576 5' G A G C C A C T C C A C G C A C T C
146 HLA-A 539-557 5' C C C T C C A G G T A G G C T C T C T
167 HLA-A 559-576 5' G A G C C A C T C C A C G C A C C G
168 HLA-A&B 559-576 5' G A G C C A C T C C A C G C A C G T
170 HLA-A 538-556 5' C C T C C A G G T A G G C T C T C T G
171 HLA-A 391-407 5' C C G C G G A G G A A G C G C C A
184 HLA-B 512-528 5' C G C A C G G G C C G C C T C C A
213 HLA-B 387-402 5' G A G G A G G C G C C C G T C G
214 HLA-A&B 419-435 5' C T T G C C G T C G T A G G C G G
215 HLA-B 420-438 5' A T C C T T G C C G T C G T A G G C T
216 HLA-B 435-454 5' C G T T C A G G G C G A T G T A A T C T
217 HLA-B 544-561 5' C G T G C C C T C C A G G T A G G T
218 HLA-A&B 559-576 5' G A G C C A C T C C A C G C A C T C
219 HLA-B 572-589 5' C C A G G T A T C T G C G G A G C G
220 HLA-B 603-619 5' C C G C G C G C T C C A G C G T G
221 HLA-B 605-622 5' T A C C A G C G C G C T C C A G C T
223 HLA-B 353-372 5' G C C A T A C A T C C T C T G G A T G A
224 HLA-B 361-379 5' C G T C G C A G C C A T A C A T C A C
225 HLA-B 527-544 5' C T C T C A G C T G C T C C G C C T
228 HLA-A&B 411-438 5' T C G T A G G C G T C C T G G T G G
229 HLA-B 499-516 5' C T C C A A C T T G C G C T G G G A
232 HLA-B 246-265 5' G T G T G T T C C G G T C C C A A T A T
236 HLA-B 354-371 5' C C A T A C A T C G T C T G C C A A
237 HLA-B 302-318 5' G C G C A G G T T C C G C A G G C
238 HLA-A&B 559-576 5' G A G C C A C T C C A C G C A C A G
241 HLA-B 463-479 5' G C C G C G G T C C A G G A G C T
244 HLA-A&B 571-588 5' C A G G T A T C T G C G G A G C C C
247 HLA-B 463-479 5' G C G G C G G T C C A G G A G C G
249 HLA-A&B 538-556 5' C C T C C A G G T A G G C T C T C A A
250 HLA-B 299-316 5' G C A G G T T C C G C A G G C T C T
276 HLA-A&B 499-515 5' T C C C A C T T G C G C T G G G T
277 HLA-B 387-403 5' G G A G G A A G C G C C C G T C G
281 HLA-B 280-298 5' C T C G G T C A G T C T G T G C C T T
282 HLA-B 280-299 5' T C T C G G T A A G T C T G T G C C T T
285 HLA-B 412-430 5' C G T C G T A G G C G T A C T G G T C
287 HLA-A&B 559-576 5' G A G C C C G T C C A C G C A C T C
298 HLA-A 423-443 5' A T G T A A T C C T T G C C G T C G T A A
299 HLA-A 555-572 5' C A C T C C A C G C A C G T G C C A
300 HLA-A 448-466 5' A G C G C A G G T C C T C G T T C A A
301 HLA-A 414-431 5' C C G T C G T A G G C G T G C T G T
302 HLA-A 453-471 5' C C A A G A G C G C A G G T C C T C T
303 HLA-A 527-544 5' C T C T C T G C T G C T C C G C C G
377 HLA-B 538-556 5' C C T C C A G G T A G G C T C T C C A
392 HLA-B 419-436 5' C C T T G C C G T C G T A G G C G A
393 HLA-B 412-429 5' G T C G T A G G C G T C C T G G T C
394 HLA-A 364-382 5' C C A C G T C G C A G C C A T A C A T T
429 HLA-A 259-278 5' G C C T T C A C A T T C C G T G T G T T
431 HLA-A 559-575 5' A G C C C G T C C A C G C A C C G
486 HLA-A 257-276 5' C T T C A C A T T C C G T G T C T C C T
494 HLA-A 299-316 5' G C A G G G T C C C C A G G T C C A
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12 Appendix 2 – HLA- B Sequencing Primers  
Table 12-1. HLA-B Primers Used for Library Preparation  
 
Name Primer 
HLA F-Sp 1 CACGTAGCCCACTGAGATGAAG 
HLA F-Sp 2 AGGTATCTGCGGAGCCACT 
HLA F-Sp 3 GGGTGCGTGGGGACTTTAG 
HLA F-Sp 4 CTGAAGGGCTCCTGCTTTCC 
HLA F-Sp 5 GCCGTACGTGGGGGATG 
HLA F-Sp 6 CGCGGCTCCTCAGGTC 
HLA F-Sp 7 ACTCAGGAAAACTCATGCCATTC 
HLA F-Sp 8 CGACACAAGTTGGGAGAAGAAGT 
HLA F-Sp 9 CAGTGTCCTGAGTTTGGTCCTC 
HLA F-Sp 10 CCCACTCTAGACCCCAAGAAT 
HLA F-Sp 11 CACTTCTACCTGGGGCTTGAAA 
HLA F-Sp 12 GTCCTGATCCCTCTTCTCCTACA 
HLA F-Sp 13 GGAAGTAAGAAGTTGCAGCTCAGT 
HLA F-Sp 14 CCCCCACAGCCTTCTCCA 
   
HLA R-Sp 1 GCGGTCCCAGTTCTAAAGTCC 
HLA R-Sp 2 GCGTTTACCCGGTTTCATTTTCA 
HLA R-Sp 3 TGTAGGAGAAGAGGGATCAGGAC 
HLA R-Sp 4 CATCAGACCCCCCAAAGACAC 
HLA R-Sp 5 AGGCTCCCACTCCATGAGG 
HLA R-Sp 6 ACTTCTTCTCCCAACTTGTGTCG 
HLA R-Sp 7 CATGACCAGTACGCCTACGAC 
HLA R-Sp 8 GTGCTCAGTTTCCCTACACAAGA 
HLA R-Sp 9 GCTCAGAGACTCGAACTTTCCAA 
HLA R-Sp 10 GGGTCTGTAGTCATACTTCTGGAAA 
HLA R-Sp 11 GTAAGGAGGGGGATGAGGG 
HLA R-Sp 12 GCGGTGCCTTCAGAGAAAACT 
HLA R-Sp 13 ACCAGAATTTGTTCATGACTGTTGTT 
HLA R-Sp 14 GTGACCCCTGTTCCCATGC 
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Figure 12-1. Map of HLA-B Amplicons 
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13 Appendix 3 – MICA Sequencing Primers  
Table 13-1. MICA Primers Used for Library Preparation 
Name Primer  
MICA F-Sp 1 GTTTGTGGTCTGAGCGGTTCTAC  
MICA F-Sp 2 TCTGTCCTGGAAGGAACAAGC  
MICA F-Sp 3 TTCTAAATCTCCCCAGGTCTCCA  
MICA F-Sp 4 TATCCTCCCACCCTCACAGTTTT  
MICA F-Sp 5 GATGGTCAGCCCTTCCTG  
MICA F-Sp 6 GAGAAGTCACTGCTGGGTGG  
MICA F-Sp 7 CAGAGTGAGGACAGACTTGCAG  
MICA F-Sp 8 AGGCCTCAGAGGGCAACAT  
MICA F-Sp 9 GGGATGGCTGTGGCTCTCT  
MICA F-Sp 10 AGTCCCCAGGGAATAAACACAAC  
MICA F-Sp 11 CCACAGGGATGCCACACAG  
    
MICA R-Sp 1 AGTACAGCTCCAACTTCATAAGCA  
MICA R-Sp 2 CCCGGAACTTAGGGCCAATC  
MICA R-Sp 3 CGACCCCCGGAAACGTC  
MICA R-Sp 4 CCAGGACATCTTCTGCCCAC  
MICA R-Sp 5 CCCTGTGTGGGCTGAGTG  
MICA R-Sp 6 GGAGAGGAGAGCCCCTG  
MICA R-Sp 7 CTGGTAGGTTCCATTCCCATCAG  
MICA R-Sp 8 GGACTTGTTATACACTGGGCAGA  
MICA R-Sp 9 AATTCCCCAACTTTCATCCCCTG  
MICA R-Sp 10 ATTTTGCAGCCTCCAACAACAAT  
MICA R-Sp 11 CCGTGCCTGGCCTGAGA  
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Figure 13-1. Map of HLA-B Amplicons 
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14 Appendix 4 – KIR3DL1 Sequencing Primers  
Table 14-1. KIR3DL1 Primers used for Library Preparation 
 
 
Name  Primer 
KIR3DL1 F-Sp 1 AGACGTGTTTTGAGTTGGTCATAGT 
KIR3DL1 F-Sp 2 GAGTTTACCTTCAGCCCAGCAAG 
KIR3DL1 F-Sp 3 CCTCCCCCTGTTTGTTGGTATC 
KIR3DL1 F-Sp 4 GAAACTGCCTCTTCTCCTTCCAG 
KIR3DL1 F-Sp 5 CCTCTCTCCAGGACTCTGATGAA 
KIR3DL1 F-Sp 6 GAGGACACGTGACTCTTCGG 
KIR3DL1 F-Sp 7 TGGTAGGAGCCTTAGAAAGTGGA 
KIR3DL1 F-Sp 8 TAACAGAGTGTTGGCCATGAACC 
KIR3DL1 F-Sp 9 GCACAAAGAGGGGATCTCTAAGG 
KIR3DL1 F-Sp 10 GGGATATGGGCACAGAAAAGACA 
KIR3DL1 F-Sp 11 CCTGTCAATCAAGAAATGCAAGACA 
KIR3DL1 F-Sp 12 CGTCTTCTAGGGAGACAACAGC 
KIR3DL1 F-Sp 13 GCTTAGCCCACAGTTCTCCATTT 
KIR3DL1 F-Sp 14 GAGACAGAGAGAGAGCAAACCATGAG 
KIR3DL1 F-Sp 15 TGCATAATCCTTCCCTGGGAGTT 
  
KIR3DL1 R-Sp 1 CACTCCCTCCCTCGATTCCC 
KIR3DL1 R-Sp 2 CAGAGCTTGACTCAGGAAAGGG 
KIR3DL1 R-Sp 3 AAACGCAGTGATCCAACTGTGC 
KIR3DL1 R-Sp 4 GGACATGAGAGAGATATGGGCTT 
KIR3DL1 R-Sp 5 GAGGAGCGATGCCCTAAGATG 
KIR3DL1 R-Sp 6 CTCCCTTGACCCCAAATACAGTC 
KIR3DL1 R-Sp 7 ACATGTGTAGTTCCCTGCATGTG 
KIR3DL1 R-Sp 8 TAAGAGACTTCGCTGAGCCCTTT 
KIR3DL1 R-Sp 9 GTCTCTGTTGGTACAGACCTCAC 
KIR3DL1 R-Sp 10 CATCATGGGACCGATGGAGAAAT 
KIR3DL1 R-Sp 11 AGGGAGTCTGGTGCTCTCTCTA 
KIR3DL1 R-Sp 12 GTAAGTGCCACGTCAAGAGGG 
KIR3DL1 R-Sp 13 AGCGGTTTCTTTCAGCGAATACA 
KIR3DL1 R-Sp 14 TTTTATCTGAGATTCAAACTCTTCTTCCTGTG 
KIR3DL1 R-Sp 15 CAGTGGGTGCTCGCTCA 
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Figure 14-1. Map of KIR3DL1 Amplicons 
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15 Appendix 5 - Questionnaire for Reporting Clinicians – 
Prospective Surveillance of Ophthalmic Manifestations of 
Behçet’s Disease. 
 
 
 
Doctor Questionnaire – Ophthalmic Manifestations of Behcet’s Disease Version 7 25/8/2016 
351436 
Study code OBD/87 
Mr Harry Petrushkin - Uveitis Fellow, Medical Retina Department, Moorfields Eye Hospital 
Telephone: 0207 566 2036  E-mail:  harry.petrushkin@moorfields.nhs.uk 
Page 1 
Ophthalmic manifestations of Behçet’s Disease; a national prospective study of 
incidence and management. 
 
In cooperation with the British Ophthalmological Surveillance Unit (BOSU) - A national population based study to 
determine the incidence and treatment strategies in the United Kingdom.   
 
 
Age    ___  
Gender   q Male q Female  
First half of postcode  ______________  
 
Ethnicity 
White q British 
q Irish 
    Other White (Please specify) _______________ 
Mixed/multiple ethnic groups q White and Black Caribbean 
q White and Asian 
q White and Black African 
     Other Mixed (Please specify) _______________ 
Asian/Asian British q Indian 
q Pakistani 
q Bangladeshi 
q Chinese 
     Other Asian (Please specify)_______________ 
Black/ African/ Caribbean/ 
Black British 
q African 
q Caribbean 
     Other Black (Please specify) _______________ 
Other Ethnic groups q Middle Eastern 
     Any other ethnic group (Please specify)______________ 
 
Which eye(s) are affected   q Right    q Left   q Both  
 
Date patient first seen with ophthalmic manifestation 
of Behçet’s Disease  
DD/MM/YYYY     
Date Behçet’s Disease was diagnosed (if applicable) MM/YYYY 
 
Year of first systemic symptom of BD 
 
YYYY 
 
 232 
 
 
 
 
 
 
 
Doctor Questionnaire – Ophthalmic Manifestations of Behcet’s Disease Version 7 25/8/2016 
351436 
Study code OBD/87 
Mr Harry Petrushkin - Uveitis Fellow, Medical Retina Department, Moorfields Eye Hospital 
Telephone: 0207 566 2036  E-mail:  harry.petrushkin@moorfields.nhs.uk 
Page 2 
Systemic manifestations of Behçet’s Disease at any point in the past 
 
q None 
q Recurrent Oral Ulceration: 
Minor aphthous, major aphthous, or herpetiform ulceration observed by physician or patient, which 
recurred at least 3 times in one 12-month period. 
q Recurrent genital ulceration: 
Aphthous ulceration or scarring, observed by a physician or patient. 
q Eye lesions: 
Anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination; or retinal vasculitis 
observed by an ophthalmologist. 
q Skin lesions: 
Erythema nodosum observed by physician or patient, pseudofolliculitis, or papulopustular lesions; or 
Acneiform nodules observed by a physician in post-adolescent patients not on corticosteroids. 
q Positive Pathergy test 
Read by a physician at 24 - 48 hours 
Other ________________________  
 
 
Best Corrected Visual Acuity at presentation  RE: _______________ LE:____________ 
 
Reason for poor visual acuity (if reduced) 
 Right Eye Left Eye 
Amblyopia q q 
Corneal Opacity q q 
Cataract q q 
Vitritis q q 
Macula Oedema q q 
Ischaemia q q 
Other   
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Ocular Manifestations of Behcet’s Disease 
 
 Right Eye Left Eye 
Ocular Surface Inflammation  Specify________________ Specify________________ 
Scleritis/ Episcleritis  Specify________________ Specify________________ 
Anterior Uveitis  q q 
Hypopyon  q q 
Posterior Synechiae  q q 
Vitritis  q q 
Macula Oedema  q q 
Retinal Infiltrate (see case 
definition)  
q q 
Vascular occlusion (central, 
branch, multiple, peripheral)  
 
Specify________________ 
 
Specify________________ 
Neovascularisation   
Specify________________ 
 
Specify________________ 
Other   
 
 
 
 
Existing Treatment prior to onset of eye disease 
Oral Steroid  q 
Conventional Immunosuppressive  q 
Multiple Immunosuppressives  q 
Biologic  q 
Steroid Mouth Wash q 
 
 
First line treatment for ophthalmic manifestation of Behcet’s Disease 
 Right Eye Left Eye 
Topical steroid q q 
Topical intraocular pressure-
lowering agent 
q q 
Intravitreal steroid q q 
Periorbital steroid q q 
Oral steroid q q 
Conventional Immunosuppression q q 
 Intravenous Methylprednisolone q q 
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Was the patient referred from another centre?     Yes q   No q 
Please Specify___________________ 
(please note this information is for validation purposes only)  
 
Was the patient referred to another centre for further treatment?  Yes q   No q  
Please Specify___________________ 
(please note this information is for validation purposes only)  
 
Form completed by _______________________________________________________ 
 
Thank you for taking the time to fill in this questionnaire 
 
Please return the questionnaire to in the envelope provided to: 
 
Harry Petrushkin - Uveitis Fellow 
Medical Retina Department 
Moorfields Eye Hospital 
EC1V 2PD 
London 
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